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ABSTRACT 
The αβ T cell receptor (TCR) is responsible for mediating T cell recognition 
of self and non-self tissues, through recognition between a complex of a peptide and a 
product of the major histocompatibility complex (pepMHC) on target cells.  In the 
immune response to cancerous tissue, the immune repertoire of T cells is often 
insufficient to target pepMHC complexes associated with cancer cells, as these tumor 
antigens have often induced tolerance or the tumor microenvironment promotes 
immunosuppression of T cells. To improve the response to tumors, gene therapy with 
tumor specific T cell receptors provides an attractive approach to effectively arm 
patient’s T cells for cancer cell destruction.  An inherent difficulty, however, is 
generation of T cell receptors of sufficient affinity to redirect both CD4+ and CD8+ T 
cells.  This thesis describes the development of engineering strategies for human 
single-chain T cell receptor variable fragments (scTv), with the goal of understanding 
the properties that allow scTv to be expressed and deployed in a therapeutic mode.  
Stable scTv receptors can be used to generate high-affinity TCRs specific for disease-
associated pepMHC complexes and produced in soluble expression systems for 
subsequent biochemical and biophysical characterization.  This work also develops 
scTv and scFv (antibody variable fragments) as fusion proteins, collectively called 
chimeric antigen receptors, for cell mediated therapies to redirect T cells to specific 
antigens 
In chapter 2, two human Vα2+ T cell receptors specific for human 
immunodeficiency virus and human T cell lymphotrophic virus derived pepMHC 
complexes were engineered for improved stability as scTv proteins, consisting of only 
the variable domains of the T cell receptor attached by a flexible linker.  High-
affinity, stabilized scTv proteins could be expressed as soluble proteins in E. coli and 
used for detection of low levels of HIV pepMHC antigens, suggesting that these 
receptors have potential diagnostic applications for the detection of HIV infected 
cells.  Finally, the results suggest that other Vα2+ TCRs with different specificities 
can be engineered for enhanced affinity by yeast display.   
 Chapter 3 describes the development of chimeric antigen receptors, that 
consist of scTv-fusion proteins, for T cell targeting of tumor antigens.  scTv proteins 
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engineered for improved stability by yeast display were fused to the intracellular 
signaling domains of CD28,CD3ζ, and LCK and introduced into murine T cells.  The 
high affinity scTv, called m33, that is specific for the pepMHC SIY/Kb was used to 
redirect T cells with similar antigen sensitivity to the full-length m33 TCR.  An 
inherent problem with full-length TCR gene therapy is the generation of receptors of 
unknown specificity through mispairing between introduced and endogenous TCR, 
leading to graft versus host disease or autoimmunity.  I show that the scTv-fusions 
avoided mispairing with endogenous αβ TCRs and allowed for endogenous TCR 
surface expression at high levels.  A human HIV-specific scTv (chapter 2) was also 
expressed as a fusion to intracellular signaling domains and it also mediated antigen 
specific T cell activity.   
 In chapter 4, the murine m33 scTv fusion was compared to an antibody 
derived chimeric antigen receptor called 237.  The 237 antibody single-chain 
fragment variable (scFv) is specific for a tumor antigen resulting from a glycopeptide 
defect that is created by a mutant chaperone protein.  Fusion of the 237 scFv to 
intracellular domains, as with the m33 scTv, mediated T cell activity against tumor 
cells that expressed the glycopeptide defect.  Results with T cells transduced with 
chimeric antigen receptor in the absence or presence of coreceptor CD8, showed that 
CD8 could contribute to target cell recognition, presumably through its interactions 
with MHC molecules that are proximal to the antigen epitope.  
Chapter 5 describes the engineering of a murine T cell receptor, called 3D, for 
enhanced affinity to the model Wilm’s tumor antigen (WT-1/Db).  Using a novel T 
cell display system, mutated TCR libraries were displayed on the surface of T cell 
hybridomas in the absence of the coreceptor CD8.  Selection with fluorescently 
labeled dimers of WT-1/Db resulted in the isolation of two high affinity 3D TCR 
variants, one which mediated T cell activity in the absence of CD8.  Analysis of the 
TCR residues used by human and murine TCRs specific for the identical WT-1 
peptide suggested that there is homology between human and mouse TCR CDR3 
sequences, indicating that these residues have strong selective pressures to bind to the 
identical peptide epitope. Thus, one may be able to engineer high-affinity TCRs in the 
human TCR based on knowledge from the mouse TCRs. 
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CHAPTER ONE 
 
INTRODUCTION 
 
A Brief Historical Overview of Immunology 
 The concept of immunity can be traced as far back as the 5th century B.C. in 
Greece when the plague raged through Athens.  Thucydides recorded that a small 
population of individuals who had previously contracted disease were “exempt’ from 
the current bought of plague, the first recorded instance where some individuals 
demonstrated protection from disease (1).   It was not until centuries later that Edward 
Jenner developed the concept of vaccination, a way to protect from future infection 
by inoculation with a similar antigenic mixture (2).  Jenner exposed his neighbor’s 
son to cowpox derived from a lesion on the hand of a milkmaid and subsequently 
infected the young boy with small pox.  The boy survived the smallpox infection 
because he had been previously exposed to the similar cowpox virus.  Smallpox now 
represents a great achievement for modern vaccination, as the World Health 
Organization declared the virus eradicated by the 1970s (3). 
Although vaccination became a common practice over the century following 
Jenner’s work, it was not until the work of Robert Koch and Louis Pasteur that the 
basis of disease was elucidated.  Robert Koch developed the germline basis of 
disease, demonstrating that microorganisms caused disease and elucidated 
Mycobacterium tuberculosis as the causative organism of tuberculosis (4).  This 
finding allowed for the extension of Jenner’s early ideas of vaccination by Louis 
Pasteur, who is now widely regarded as the ‘parent’ of immunology.  Pasteur 
developed vaccines against cholera in chickens and rabies in humans prior to the start 
of the 20th century (5).  Koch and Pasteur were contemporaries, but were fierce 
enemies during and following the outbreak of the Franco-Prussian war and there are 
recorded reports of Koch, provoked by Pasteur at a meeting, stating: "When I saw in 
the program that Monsieur Pasteur was to speak today on the attenuation of viruses, I 
attended the meeting eagerly, hoping to learn something new about this very 
interesting subject.  I must confess that I have been disappointed, as there is nothing 
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new in the speech which Monsieur Pasteur has just made. I do not believe it would be 
useful to respond here to the attacks he has made on me...I will reserve my response 
for the pages of the medical journals" (6).  Their competitive nature drove the 
development of the germ theory, as each raced to elucidate the causative organisms 
for disease. 
Simultaneously with the development of the germ theory, a debate raged 
amongst Koch and Pasteur’s contemporaries regarding immunity, with support for 
either a humoral (from soluble substances) or cellular (from phagocytosis) basis for 
protection from foreign organisms.  The humoral hypothesis was led by work by Emil 
Von Behring and Shibasaburo Kitasuto who demonstrated that anti-toxins existed in 
the blood.  Transfer of blood from an infected animal led to protection from infection 
in a separate host, an approach which they referred to as serum therapy (7),(8).  It was 
not until much later that the substances in the serum were identified as antibodies, but 
this early demonstration of serum therapy resulted in Von Behring and Kitasuto 
receiving the first Nobel prize in physiology or medicine (9).  Four years later, Robert 
Koch would receive the Nobel prize for his germ theory postulate (10).   
Shortly after the demonstration of serum therapy, Paul Ehrlich, a German 
scientist, developed his side-chain theory: that side chains on cells bound to specific 
antigens, leading to the release of these side-chains and neutralization or eradication 
of foreign substances (11).  Ehrlich’s postulates are now considered the basis for 
chemotherapy and targeting of specific molecules in immunotherapy.  Among 
Ehrlich’s many accomplishments was a cure for syphilis, which was widely used 
prior to the introduction of penicillin. 
In contrast to the humoralist approach, Ilya Metchnikoff developed a cellular 
hypothesis based on the ability of some species to ‘engulf’ other organisms (12).  
While studying the larvae of starfish Metchnikoff developed the phagocytosis 
hypothesis, that the cells of the immune system may operate in the same way that 
small organisms engulf other microorganisms.  The macrophage immune cell type is 
now known to express receptors for many bacteria constituents and can phagocytose 
invading organisms to promote inflammation, providing a quick response to infection.  
The hypothesis at the time was that white blood cells took up microorganisms and 
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allowed septicemia to progress by spreading bacteria throughout the body.  Only later 
would others demonstrate that quite the opposite was occurring, with white blood 
cells removing infectious agents.  Metchnikoff and Ehrlich were awarded a Nobel 
prize for their contribution to immunology in 1908 (13). 
The humoralist basis for immunity predominated until after World War II, 
when Peter Medawar began working with skin grafts.  Medawar discovered that 
grafts from different individuals (an allograft) were rejected, while grafts of skin from 
the same individual to different locations were accepted (14).  It was not until years 
later that the cellular basis of this response was understood, when James L. Gowans 
identified a specific blood cell type, known as the T lymphocyte, which was 
responsible for mediating recognition of self (syngeneic) and non-self (allogeneic) 
tissues (15).  Thus, it was clear that there was a cellular component to immunity.   
Despite these seminal experiments demonstrating a cellular, lymphocyte 
component to immunity, the humoral view of immunity was still widely accepted.  In 
the mid 1950s Niels Jerne, David Talmage, and Frank Burnet developed the clonal 
selection theory (16), which stated that lymphocytes expressed receptors specific for 
antigens and that upon antigen encounter, the lymphocytes proliferated and released 
many receptors of a single specificity into serum to clear infection (17-19).  These 
experiments solidified that there was a humoral (antibody) component to immunity.  
The humoral and T cell response to infection is today referred to as adaptive 
immunity.  In 1960, Medawar and Burnet were awarded the Nobel prize for the 
discovery of acquired immunological tolerance (20) and Jerne received a Nobel prize 
in 1984 for theories concerning immune system development (21).   
Nearly a decade after the clonal selection theory, Kohler and Milstein 
demonstrated the ability to produce monoclonal antibodies from cell culture (22).  
Around the same time, the three dimensional structure of an antibody binding 
fragment, called an Fab’, was elucidated (23).  The understanding of antibody 
recognition and its potential for therapeutics has led to the development of a billion 
dollar industry with monoclonal antibodies targeting a diverse array of antigens (24).  
Thus, the role of B lymphocytes in antibody production was solidified by the early 
1970s. 
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The clonal selection theory, however, failed to explain how T lymphocytes 
recognize antigen.  Breakthroughs in understanding the antigen recognized by T cells 
came from studies of tumor graft rejection in mice by George Snell (reviewed in (25)) 
and blood cell agglutination in transfusion by Jean Dausset (reviewed in (26)).  Snell 
identified the murine version and Dausset the human version of what is now referred 
to as the major histocompatibility complex, for which both were awarded the Nobel 
Prize in 1980 (27).   
The link between T cells and MHC protein was not clear until Rolf 
Zinkernagel and Peter Doherty determined that T cell recognition was restricted to 
MHC molecules (28).  In a seminal experiment in the field of immunology, mice 
were infected with meningitis and their spleens were isolated.  T cells from in-bred 
mice were able to kill the infected splenocytes, but T cell from mice of different 
strains were unable to kill the infected splenocytes.  This demonstrated that T cells 
must recognize a ‘self’ component (MHC molecule) and a ‘foreign’ component 
(peptide), although the identity of the foreign component as a small peptide would not 
come until much later.  Zinkernagel and Doherty were awarded the Nobel prize in 
1996 for their discovery of MHC restriction in relation to T cell activity (29).  It was 
not long after the discovery of MHC restriction that Phillipa Marrack and John 
Kapplar identified the T cell component of MHC recognition, the T cell receptor 
(TCR) (30).  A number of seminal studies followed demonstrating that antibody (31, 
32) and T cell receptor diversity (33) were generated by gene rearrangement.  The 
gene sequence of a murine T cell receptor was subsequently isolated by Herman 
Eisen and colleagues, prompting the start of a new era probing the molecular basis of 
T cell antigen recognition (34, 35).    
Improvements in the ability to express and crystallize recombinant protein 
permitted the elucidation of the structures of immunologically relevant proteins.  Jack 
Strominger and Don Wiley solved the crystal structure of the human MHC molecule, 
HLA.A2, which is the most prevalent human class I MHC allele (36).  This was 
followed by studies detailing a structure of the TCR:pepMHC complex (37). All of 
these studies probing the molecular basis of antibody and T cell recognition have 
solidified the components of the adaptive immune response.  It is now well described 
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that the immune system has two components, a fast acting innate immune system and 
a slower acting adaptive immune response (T cell and B cells) that can provide 
immunological memory and prevent future infections.   
 
Innate Immunity 
 In response to pathogens, the immune system utilizes a number of cell types 
such as neutrophils, macrophages, and natural killer (NK) cells that can mediate 
inflammation relatively rapidly, within ~4 hours of infection.  The inflammatory 
response serves to deliver effector molecules to the site of infection, to form a 
physical barrier by promoting microvascular coagulation, and to increase blood flow 
to repair damaged tissue.  Neutrophils are the most short-lived of the blood cells of 
the innate immune system and engulf bacteria by phagocytosis (38).  The white pus 
often observed at a site of infection is due to the infiltration of neutrophils.  In non-
infectious states, neutrophils reside in the bloodstream and upon encounter with 
foreign substances, release chemicals and proteins of the CXCL family that promote 
migration to areas of infection (39).  The chemokines attract more neutrophils which 
are also secreting proteins that can mediate inflammation called cytokines.   
Macrophages are a much longer lived cell lineage compared to neutrophils 
and also engulf bacteria and toxins to promote inflammation (40).  The macrophages 
secrete numerous pro-inflammatory cytokines called interleukins (IL-1, IL-6, IL-8, 
and IL-12) that promote inflammation and the eventual destruction of pathogens (41).  
More recently, a continuum of macrophage differentiation states have been identified 
with important roles in immune suppression collectively referred to as myeloid 
derived suppressor cells (42).  Finally, NK cells recognize altered-self cells that lack 
MHC molecules through a variety of receptors and are important in the elimination of 
cells that are infected with virus and downmodulate MHC protein expression (43). 
 The cells of the innate immune system recognize specific pathogen associated 
molecular patterns (PAMPs) which are highly conserved among bacteria and viruses. 
Toll-like receptors (TLRs) are one class of receptors responsible for PAMP 
recognition that were initially isolated in Drosophila (44).  In humans, TLRs are 
expressed on the surface of cells of the innate immune system, and promote the 
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release of cytokines as well as the upregulation of costimulatory molecules that are 
important for the adaptive immune response (45).  For instance, dendritic cells, an 
important class of professional antigen presenting cells, upregulate costimulatory 
molecules required for T cell function upon TLR binding to bacterial or viral 
determinants (46).  TLRs provide a critical link between innate and adaptive 
immunity, in that they prime the immune response for antibody and T-cell mediated 
responses (47).  For this reason, many vaccines that consist of antigen in the form of 
DNA or protein are packaged with adjuvant, usually in the form of heat killed 
bacteria or polysaccharides to promote immunological protection.  Recently, it was 
demonstrated that T cells also express toll-like receptors, suggesting that the TLRs 
may provide some benefit to effector cells by promoting release of proinflammatory 
cytokines (48).  
 
Adaptive Immunity 
B Cells and Antibody Response in Immunity 
 Antibody Diversity and Structure - Antibodies are produced by B cells in 
response to foreign antigens.  Each antibody consists of two heavy and light chains, 
with each heavy and light chain containing variable and constant domains. The 
variable-heavy (VH) and variable-light (VL) domains mediate antigen recognition, 
with each antibody containing two VH-VL heterodimers (Figure 1.1A).  The 
remarkable diversity of the antibody repertoire (estimated on the order of 1011 unique 
receptors) is a result of 1) combinations of VH and VL gene segments, 2) somatic gene 
rearrangements that occur during development, and 3) somatic hypermutation that 
occurs in peripheral lymphoid organs (49).  The true size of the antibody repertoire, 
however, is dependent on the number of mature B cells in an individual which is 
estimated to be between 108 and 109 B cells .   
B Cell Development: B cells mature in the bone marrow, where they 
encounter soluble and cell bound self-derived antigens (50).  B cells expressing 
membrane bound antibodies that bind to self tissue either become anergic (inactive) 
or continue gene rearrangement until an antibody is expressed that does not bind to 
self-tissue.  The B cells expressing cell-bound versions of these antibodies escape into 
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the periphery, and upon foreign antigen encounter, a single B cell expressing a single 
antibody proliferates, producing soluble antibody molecules containing various 
fragment crystallizable (Fc) regions (Figure 1.1A) (51).  Naive B cells produce IgM 
isotype antibodies, and following interaction of B cells with helper CD4+ T cells, 
class switching to other isotypes such as IgG occurs (52).  Upon initial antigen 
encounter, B cells also differentiate into a memory cell population which provides 
protection and fast-acting responses upon second encounter with the same antigen 
(53).   Generation of the B cell memory population is a goal of current vaccination 
strategies to provide long-term host immunity. 
The term antibody Fc originates from initial experiments where antibody 
digestion with pepsin yielded two fragment antigen binding (Fab) molecules and one 
Fc region (Figure 1.1A).  The fragment antigen binding has been further modified, to 
create antibody single chain fragment variable proteins (scFv), consisting of the VH 
and VL region of an antibody Fab attached by a flexible linker, for therapeutic 
applications and antibody biophysical characterization (Figure 1.1B).  For instance, 
antibody scFv directed against tumor antigens have been fused to anti-CD3 
antibodies, to promote T cell activation of T cells near cancer cells (54).  The Fc 
region of soluble antibodies determines the antibody isotype; specific antibody 
isotypes (IgG,IgA,IgE) can bind to Fc receptors on the surface of various immune 
cells (i.e. NK cells) which can result in phagocytosis of pathogens bound to 
antibodies or activation of immune cells to secrete proinflammatory cytokines (55-
57).  A second mechanism of antibody action involves the binding of soluble proteins 
collectively called complement to antigen:antibody complexes (58).  A cascade of 
complement proteins direct the destruction of antigen or phagocytosis of 'foreign' 
substances.  B cell activation, however, often requires priming by helper CD4+ T cells 
of the adaptive immune system. 
 
T Cells  
 Classes of T Cells. Two classes of T cells that express αβ full-length TCRs 
mediate immunity and are defined based on their coreceptor expression (59).  
Expression of the coreceptor CD8 is associated with recognition of class I 
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peptide:MHC molecules, and CD8+ T cells are referred to as cytotoxic T lymphocytes 
(CTLs) because these cells mediate lysis of target cells expressing cognate pepMHC.  
CD8 acts as a coreceptor to bind to an invariant region of the α3 domain of MHC 
molecules (60) and improves class I restricted TCR sensitivity to antigen by 
recruiting kinases, such as LCK, to the T cell receptor signaling complex, initiating T 
cell activation (61).  Upon antigen encounter, CD8+ T cells release a variety of 
cytokines, including interleukin-2, that allow for expansion of T cells of the same 
specificity, a process called clonal selection.  The CTL releases granzymes and 
perforins that ultimately cause lysis of the pepMHC expressing target cell (62).   
 A second class of αβ TCR expressing cells, called CD4+ (helper) T cells, 
recognize peptides in the context of MHC class II molecules.  The coreceptor CD4 
binds to nonpolymorphic regions of the class II MHC, stabilizing the TCR:pepMHC 
interaction and initiating T cell signaling (63,64).  TCR binding results in 
differentiation of the CD4+ T cells into Th1, Th2, and Th17 cell types, with 
differentiation determined by interaction with other immune system cells and the 
local cytokine environment (65).  For instance, the presence of IL-12 and the absence 
of IL-4 leads to differentiation of CD4+ T cells to the Th1 fate (66).  Th1 cells are 
specialized for macrophage activation, permitting macrophages to release cytokines 
and other mediators of the immune response (67).  Th2 cells primarily activate B 
cells, and contribute to the humoral, antibody response to infection.  Th17 cells are a 
recently defined subset of CD4+ T cells that are important for mediating immunity at 
mucosal barriers, and excessive differentiation into the Th17 phenotype is thought to 
play a role in autoimmune disease (68). CD4+ T cells can prime CD8+ T cells for 
activation, through CD4+ T cell interaction with dendritic cells (69).  CD4+ T cells 
express CD40L (ligand) upon T cell activation and bind to CD40 on dendritic cells, 
which can subsequently prime a CD8+ T cell response (70,71).  A fourth class of 
CD4+ T cell, with the phenotype CD4+,CD25+, FOXP3+ are referred to as regulatory 
T cells and represent another newly defined class of T cells that serve as a safe-guard 
to prevent autoimmunity and maintain peripheral tolerance (72). 
 Other T cell lineages exist that express a different class of TCR, called γδ T 
cells, comprise <5% of the total T cell population (73). Unlike αβ TCR positive T 
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cells, γδ T cells recognize non-classical MHC molecules, such as the glycopeptide 
CD1c, and these cells are thought to provide protection in the gut and other mucosal 
barriers.  The γδ lineage of T cells also demonstrates some components of innate 
immunity, in that these cells can perform phagocytosis and recognize cellular stress 
signals including pathogen associated molecular patterns (PAMPs) through TLRs.  
Nonetheless, the γδ T cell lineage undergoes gene rearrangement like αβ TCRs, and 
thus is considered a component of the adaptive immune system despite their innate 
like functions.  
  Development of αβ T Cells. T cell recognition is restricted to MHC antigens 
during development in the thymus (74).  Different combinations of variable α and β 
gene segments create diversity among αβ TCRs.  A conservative estimate suggests 
that in human TCRs there are at least 1400 combinations of TCR α and β chains.  An 
additional source of TCR diversity is recombination of variable region TCR genes 
(V-J or V-D-J recombination), similar to the recombination events that occur in the 
generation of antibodies.  Cells initially start as double negative (CD4- CD8-)  
thymocytes, and rearrange alpha and beta TCR gene loci until a productive αβ TCR 
pair is formed.  T cells then progress to a double positive (CD4+ CD8+) fate.  To 
receive a survival signal, αβ TCRs must recognize a self-pepMHC.  This process of 
restricting T cells to pepMHC antigens is called positive selection, and assures that T 
cells recognize antigens in the context of self-MHC proteins (75).   
The presence of coreceptor enhances binding affinity to either class I or class 
II MHC, and T cells progress to either a CD4+ or CD8+ fate (76).  A small percentage 
of cells may escape as double positive cells, but this percentage is quite small relative 
to the number of cells that escape as single-positive CD4+ or CD8+ cells.  A 
transcription factor, called AIRE, allows for the transcription of nearly every self 
protein such that peptides derived from all 'self' protein are expressed in the context 
of MHC proteins (77). Subsequently, TCRs that bind with too high affinity to self 
pepMHC undergo cell death, a process called negative selection (78).  As a 
consequence, the affinity of most TCR:pepMHC interactions is quite low (KD=1-100 
μM).  This thymic selection process is crucial to assure that T cells do not escape into 
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the periphery that are capable of tight binding to self-pepMHC, which would 
ultimately result in T cell mediated autoimmunity.  For instance, T cells specific for 
myelin basic protein:MHC complexes have been implicated in multiple sclerosis 
disease progression (79).  The T cells that cause multiple sclerosis are thought to have 
escaped negative selection (central tolerance), and avoid peripheral T cell tolerance 
mechanisms following T cell expansion from exposure to microbial peptides that 
mimic peptides derived from MBP.  The T cells that proliferated in response to 
bacterial infection then react with myelin basic protein peptides in the context of 
MHC, resulting in autoimmune destruction of the central nervous system. 
Generation of a T Cell Memory Population. Prior to foreign antigen 
encounter, it is estimated that the initial T cell population has roughly 1 in 100,000 T 
cells specific for a given foreign antigen (80).  After antigen exposure, there is a rapid 
expansion of T cells specific for a given antigen (estimated to be 50,000-fold in 
number) (81).  Once infection has resolved, the majority of T cells specific for the 
foreign antigen undergo apoptosis, and a residual 'memory' cell population of T cells 
survives such that upon second encounter with the identical antigen, infection is 
easily cleared (82).  In the case of smallpox in humans, vaccination has been shown 
to provide T cell memory for as long as 75 years (83).   
 
Molecular Basis for αβ T Cell Antigen Recognition 
 T Cell Receptor Proteins. Recognition of antigenic pepMHC leads to lysis of 
target cells and the rapid expansion of clonal T cell populations that ultimately 
eliminate infected or transformed cells expressing ‘foreign’ antigens.  Recognition of 
these ‘foreign’ antigens, in the form of non-self peptide in the context of self MHC 
proteins, is mediated by the αβ T cell receptor (84).  The TCR is an αβ heterodimer, 
most analogous to a Fab fragment, with each chain containing a membrane proximal 
constant domain and a membrane distal variable domain (Figure 1.1C) (85).  The 
variable domains of the α and β chain mediate recognition of pepMHC. Within the 
variable domains six complementarity determining regions (CDR) or loops of the 
TCR contribute the majority of the binding energy for interaction with peptide-MHC.  
Because the TCR variable domains mediate antigen recognition, our lab has 
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previously developed a single-chain TCR variable (scTv) format (Figure 1.1D) for 
engineering and protein expression, consisting of the TCR variable domains attached 
by a flexible linker (86).  The scTv receptor format provides a potential advantage for 
TCR engineering in that yeast surface display levels of scTv are higher than full-
length TCR.  As a potential therapeutic the scTv also provides potential advantages, 
in that the scTv might have improved tissue penetration relative to soluble full-length 
TCR or cell mediated targeting strategies.   
 Major Histocompatibility Complex (MHC) Proteins.  The major 
histocompatibility complex protein is one of the most polymorphic proteins known, 
with more than 1500 variants for the human class I allele currently elucidated (87).  
The MHC proteins are also polygenic, meaning that each individual usually expresses 
three different class I MHC alleles and three different class II MHC alleles. Two 
classes of MHC proteins present to T cells: class I MHC proteins present peptides 
between 8 to 11 amino acids in size to CD8+ T cells and these MHC proteins are 
expressed on all nucleated cells in the body (88), whereas class II MHC proteins 
present longer peptides of between 12-19 amino acids to CD4+ T cells and are only 
expressed on certain professional antigen presenting cell lineages.  Notably, class I 
MHC present peptides generated by proteasome mediated destruction of intracellular 
proteins (class I MHC) (89).  In contrast, class II MHC present peptides derived from 
endocytic vesicles in macrophages, B cells and dendritic cells (class II MHC) (90).  
This allows T cells to mount a response against extracellular pathogens that are 
phagocytosed in the periphery. 
  The crystal structure of numerous class I pepMHC proteins has revealed that 
the class I binding peptides are often bulged at the center, with residues in the center 
of the peptide more TCR exposed (91).  Class I peptides generally have N and C 
terminal peptide anchor residues in close contact with the MHC (92).  Our lab has 
previously characterized class I MHC peptide binding variants, and demonstrated that 
mutations at nearly any position of the peptide will have some effect on TCR or MHC 
binding (93),(94). The class II MHC, in contrast, presents longer peptides with less 
characteristic bulge directed at the TCR (95). Thus, there are certain constraints for 
peptide binding to different MHC alleles to assure surface lifetime of peptide MHC is 
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sufficient to mediate a T cell response (i.e. weak binding peptides may be less 
immunogenic).  The requirement for MHC restriction in T cell response allows for T 
cell targeting of intracellular and extracellular pathogens (uptake by MHC Class II), 
as opposed to antibody mediated responses that are often directed against primarily 
cell surface antigens. 
 Structure of the T Cell Receptor/pepMHC Complex: The interaction of 
pepMHC with TCRs has been characterized by structural, thermodynamic, and 
kinetic studies.  The structures of numerous TCR/pepMHC complexes have shown 
that the TCR engages class I pepMHC in a diagonal orientation (Reviewed in (59)).  
TCR complementarity determining regions 3 (CDR3) interact largely with the 
peptide, while CDR1 and CDR2 are focused toward the MHC (96),(97).  Flexibility 
of the TCR CDR loops and the diversity of the T cell population (~108-1010 unique 
TCRs limited by the number of naive T cells in an individual) permits cross-reactivity 
with other peptides, allowing for recognition of a diverse array of non-self (foreign) 
antigens (98, 99). 
Relationship Between TCR:pepMHC Affinity and T Cell Activity. If binding 
between T cell receptor and pepMHC is of sufficient affinity, T cells enter various 
states of activation resulting in death of the antigen presenting cell (APC) and 
proliferation of the antigen-specific T cell (100).  Studies performed by our lab using 
TCRs engineered with greater than 1000-fold increases in affinity relative to the wild-
type TCR for foreign pepMHC (SIY/Kb) showed that improved affinity TCRs could 
mediate enhanced antigen sensitivity (IL-2 release) (101).  Our lab has now 
extensively characterized the binding parameters for murine TCR:pepMHC 
interactions, and defined a threshold delineating CD8 independent T cell activation.  
TCRs with affinities lower than KD= 1 μM can mediate T cell activation independent 
of the coreceptor CD8 (102).  Engineering of receptors with affinities below this 
threshold could provide potential advantages for experimental therapeutics because 
class I restricted TCRs could be introduced into CD4+ T cells to redirect a helper T 
cell response.  
T Cell Signaling. T cell activation is thought to require two signals: signal 1 is 
transmitted through T cell receptor (TCR) recognition of pepMHC and signal 2 is 
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mediated through costimulatory molecules on the T cell that recognize specific 
ligands on APCs, such as CD28 on T cells interacting with ligand B7 on APCs (103).  
The αβ TCR must assemble with other proteins, known as CD3 proteins, at the 
surface of T cells to mediate signal 1.  Biochemical studies have now identified that 
the minimal T cell signaling subunit consists of an αβ TCR with two heterodimers of 
CD3δε and CD3γε and a homodimer of CD3ζζ (Figure 1.2A) (104).  The CD3ζ 
subunits contain immune tyrosine activation motifs (ITAMs) which are 
phosphorylated upon T cell receptor engagement, and phosphorylation of these 
tyrosine motifs leads to downstream signaling events that mediate T cell activation 
(105).  Although it remains unclear how the full-length TCR transmits signals from 
the extracellular environment to mediate T cell activity, two predominant hypotheses 
exist.  The first proposes that a conformational change occurs upon pepMHC binding 
within the TCR constant domains that allows ITAMS to be more accessible (106).  
The alternative hypothesis supports a model of T cell receptor clustering, whereby 
engagement of multiple TCRs in close proximity leads to antigen signaling (107).  
Although the exact mechanism of TCR mediated signaling remains unclear evidence 
exists that an intracellular kinase, called LCK, interacts with ITAMs on CD3 proteins 
as one of the initial events in TCR signaling (108).  The coreceptor CD8 is known to 
sequester LCK to the immunological synapse and lower the barrier for T cell 
activation improving T cell sensitivity to antigen (61).  Another cell surface molecule, 
CD45, regulates LCK activity and is not incorporated into lipid rafts near the T cell 
receptor providing a way to regulate T cell activity (109, 110).  The numerous 
components required for T cell activity assure that there is not aberrant T cell 
reactivity with self antigens. 
 Regulatory Mechanisms to Dampen the Immune Response. Given the multiple 
ways in which the immune system can generate proinflammatory responses, a number 
of safeguards have evolved to prevent autoimmunity.  Excessive stimulation through 
CD28 leads to upregulation of CTLA-4 on CD4+ T cells, and CTLA-4 binds to B7 on 
APCs and inhibits T cell activation (111).  A new class of T cells has also been 
identified that secrete inhibitory cytokines, known as regulatory T cells (Tregs), that 
suppress CD4+ and CD8+ T cell activity.  A continuum of various states of 
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macrophage differentiation, referred to a myeloid derived suppressor cells (MDSCs) 
that are CD11b+, GR1+ also are thought to suppress T cell function (42, 112).  In 
disease states where the immune system is insufficient to provide host protection (i.e. 
T cell tolerance of cancerous tissue), therapies that inhibit these immune modulators 
may provide clinical benefit.  For instance, clinical trials are underway for various 
malignancies to evaluate anti-CTLA-4 antibodies to prevent T cell anergy (113).  In 
the setting of transplant tolerance and autoimmune disease, however, it would be 
advantageous to stimulate these immune regulatory cells (i.e. MDSCs could aid in 
tolerance of foreign tissue in transplantation) (114). 
 
Immune Response In Organ Transplantation (Allografts) 
 The T cell receptor is integral in discrimination of self and non-self tissue.  
Individuals who have had organ transplants, even from MHC-matched (HLA) donors 
must take immunosuppressive medications to avoid host vs. graft disease and 
rejection of transplanted tissue, predominantly from host T cells binding to 
transplanted tissue and mounting an immune response.  It has been reported that 
>10% of T cells can react with foreign pepMHC molecules, but the molecular basis 
for this reactivity has not been fully explained (115).    
 Two views of TCR recognition of allogeneic (foreign) MHC propose that 
either the TCR recognizes polymorphisms present among the foreign MHC allele 
with limited peptide recognition (116), or rather, that the TCR recognizes 
evolutionarily conserved residues between the foreign and self MHC molecule, with 
binding energy focused predominantly on the peptide (117).  Elucidating which 
binding orientations predominate for allo-MHC recognition has been limited by the 
fact that relatively few allogeneic peptide ligands have been identified, and 
difficulties in expressing and crystallizing TCRs. Using yeast display, our lab was 
able to engineer a stabilized scTv version of the murine 2C TCR (118).  
Subsequently, the structure of the murine 2C scTv with both self and foreign 
pepMHC demonstrated that the TCR binds pepMHC in a similar docking orientation, 
but uses different conserved residues to recognize foreign (QL9/Ld, allogeneic) and 
self (DEV8/Kb, syngeneic) MHC (97).  The implication of this study was that both 
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peptide and MHC-centric contacts with TCR mediate cross-reactivity.  More crystal 
structures, however, with self and foreign MHC ligands need to be elucidated to 
determine if this docking mode can be generalized to other foreign MHC interactions, 
which ultimately should provide insight into the molecular mechanisms of allo-
recognition.     
Crystallization of the 2C scTCRs in complex with cognate and allogeneic 
pepMHC was only made possible through the production of soluble αβ single-chain 
TCRs (scTvs) engineered by yeast display.  Difficulties in expressing soluble forms 
of other TCRs have limited analysis of T cell allorecognition, and, as a consequence, 
strategies are needed to improve TCR production as soluble molecules.  
 
Immune Response to Cancer 
Multiple studies have now demonstrated the importance of T cells in the 
elimination of human cancers.  For example, the importance of a T cell response was 
implied in recent analyses of ovarian carcinomas (119), breast carcinomas (120), 
renal carcinomas (121), and in studies involving the adoptive transfer of ex vivo 
expanded T cells in melanoma (122,123,124,125), and breast cancer (126) patients.  
In the ovarian cancer study, the five year survival rate of patients with tumor 
infiltrating T cells was 83%, in comparison to a survival rate of 44.5% in patients 
who failed to have significant T cell infiltration (119).  Intratumoral T cell infiltration 
has been strongly correlated to MHC class 1 surface expression in melanoma patients, 
suggesting that CD8+ cytotoxic T lymphocytes (CTLs) are central to cancer 
elimination (127).  Numerous tumor antigens in the form of specific pepMHC 
complexes have now been defined allowing for the generation of T cell receptors of 
defined specificity to redirect T cells towards cancerous tissue.  
One promising approach to tumor elimination involves the use of adoptively 
transferred T cells directed against tumor cells.  The regression of tumors using an 
adoptive immunotherapy approach has been demonstrated successfully subsequent to 
lymphodepletion in melanoma patients (128-130) and the persistence of T cell 
populations specific for cancerous tissue has been observed one month after transfer 
(128).  Adoptive immunotherapy strategies provide a route to target cancer tissue 
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specifically, while generating a T cell memory population that could eliminate 
residual disease.  Because CTLs against “self” peptides are deleted in the thymus 
during T cell development, individuals may be left with a T cell repertoire that is 
unable to eliminate the cancer tissue.  The absence of these T cells represents a major 
problem with current T cell based strategies: an individual may lack appropriate anti-
tumor T cells due to tolerance mechanisms that operate against self-antigens.   
To overcome the lack of tumor specific T cells, gene transfer of T cell 
receptors ex vivo provides an attractive alternative.  T cells specific for tumor 
associated antigens (TAAs) can be generated from the peripheral blood of healthy 
donors, and isolation of TCR genes specific for these TAAs allows for use in many 
patients.  Thus, a high affinity TCR specific for tumor associated pepMHC can be 
introduced into patients’ CD4+ or CD8+ T cells in vitro, and transfer of transduced T 
cells can eradicate tumors (Figure 1.3). Regression has been observed in as high as 
30% of patients following adoptive transfer of TCR gene modified T cells (131, 132).  
Recently, TCR gene transfer with an adoptive transfer protocol was used to eradicate 
metastatic melanoma in a small subset of patients in the brain (133).  Adoptive 
therapy clinical trials using TCR gene therapy are ongoing for melanoma, but it is 
unclear if the TCRs selected are of optimal affinity for targeting tumor antigen.  The 
TCR gene therapy approach holds promise for treating a variety of tumors provided 
receptors can be engineered with sufficient affinity for tumor antigen.  Our lab and 
others have previously engineered T cell receptors for high affinity, but there are still 
relatively few in vitro engineered human, high affinity TCRs. 
Challenges for Current T Cell Adoptive Therapies.  In TCR gene therapy 
based approaches, the lack of many high affinity receptors limits the possible antigens 
and tumor types that can be targeted. While multiple studies at the NIH have explored 
targeting the melanoma antigens MART-1 and GP100 (132), the in vitro binding 
affinities of these receptors have not been measured by biochemical methods.  There 
are still a multitude of other tumor associated pepMHC antigens derived from either 
mutated self or overexpressed self proteins that need to be evaluated for TCR gene 
therapy (listed in (134).  Clearly, development of straightforward methods to engineer 
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TCRs derived from tumor specific T cell clones would be of great value, and this is a 
focus of chapters 2 and 5 of this thesis. 
TCR gene transfer is also potentially dangerous in that introduced alpha and 
beta TCR chains can mispair with endogenous TCR chains to create mismatched 
heterodimers of unknown specificity, leading to autoimmunity (Figure 1.3B) (135, 
136).  Strategies that eliminate mispairing between introduced and endogenous TCRs 
need to be evaluated to avoid autoimmunity from these mismatched receptors. A 
variety of strategies have been explored to prevent mispairing, but the extent to which 
these strategies prevent mispairing has not been elucidated (137).  It is important to 
develop TCR reagents that can recognize MHC-restricted antigens, in addition to 
antibodies against cell surface antigens, to ensure that support cells, collectively 
called tumor stroma, are targeted.  Studies have demonstrated that stromal cells can 
take up peptide antigen and cross-present tumor associated peptides on MHC 
molecules (138, 139).  Targeting of tumor stroma may be necessary to destroy solid 
tumors, and antigens cross-presented on tumor stroma are potentially neglected by 
antibody based therapies (140).   
Monoclonal Antibody Based Therapeutics. - Another approach to tumor 
immunotherapy utilizes monoclonal antibodies specific for tumor associated proteins.  
In the mid-2000s, there were at least 400 monoclonal antibodies in clinical trials with 
specificity for a variety of tumor antigens (141).  Although the exact mechanisms of 
monoclonal antibody destruction of tumors remain elusive, it is thought that soluble 
antibody binding to tumor cells marks tumor cells for antibody dependent cell 
cytotoxicity or promotes activation of other immune cells in the tumor 
microenvironment.   
Some tumor cells express low levels of antigen and as a consequence, soluble 
antibodies are inefficient in destroying tumor tissue.  To improve response to low 
levels of antigen, numerous groups have developed chimeric antigen receptors 
(CARs).  The scFv CARs combine TCR activation signal 1 and signal 2 on one 
molecule, and, when endowed with the appropriate intracellular signaling domains, 
can operate independently of the full-length TCR signaling subunits (Figure 1.2B) 
(142, 143).   Transduction of CAR constructs allows for the redirection of T cell 
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mediated responses to tumor tissue in adoptive therapy formats.  The CAR constructs 
usually consist of a single-chain fragment variable (scFv) fused to intracellular 
signaling molecules.  The scFv is derived from the variable domains of an antibody 
attached by a flexible linker, while the intracellular signaling subunits almost 
exclusively include the CD3ζ subunit.  Second generation constructs contain 
additional intracellular signaling subunits that promote T cell costimulation, such as 
CD28, CD3ζ, LCK or CD28, 4-1BB, CD3ζ (144).  Antibody CAR based approaches 
are potentially limited by their inability to target tumor stroma, since antibodies often 
target cell surface proteins that are not cross-presented.  
 
Engineering T Cell Receptors in vitro For Improved Stability and Affinity 
 Difficulties in producing soluble TCRs, relative to antibodies, have limited the 
ability to characterize the binding affinities and cross-reactivities of TCRs for specific 
pepMHC. The challenges of producing T cell receptors are highlighted by the 
relatively few TCR:MHC crystal structures solved to date relative to antibodies.  As 
of 2004, less than 30 murine and human structures of the TCR and pepMHC in 
complex had been solved (59), whereas a conservative estimate for antibodies suggest 
that by 2004 more than 500 antibody structures had been elucidated (145).   
 Previously, our lab has developed a single-chain TCR format, consisting of 
only the TCR binding domains attached by a flexible linker (Vα-L-Vβ or Vβ-L-Vα) 
(reviewed in (146).  We have termed these receptors single-chain TCR-variable, by 
analogy but distinct from antibody scFv.  The ability to engineer TCRs in vitro is 
important, since the process of negative selection leaves a repertoire of T cells with 
relatively low affinity for pepMHC (KD=1-100 μM).  Our lab has previously 
developed two systems, yeast display and T cell display (147), to engineer T cell 
receptors for enhanced affinity for pepMHC (Figure 1.4).  In the course of 
engineering a number of T cell receptors, we have found that not all TCRs are 
amenable to engineering by yeast display (86) and hence, have also used a T cell 
display platform for engineering.  Others have used phage display for isolation of 
high affinity TCRs as full-length receptors (148-150), but to date there are still 
relatively few in vitro engineered human, high affinity TCRs.   
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High affinity TCRs have potential immunotherapy applications as both 
soluble and cell mediated therapies for targeting pepMHC antigens.  Soluble TCRs 
could be used in therapeutic applications, to potentially deliver a toxic payload to 
tumor cells overexpressing antigen (in the form of pepMHC) or in diagnostic 
applications to identify tissues overexpressing tumor or virus associated pepMHC 
molecules.  In cell mediated applications, high affinity TCRs could be introduced into 
patients using TCR gene therapy (Figure 1.3).  In vitro studies with high affinity 
murine TCRs have demonstrated that improving affinity beyond a certain threshold 
confers CD8 independence, allowing class I restricted TCRs to have enhanced 
sensitivity to antigen in response to foreign pepMHC, and the potential to redirect 
CD4+ T cells to class I restricted antigens (147,151). 
 
Overview of Thesis Work 
 Understanding the molecular basis of T cell receptor recognition has been 
severely limited by difficulties in expressing and crystallizing soluble forms of T cell 
receptors.  Because variable domains of the T cell receptor are all that is required to 
mediate recognition of specific pepMHC, our lab has extensively developed scTv 
molecules to study T cell receptor interaction with pepMHC.  Since the scTv 
molecules are unstable in the absence of TCR constant domains, mutations must be 
generated that permit expression of the scTv.  Yeast surface display of mutant scTvs 
has allowed for screening and isolation of TCRs of improved stability, with surface 
display correlated with soluble secretion efficiency and thermal stability (152).  
Subsequent production of soluble versions of stabilized scTv fragments permitted 
analysis of the binding properties of soluble TCRs to cognate pepMHC by surface 
plasmon resonance, as well as crystallization of single-chain TCRs to assess cross-
reactive among syngeneic and allogeneic MHC recognition, which is of great 
importance for understanding transplant rejection.   
 The stabilized scTv templates were also used to generate high affinity T cell 
receptors in vitro using yeast display.  High affinity variants of the murine CD8+ 2C 
TCR specific for pepMHC molecules SIY/Kb (101) and QL9/Ld (153) and CD4+ 3.L2 
TCR specific for the pepMHC molecule Hb/I-Ek (154) have been isolated and 
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characterized.  When the high affinity receptors were reintroduced into T cells as full-
length receptors, in all cases improvements in T cell affinity enhanced T cell activity 
in response to low levels of antigen. 
 Successes with yeast display, however, have previously been limited to 
murine T cell receptors that had antibodies specific for the properly folded Vα and 
Vβ domains of the scTv that permitted isolation of stable scTv templates for 
engineering. To translate these findings into human TCR systems, the goal of this 
thesis work was to engineer human T cell receptors in a single-chain format for 
immunotherapy applications.  Subsequently, I sought to develop ways to utilize 
single-chain TCRs in the context of T cell mediated targeting therapy, by creation of 
scTv fusions to transmembrane and intracellular proteins referred to as chimeric 
antigen receptors (CARs).  I compared the efficacy of CARs with scFv or scTv 
extracellular binding domains in targeting tumor cells and peptide pulsed cells.  
Finally, I extended another engineering platform, known as T cell display, to the 
engineering of a murine T cell receptor against a model tumor antigen. 
 In chapter 2, the engineering of improved stability variants of two human TCRs 
specific for peptides derived from human T cell lymphotrophic virus (HTLV) and 
human immunodeficiency virus (HIV) is described.  These receptors were previously 
engineered by phage display in a full-length format for enhanced affinity (148, 149), 
allowing for selection of stabilized scTvs using pepMHC streptavidin:phycoerythrin 
tetramers.  Notably, both of the engineered human receptors utilize the same human 
Vα2 gene segment (IMGT nomenclature: TRAV12-2).  Evaluation of the improved 
stability version of the HIV-specific receptor, called 868, demonstrated that few Vα 
mutations were required for yeast surface display and production as inclusion bodies 
in E. coli, suggesting that other human Vα2 gene segment may be amenable to 
engineering in an scTv format using yeast display.  Production of other soluble scTv 
molecules should allow for measurement of wild-type TCR binding affinity, as well 
as the generation of scTvs of enhanced affinity against a wide variety of clinically 
relevant human antigens.  The ability to engineer human TCRs should allow for 
future analysis of T cell receptor cross-reactivity to improve understanding of self vs. 
nonself discrimination. The soluble, human 868 scTv was also used for detection of 
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low nanomolar concentrations of HIV-specific peptide on the surface of target cells, 
demonstrating a diagnostic application of the scTv. 
 Previously, our lab has established single-chain, high affinity versions of the 
murine 2C TCR called m33 (101).  In chapter 3, chimeric antigen receptors consisting 
of 2C (low affinity) or m33 (high affinity) scTv fused to the intracellular signaling 
molecules CD28, CD3ζ, and LCK were evaluated.  The scTv constructs avoid 
mispairing with endogenous TCRs, which has been shown in murine (135) and 
human systems (136) to cause autoimmunity through generation of receptors of 
unknown specificity.  These receptors provide a potential advantage relative to other 
CAR constructs in that they may be able to target tumor stroma cross-presenting 
pepMHC.  I compared m33 full-length TCR to m33 scTv for mediating T cell 
cytokine release and demonstrate that stabilized scTv can be introduce into CAR 
constructs to redirect T cells to antigen.  I also extended this study to the HIV-specific 
868-z11 scTv engineered for improved stability by yeast display (chapter 2), and 
demonstrate that a human scTv can mediate antigen specific T cell activity in murine 
58-/- T cells.  
 A number of chimeric antigen receptors derived from antibody scFv are currently 
being explored to target a variety of tumors (155).  In chapter 4, I created a scFv 
chimeric antigen receptor derived from an antibody, called 237, isolated by Professor 
Hans Schreiber’s Lab (U. of Chicago) that recognizes a mutated glycopeptide present 
only on tumor cells.  The 237 scFv CAR contained CD28,CD3ζ,and LCK 
intracellular subunits analogous to the m33 scTv CAR described in chapter 3.  The 
237 scFv CAR mediated T cell activity in response to tumor cells expressing mutated 
glycopeptide, but not tumor cells that have been transfected with a chaperone that 
repairs the glycosylation defect.  I propose a model for CD8 contribution to scFv 
CAR activity, where CD8 coadhesion to MHC molecules that neighbor 237 
glycopeptide epitopes aid in generating T cell activation.  This finding has 
implications for CAR-mediated activity directed against tumor cells, in that tumor 
cells can downmodulate MHC molecules to evade the immune response, and in these 
instances, CAR constructs introduced into CD4+ T cells may provide less potent 
responses.  Chapter 4 also describes the modification of the original m33 scTv CD28, 
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CD3ζ, LCK construct to contain the 4-1BB intracellular signaling domain, which has 
been shown by others to improve CAR-transduced T cell persistence in vivo (144).  A 
construct consisting of m33 scTv fused to CD28, 4-1BB, and CD3ζ was compared 
with the LCK containing m33 scTv and the m33 full-length TCR.  I describe the 
requirement of endogenous LCK and LCK attached to the CAR construct in 
promoting T cell cytokine release. 
 In the final chapter, the engineering of two improved affinity variants of a murine 
TCR, called 3D, specific for the model tumor antigen WT-1/Db is described.  
Difficulties in creating stable platforms to engineer enhanced affinity T cell receptors 
led us to explore a T cell display platform that was used to isolate an improved 
affinity variant of the 2C TCR (147).  Using a similar strategy, two higher affinity 
variants of the 3D TCR were isolated, one of which permitted CD8-independent 
activation.  Professor Phillip Greenberg’s lab (U. of Washington) has isolated a 
number of human WT-1 specific TCRs that recognize an identical peptide to the 
murine 3D TCR in the context of a human MHC.  Homology was observed in a 
number of the CDR loops, suggesting that there may be some conserved interactions 
between murine and human TCRs in contacting a self-peptide.  The 3D high affinity 
variants provide valuable reagents for studying the affinity thresholds that dictate 
peripheral and central tolerance.  These TCRs should also allow for the development 
of an adoptive therapy model system to study the optimal affinity TCR range for 
targeting overexpressed self-antigen, providing maximal T cell function while 
limiting autoimmunity directed against non-malignant tissues.  
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FIGURE 1.1  Formats of T Cell Receptors and Antibodies.  (A) Schematic of an 
IgG antibody, with fragments resulting from pepsin digestion as indicated. 
Fab=Fragment Antigen Binding,  Fc=Fragment Crystallizable,  VH=variable heavy 
domain, VL= variable light domain, CH=constant heavy domain, CL= constant light 
domain, GalNc=synthetic peptide antigen. (B) Schematic and crystal structure of 237 
scFv in complex with GalNc (Magenta) synthetic glycopeptide (PDB: 3IET) (259).  
(C) Schematic of an αβ T Cell receptor binding to pepMHC.  TCR domains:  
Vα=Variable alpha, Variable beta, Cα=Constant alpha, Cβ=Constant beta. (D) 
Schematic and crystal structure of the 2C TCR (shown as scTv) with SIY/Kb (PDB: 
1G6R) (91).   
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Figure 1.2. T Cell Receptor and Chimeric Antigen Receptor Complexes. (A) 
Schematic of the T cell receptor signaling complex with associated CD3 subunits. 
Yellow squares= immune tyrosine activation motifs (ITAMs). CD8 coreceptor binds 
to the intracellular kinase, Lck (yellow starburst), sequestering the kinase to the CD3 
subunits. (B) Schematic of two chimeric antigen receptor that can mediate T cell 
activity independently of the endogenous CD3 subunits. 
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Figure 1.3. Overview of Adoptive T Cell Therapy with TCR Gene Transfer, and 
Potential for Generation of Receptors of Unknown Specificity. (A) An overview 
of TCR gene therapy. Green = Retroviral supernatent containing TCR genes.  Blue = 
T cells expanded from patient (pink). Figure (A) from Schmitt et al. (197). 
reproduced with permission from Mary Ann Liebert publications. (B) TCR gene 
transfer into host T cells can either involve pairing between introduced α and β 
chains, or can cause creation of mismatched receptors between introduced (tumor-
specific) and endogenous TCR, potentially leading to autoimmunity. 
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Figure 1.4. Yeast and T cell Display Platforms for TCR Engineering. (A) Yeast 
display of full-length and single-chain TCR variable (scTv).  Yellow starbursts 
represent non-native cysteine residues in full-length yeast displayed TCR. (B) T cell 
receptor surface expression on 58-/- T cells in the absence of CD8.  Pertinent features 
of each display system as described.  Subunits as indicated.  δ=CD3 delta, ε=CD3 
epsilon, γ=CD3 gamma, ζ= CD3zeta 
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CHAPTER TWO 
 
IDENTIFICATION AND ENGINEERING OF HUMAN VARIABLE 
REGIONS THAT ALLOW EXPRESSION OF STABLE  
SINGLE-CHAIN T CELL RECEPTORS 
 
Introduction 
 
T cell receptors (TCRs) mediate recognition of a foreign or self-peptide 
presented in the context of a self major histocompatability (MHC) complex protein 
(59).  During development, T cells that express the highest affinity receptors are 
deleted in the thymus (negative selection).  Survival of the T cell, however, depends 
on a minimal affinity for self MHC (positive selection), assuring that T cell 
recognition is MHC restricted (76).  After development, if recognition of 
peptide:MHC (pepMHC) is of sufficient affinity, the T cell becomes activated and 
secretes cytokines or causes lysis of the target cell.  The affinity of TCR:pepMHC 
interactions are relatively low, with KD values in the range of 1 to 500 μM (84, 100, 
156).  
In recent years, in vitro engineering by yeast and phage display has yielded T 
cell receptors with >1,000 fold improvements in affinity for class I MHC ligands 
(101, 148-150, 157, 158) and class II MHC ligands (154). To date there have been 
only a few MHC-restricted human TCRs engineered for improved affinity by phage 
display (reviewed in (159)).  These receptors were engineered in a full-length TCR 
format (148-150), with the addition of two non-native cysteines in each of the TCR 
constant domains to facilitate TCR heterodimer formation through an interchain 
disulfide bond (160).  The addition of this disulfide bond allows the TCR to be 
expressed on the surface of yeast (86) or phage (160).   
Other affinity engineering efforts have focused on using a single-chain TCR 
(scTv) format, consisting of the variable domains of the T cell receptor connected by 
a flexible linker (Vα-linker-Vβ or Vβ-linker-Vα; called scTv here to distinguish it 
from antibody scFv fragments, and from single-chain TCRs that contain three 
domains, typically Vα, Vβ, and Cβ; (161-163)).  Although analogous to antibody 
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fragments in many aspects, unlike antibody scFv, the scTv requires mutations to 
allow for stable expression of the variable domains in the absence of the constant 
domains (86). Previously, scTv fragments have been isolated by yeast display through 
random mutagenesis and subsequent selection with clonotypic antibodies to select for 
mutations that stabilize the scTv and allow for yeast surface expression and/or 
thermal stability (154, 164, 165). These stable scTv scaffolds were subsequently used 
for engineering receptors of enhanced affinity and for expression as stable, soluble 
scTv (154, 157, 166).   
Like scFv fragments compared to the full antibody molecule, scTv fragments 
potentially afford significant advantages compared to the full-length TCR format for 
engineering, soluble protein expression, and therapeutic potential.  Higher surface 
levels of the scTv can be achieved relative to the full-length TCR in the yeast display 
system (86).  This allows for more TCR molecules to be displayed on the surface of 
each yeast cell, and improved avidity effects in the detection of peptide-MHC 
multimers.  In addition, the scTv is produced as a single-polypeptide, which avoids 
the requirement for production of each TCR chain as separate polypeptides.  This 
allows for production of large quantities of scTv fragments in relatively short time in 
comparison to proteins expressed and refolded in the full-length format.  Most 
importantly, the scTv has potential applications as therapeutic or diagnostic reagents 
in vivo similar to scFv fragments, for example as bispecific single-chain molecules 
(167) or as immunotoxins (168). The scTv has the added potential of improved tissue 
penetration because of the reduced size of the scTv relative to the full-length receptor. 
This is especially important in cases where the TCR is directed against a tumor 
antigen, where tumor stroma could be targeted to effectively destroy cancerous cells 
(139, 140, 169).  
Previous efforts to engineer single-chain TCRs were dependent on having 
probes available to assess folding of the TCR Vα and Vβ domains. In the well-
characterized 2C (164) and 3L.2 (154) TCR systems, stabilized scTv fragments were 
identified by probing with clonotypic antibodies that recognized the conformation of 
the properly folded Vα and Vβ domains.  Because the wild-type affinity of these 
receptors for specific pepMHC is relatively low, pep:MHC tetramers could not be 
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used to detect properly folded, stabilized scTv fragments. It has been known for some 
time that expression of the extracellular regions of the TCR as soluble protein is often 
problematic (59), and that the scTv format is typically unstable (86). The explanations 
for scTv instability are probably analogous to the long-standing observations that 
particular VH families are more stable as scFv than other VH families. Thus, the 
human VH3 family confers enhanced stability, but stability is influenced by 
framework residues and complementarity determining regions (CDRs) (170).  Efforts 
to understand the structural basis of these effects are important because various scFv 
fragments as bispecific proteins are currently in various phases of clinical testing 
(171), and the development of a single, highly stable human scFv platform for 
different antigen specificities would be desirable (172).  To this end, scFv libraries 
with randomized residues in all six CDR loops have been produced to obtain 
antibodies with high-affinity for various antigens (173). 
In the current study, I explored whether human scTv fragments might also be 
developed using a single platform, allowing the natural antigens of the TCR, peptides 
bound to HLA, to be targeted.  I used in vitro engineered, high-affinity T cell 
receptors in a single-chain format to isolate the first human stabilized scTv fragments 
(Vβ-linker-Vα), and I determined various features of the scTv that allowed them to 
be expressed as stable proteins, both on the surface of yeast and in soluble form from 
E. coli.  High-affinity TCRs were used as templates for random mutagenesis (error-
prone PCR), and stabilized scTv fragments were isolated by selection with soluble 
peptide:HLA-A2 tetramers.  I describe the isolation of variants of two stabilized, 
human scTCRs, the A6 scTv that is specific for a peptide derived from the human T 
cell lymphotrophic virus Tax protein (peptide: Tax11-19, LLFGYPVYV), and the 868 
scTv that is specific for a peptide derived from the human immunodeficiency virus 
Gag protein (peptide: SL977-85, SLYNTVATL).  Both of these TCRs used the same 
exceptionally stable Vα domain: Vα2 (IMGT: TRAV12 family), whereas other 
human scTv fragments that were not able to be displayed, contained other Vα 
regions.  I also demonstrated that a single polymorphic residue at position 49 of the 
Vα2 controlled susceptibility to thermal denaturation and influenced the stability of 
the corresponding Vβ domain of the scTv.  Furthermore, the two scTv fragments 
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could be expressed in soluble form from E. coli and were capable of recognizing their 
cognate peptides bound to HLA-A2 on antigen presenting cells. 
 
Materials and methods 
 
Antibodies, Peptide/HLA.A2 Tetramers, and Flow Cytometry 
 Antibodies used to detect yeast surface expression included: anti-human 
Vβ5.2, clone 1C1 (FisherThermo Scientific), anti-HA eptiope tag clone HA.11 
(Covance), anti-human Cβ clone 8A3 (Endogen/Pierce), anti-human Cα clone 3A8 
(Endogen/Pierce), goat anti-mouse IgG F(ab’)2 AlexaFluor 488 secondary antibody 
(Invitrogen), goat-anti-mouse IgG F(ab’)2  AlexaFluor 647 secondary antibody 
(Invitrogen), and streptavidin-phycoerythrin (SA:PE, BD Pharmingen). Peptides that 
bind to HLA.A2 (Tax11-19: LLFGYPVYV, NYESO-Val157-165: SLLMWITNV, SL977-
85 (HIV-Gag): SLYNTVATL, and WT-1126-134: RMFPNAPYL) were synthesized by 
standard F-moc (N-(9-fluorenyl)methoxycarbonyl) chemistry at the Macromolecular 
Core Facility at Penn State University College of Medicine (Hershey, PA.). HLA.A2 
heavy-chain was produced as inclusion bodies and refolded in vitro with HLA.A2 
binding peptides and human β-2 microglobulin as described (174).  The HLA.A2 
heavy chain contains a biotinylation substrate sequence which allows for in vitro 
biotinylation (Avidity, BirA enzyme) and subsequently for formation of 
strepavidin:phycoerythrin peptide/MHC tetramer.  All tetramer and antibody staining 
of yeast cells was performed on ice for 45 minutes using ~1x106 cells.  Cells were 
subsequently washed with 500 μL PBS/BSA (0.5%) and analyzed by flow cytometry 
with an Accuri C6 flow cytometer.  
 
Cloning and Expression of Single-Chain and Full-Length T Cell Receptor Genes in 
Yeast Display Vectors 
 The single-chain genes for TCRs were synthesized by Genscript (Piscataway, 
NJ) with mutations originally isolated for improved affinity by phage display of full-
length TCR with a non-native disulfide bond in the C regions (160).  The TCRs are 
specific for various peptides in the context of HLA.A2: the A6 mutant clone 134 (KD 
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= 2.5 nM) specific for Tax from human T cell lymphotrophic virus (148), the 1G4 
mutant clone C49 (KD = 1.3 nM) specific for NYESO (175), and an 868 mutant (KD 
of at least 10 nM) specific for human immunodeficiency virus Gag peptide SL9 
(149). For the 868 mutant, the most prevalent clone listed from CDR2β (YVRGEE, 
affinity mutations underlined) and CDR3α ( CAVRGAHDYALN) was generated 
(149). The scTv genes (Figure 2.1), consisted of the variable domains attached by the 
linker region GSADDAKKDAAKKDGKS. The scTv genes were introduced into the 
yeast display vector pCT302 using NheI and XhoI restriction sites.  
For construction of full-length TCR constructs, V region genes were 
introduced into human full-length VαCα and VβCβ as described (86, 160).  In brief, 
Vβ genes of 868 and A6 were introduced into the p315 plasmid as a fusion to AGA-2 
by ligation into NheI and BglII restriction sites and a BglII site was introduced into 
the Cβ gene. Vα genes were introduced into NheI and BamHI sites, and a BamHI site 
was introduced into the Cα gene, and both were cloned into a pCT302 secretion 
plasmid. The full-length TCR constructs contained a non-native Cys in each constant 
domain (α: Thr48Cys, β: Ser57Cys) to facilitate formation of a disulfide bond (160). 
C region cysteine residues that normally participate in an interchain disulfide bond in 
the stalk region were replaced with a stop codon and the Cβ cysteine at position 71 
was mutated to a serine (Cβ: Cys71Ser).   
scTv fragments and VβCβ for full-length TCR constructs were expressed 
from yeast display plasmid pCT302 (Vβ-L-Vα scTCRs) (176) or p315 
(VβCβ, generously provided by K. Dane Wittrup, MIT) which contain a galactose-
inducible AGA2 fusion and allow for growth in Trp- media or Leu- media 
respectively. VαCα for full-length TCR constructs was expressed from pCT302-
secreted, a galactose-inducible system that allows for growth in Trp- media.  Gene 
induction involved growth of transformed EBY100 yeast cells to stationary phase in 
selection media followed by transfer to galactose containing media.  
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Construction, Display, and Selection of Mutated scTv Yeast Display Libraries 
 Error-prone PCR was used to generate random mutations, as described 
previously (86). PCR products were electroporated along with NheI and XhoI 
digested vector into yeast strain EBY100 to generate libraries by homologous 
recombination. Random mutational libraries of the A6, 868, and 1G4 scTv genes 
were induced in galactose containing media (SG-CAA) for 48 hours, washed with 
500 μL 0.5% PBS/BSA, and stained with corresponding pep:MHC SA/PE tetramers 
(100 nM). Cells were washed (5 ml, 0.5% PBS/BSA), and the most fluorescent cells 
were selected using either a MoFlo (Cytomation) or a FACS Aria (BD Bioscience) 
high-speed sorter.  In some cases, libraries were subjected to additional rounds of 
thermal stability sorting whereby yeast cells were incubated at higher temperatures 
(A6: 42°C for 45 minutes, 868 40°C for 30 min) prior to staining.  The percent 
collected and pertinent details of each sort are provided below. 
 A6 scTCR. 5 Sorts on initial error-prone Libray: Sort 1:, top 0.5%, 500,000 
cells, Sort 2: top 0.5%, 210,000 cells, Sort 3: top 0.5%, 150,000 cells, Sort 4: top 
0.5%, 100,000 cells, Sort 5: top 0.5%, 100,000 cells.  After 5 sorts, a clone was 
isolated that showed detectable binding to peptide:MHC tetramer.  This clone was 
then used as a template for an additional round of error-prone mutagenesis.  The 
second error-prone library was sorted twice: Sort 2-1: top 0.5%, 300,000 cells, Sort 2-
2: top 10%, 1,000,000 cells.  Sort 2-3: after induction in galactose containing media, 
preincubated yeast at 42°C in water bath for 45 minutes and then stained with 
Tax/HLA.A2 tetramer at 100 nM for 45 minutes on ice and collected top 0.7%, 
350,000 cells.  Individual yeast cell clone were selected from the population isolated 
after this sort and tested for resistance to thermal denaturation at 40°C (Clones X1-
X20).   
 868 scTCR. 1 Sort on initial error-prone library and 1 round of temperature 
stability sorting. Sort 1: top 2%, 500,000 cells, Sort 2: after induction in galactose 
containing media, preincubated yeast at 40°C in water bath for 30 minutes, stained 
with Tax/HLA.A2 tetramer at 100 nM for 45 minutes on ice, and collected the top 
0.5%, 21,000 cells.  Cells were expanded in selection media and individual yeast 
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clones were isolated and tested for resistance to thermal denaturation at 40°C (Clones 
Z1-Z20). 
 
Cloning of Single-Site or Multiple-Site scTv Mutants 
 The PheVα49Ser mutation was introduced using Quikchange Lightning Kit 
(Stratagene, Agilent Technologies) with forward primer: 5’ GGTAAATCTCCA 
GAATTGATCATGTCCATCTACTCTAATGGTGACAAAGAAG 3’  
 and reverse complement primer: 5’ CTTCTTTGTCACCATTAGAGTAGAT 
GGACATGATCAATTCTGGAGATTTACC 3’.  The 868 scTv with CDR2β 
(Sequence: YYEEEE) and CDR3α (Sequence: CAVRTNSGYALNFG) wild-type 
residues was synthesized by Genscript.  The high affinity mutations for each CDR 
were introduced into this template by splicing by overlap extension (SOE) PCR 
(177). 
   
Expression in E. coli, Folding, and Biotinylation of Soluble scTv Fragments  
 The 868-Z11 and A6-X15 scTv mutants were introduced into the pET28a 
expression vector using NcoI and EcorI (868-Z11, forward primer:  
5’TATACCATGGGCAGCAGCCATCATCATCATCAT 
CACAGCAGCGGCCTGGTGCCGCGCGGCAGCGAAGCTGGTGTTACTCAATC
TCC 3’ 868-Z11 reverse primer: 
AAATGAATTCTTAAATATGTGGAGTAACCCAAAAAGAAG TACC).  
Plasmids were transformed into the BL21 cell line, and after culture and gene 
induction cells were passed through a microfluidizer and inclusion bodies were 
isolated and protein purified as described (178). scTv proteins were folded from 
inclusion bodies and purified with Ni agarose resin (Qiagen, Valencia, CA) followed 
by gel filtration (Superdex 200).  Folded proteins were biotinylated using N-
hydroxysuccinimide (NHS) biotin ester (EZ-Link Sulfo-NHS-LC-Biotin Kit, 
Pierce/Thermo Scientific). Biotinylation was verified by gel-shift with streptavidin by 
SDS-PAGE.  
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Binding of scTv Proteins Measured by Surface Plasmon Resonance  
 The binding of purified refolded scTv proteins to cognate peptide-HLA.A2 
was monitored with surface plasmon resonance using a Biacore 3000 instrument. 
Complexes of the Tax11-19 and SL977-85 peptides with HLA.A2 were generated by 
refolding from bacterially-expressed heavy chain and β2m inclusion bodies as 
previously described (179) . Due to the high affinities of the scTv proteins, a kinetic 
titration assay was utilized, in which increasing concentrations of analyte were 
sequentially injected over the surface without the requirement for disruptive 
regeneration injections (180). Experiments were performed with 868-Z11 and A6-
X15 amine coupled to a standard CM5 sensor chip. Peptide/MHC analyte was 
sequentially injected at various concentrations. The amount of immobilized scTv was 
kept below 500 RU and the flow rate was set to the maximum of 100μL/min to 
minimize mass transport effects. Data were analyzed using Biaevaluation 4.1 as 
described (180). Solution conditions were 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 
mM EDTA, 0.005% surfactant P-20, 25 ºC.  SPR experiments were performec by 
Francis Insaidoo and Kurt Piepenbrink in Professor Brian Baker's Lab (U. Notre 
Dame). 
   
 Binding of scTv Proteins to Peptide-Loaded Antigen Presenting Cells 
To examine binding of soluble scTv protein to peptide presented by HLA.A2 
on cells, T2 cells (HLA.A2+) were incubated for 2 hrs with various concentrations of 
peptides.   Cells were then washed twice with 0.5% PBS/BSA, and incubated at room 
temperature for 30 minutes with biotinylated scTv at various concentration.   Cells 
were washed twice with 0.5% PBS/BSA, followed by incubation with SA:PE for 30 
minutes at room temperature.  Cells were washed twice and analyzed using an Accuri 
C6 Flow Cytometer. 
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Results 
 
Yeast Display of Human Single-Chain TCRs 
 To determine whether human TCRs could be expressed in single-chain 
formats, I cloned three human TCRs (Figure 2.1A) that had high-affinity for their 
respective pep-HLA.A2 ligands, thus allowing the pepMHC to be used as high-
affinity probes for properly folded and associated VαVβ binding sites. The TCRs 
were engineered previously for higher affinity, using a full-length TCR format and 
phage display (148, 149, 175). The variable domains contained various mutations in 
the CDRs that conferred high-affinity, and they were fused by a linker peptide (L) in 
the orientation Vβ-L-Vα (Figure  2.2).  The single-chain constructs were cloned at 
the C-terminus of the yeast cell wall protein Aga2, followed by a hemagglutinin (HA) 
peptide tag for detection of displayed proteins. 
Yeast cells containing the 1G4, A6 and 868 scTv fusions were induced, and 
the cells were stained with an anti-HA antibody (Figure 2.1B). All three constructs 
showed high levels of expression of the HA tag, as evidenced by a positive 
population (the negative population has been found in all yeast displayed systems, 
and is due to a fraction of yeast cells that lose the plasmid during induction).  To 
detect properly folded VαVβ domains, the respective peptide/A2 tetramers were used 
for staining the same induced yeast cells.  As expected, based on previous studies 
with various scTv fragments (86), neither the 1G4 nor A6 scTv were positive with 
their respective cognate pep/HLA.A2 ligands (Figure 2.1B), consistent with the 
absence of properly folded scTv proteins on the surface of yeast. Staining of the 1G4 
and A6 cells with an antibody to Vβ13 was also negative (unpublished data), 
confirming that these scTv proteins were not expressed on the yeast surface.  
Surprisingly, the 868 scTv was positive for staining with its cognate ligand, 
SL9/HLA.A2, even at the concentration of 10 nM (Figure 2.1B).  This represented 
the first time that a scTv fragment could be detected as a properly folded protein, 
without the need for random mutation and selection (86, 154, 164).   
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Engineering of Stabilized Surface Displayed scTv Fragments by Random 
Mutagenesis 
Although the features of the 868 V regions that allowed display were 
unknown, this TCR uses a Vβ (Vβ5) that differs from 1G4 (Vβ13) and A6 (Vβ13), 
while it uses a Vα that is similar to A6 (Vα2).  This may imply that the Vβ5 region of 
868 confers stability on the protein.  To gain insight into the mechanisms that enable 
scTv stability and surface display, I performed mutagenesis and selections for 
displayed proteins. First, to determine if the 1G4 and A6 scTv could be stabilized by 
specific V region mutations, the scTv genes were subjected to rounds of random 
mutagenesis and libraries were sorted with pep/HLA.A2 tetramers to isolate scTv 
mutants with improved surface expression.  Despite multiple efforts, through various 
rounds of mutagenesis and sorting with NYESO/HLA.A2 tetramers, yeast displayed 
1G4 scTv could not be isolated (data not shown).   
In contrast, stabilized mutants of the A6 scTv were isolated after mutagenesis 
and sorting with the Tax/HLA.A2 tetramers (100 nM). Previous experiments with the 
mouse TCRs 2C and 3.L2 demonstrated that selection of scTv fragments with 
increased resistance to thermal denaturation yielded mutants with significantly higher 
levels of display that correlated with soluble secretion efficiency (154, 165).  
Consequently, the A6 scTv library was sorted with Tax/HLA.A2 tetramer after 
incubation at a higher temperature (42°C) and several mutants, including a clone 
called A6-X15 with improved yeast surface levels were isolated (Figure 2.3). The 
scTv mutant A6-X15 (fluorescence intensity FI=1600) was expressed at higher 
surface levels than the A6 template scTv (FI=50) or the full-length TCR (FI=200) 
(Figure 2.3), with stabilized C region cysteines, as monitored by Tax/HLA.A2 
tetramer.  In the full-length A6 TCR, each of the Cα and Cβ antibodies detected 
higher surface levels than tetramer, suggesting that the fully folded and assembled 
dimer represents only a subset of the total α and β chains on the surface.  Notably, 
introduction of the Vβ mutations from A6-X15 into the 1G4 scTv, which shares Vβ 
usage with A6, did not allow for surface expression of the 1G4 TCR (data not 
shown). 
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 Based on our previous results (154, 165), I also sought to identify mutants of 
the 868 scTv that would exhibit increased stability.  The 868 scTv gene was randomly 
mutagenized by error-prone PCR, and the library was subjected to several rounds of 
sorting with SL9/HLA.A2 tetramer, including a round after incubation at 40°C.  
Various temperature stable clones were isolated, including a mutant called 868-Z11 
that bound to SL9/HLA.A2 tetramer at concentrations as low as 1 nM as detected by 
flow cytometry (Figure 2.4 and data not shown).  Clone 868-Z11 exhibited improved 
surface levels that were almost ten-fold improved relative to the 868 scTv template 
(Figure 2.4). In addition, like the A6 TCR, the scTv forms of the 868 TCR were also 
detected at higher levels than the full-length format that contained C regions with the 
stabilizing cysteines (Figure 2.4). This demonstrated that the single-chain format 
allows for much higher surface levels of productively arranged Vα:Vβ pairs relative 
to the full-length display format. This is consistent with a previous finding using the 
mouse 2C system, comparing the temperature-stabilized scTv and full-length TCR 
formats (86).   
To examine what mutations in the A6 and 868 scTv conferred enhanced yeast 
surface levels and temperature stability, various clones, including A6-X15 and 868-
Z11, were sequenced (Figure 2.5).  The A6-X15 clone showed only mutations in the 
Vβ13 region, with no mutations in the Vα2.  Several of these Vβ mutations (A52V, 
N63D, N66K, Q106L) were also shared with the stabilized clone A6-X3 (Figure 
2.4A).  Thus, it appeared that in A6, the Vα2 region, but not the Vβ13 region, was 
sufficiently stable to allow its expression, proper folding, and assembly with the 
mutated Vβ on the yeast surface.  
In contrast to the A6 scTv mutants, the stabilized 868 scTv clones did not 
show any shared mutations in the Vβ region, but they contained a single shared 
mutation in the Vα2 region, F49αS (Figure 4B) (Note that the numbering follows that 
used in the pdb file of A6; based on IMGT sequences, this residue is numbered 55).  
Interestingly, the Ser49 residue is also found in the Vα2 of the A6 TCR, and 
represents a polymorphism at this position (Figure 2.2).  
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Polymorphic Residue 49 of Vα2 Influences Vα and Vβ Domain Stability 
As indicated, the sequences of the five most stable 868 scTv clones (out of 20) 
isolated after temperature stability sorting shared a single Vα mutation, PheVα49Ser, 
and this was the only Vα mutation present in the most stable 868 clone, 868-Z11 
(Figure 2.5B).  To assess whether this mutation alone, and not the Vβ mutations, was 
responsible for the enhanced stability of the 868-Z11 mutant, the PheVα49Ser mutation 
was introduced into the 868 scTv.  Staining of this mutant after incubation at 40°C 
showed that this single mutation provided the protein with improved resistance to 
thermal denaturation, resulting in over a ten-fold increase in surface level (Figure 
2.6). 
 
Relative Effects of CDR and Serα49 Mutations on Yeast Display of scTv 
Our previous work with the mouse TCRs 2C and 3.L2 have shown that some 
CDR mutations can also confer increased stability to the scTv format (154, 164). It is 
possible that the 868 CDR mutations that were selected for higher affinity binding to 
SL9/HLA.A2 also contributed to stability of the scTv format.  Accordingly, the wild-
type CDR residues were cloned into the 868 scTv format (WT), with either a Pheα49 
or Serα49 residue. To approach this question, I could not use the tetramer for 
detection, due to the low affinity of the wild-type TCR. Thus, an antibody to the TCR 
Vβ5 domain was used as a surrogate to assess surface levels (Figure 2.7). The WT 
868 scTv with the Serα49 residue showed significantly improved surface levels, 
relative to the WT 868 scTv with the Pheα49 residue, which was barely detectable 
with the anti-Vβ5 antibody.  Although the Serα49 residue yielded enhanced surface 
levels with the high-affinity mutations (MUT) in the CDRs, in this case even the scTv 
with the Pheα49 residue was easily detected with the anti-Vβ5 antibody (Figure 2.7).  
Thus, the CDR mutations that yielded higher affinity also contributed to enhanced 
stability. I have observed a reciprocal selection scenario, in which stabilizing 
mutations in the CDR1α of a scTv also yielded higher affinity (154).  
 To further investigate whether the high-affinity mutations in the CDR2β 
and/or the CDR3α were responsible for the enhanced surface stability, the wild-type 
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CDR2β and CDR3α sequences were individually introduced into the template high-
affinity 868 scTv, with the Pheα49 or Serα49 residue, and yeast surface levels were 
monitored by staining with anti-Vβ5 antibody.  The high-affinity mutations in 
CDR3α conferred improved Vβ surface levels as monitored with the anti-Vβ5 
antibody, in comparison to the WT scTv with Pheα49 (Figure 2.7).  In contrast, the 
high-affinity mutations in CDR2β did not increase substantially the Vβ surface levels 
in the presence of Pheα49 but appeared to act synergistically in the presence of Serα49.  
Thus, it appears that both CDR mutations and the Serα49 mutation provided enhanced 
stability to the scTv format of this TCR.  The maximal scTv surface levels observed 
for binding of SL9/HLA.A2 tetramers to proteins that contained the high-affinity 
mutations (Figure 2.7) also substantiated these findings.      
 
Expression of Soluble Human scTv Proteins in E. coli, and Peptide:HLA.A2 Binding 
 Our previous studies with mouse TCRs 2C and 3.L2 have shown that the 
generation of yeast surface displayed mutants of the scTv proteins allowed the 
mutants to be expressed in E. coli in both secreted form and refolded from inclusion 
bodies (154, 181, 182). To determine if this were possible with the human scTv 
mutants, the A6-X15 and 868-Z11 scTv genes were cloned into an E. coli expression 
vector and the induced E. coli cells expressed the expected size proteins (data not 
shown).  The scTv proteins were refolded from inclusion bodies with yields of greater 
than 1 mg/L of culture, yielding purified scTv proteins of the expected 30 kDa 
(Figure 2.8A). 
Two different binding studies were conducted.  First, surface plasmon 
resonance (SPR) was performed with purified peptide/HLA.A2 binding immobilized 
scTv to determine solution binding affinities and kinetics. A kinetic titration 
experiment was performed, obviating the need for potentially destabilizing 
regeneration steps necessary when high affinity interactions are studied with SPR 
(180). Analysis of the data for the A6-X15-Tax/HLA.A2 and 868-Z11-SL9/HLA.A2 
interactions yielded nM and pM binding affinities for the A6-X15 and 868-Z11 
interactions, respectively (Figure 2.8B-C). The values determined reflected the 
affinities seen with the full-length proteins and confirmed the single-chain constructs 
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retained specificity and high-affinity for their cognate ligand. Differences with the 
previously published affinities (148, 149, 183) may reflect difficulties quantifying 
high affinity binding via SPR, or possibly an influence of the mutations generated via 
yeast display, or the linker, on binding affinity. These possibilities are currently being 
investigated. 
In a second approach, I determined whether cell surface pep/HLA.A2 
complexes could be detected with soluble scTv protein. The 868 scTv protein was 
biotinylated using a biotin-succinimidyl cross-linking agent that reacts with free 
amines (the 868 scTCR linker contains multiple lysines, whereas the scTv contains no 
lysines in the CDR loops). The HLA.A2-positive human cell line T2 was loaded with 
SL9 peptide or Tax (868-null) peptide at 10 μM and cells were subsequently 
incubated with various concentrations of biotinylated-868-Z11 scTv followed by 
streptavidin:PE at room temperature (Figure 2.9A).  Soluble 868-Z11 scTv detected 
SL9 peptide loaded cells at scTv concentrations below one nanomolar, whereas cells 
loaded with the null peptide Tax were not positive even at the highest concentration 
of 868-Z11 scTv (Figure 2.9A).  The concentration that yielded 50% maximal 
staining, an estimate of the KD of the reaction, was approximately 4 nM scTv (Figure 
2.9B).   
To examine the peptide sensitivity of binding by the scTv, the SL9 peptide 
was titrated on T2 cells and the antigen presenting cells were stained with 
biotinylated 868-Z11 scTv at 100 nM (Figure 2.9C).  Without any optimization of 
staining signal, the scTv detected the peptide at concentrations as low as 10 nM. The 
scTv fragments appear to be quite stable, as even after storage at 4°C for over one 
year, the protein was able to bind target cells loaded with low nanomolar peptide 
concentrations (data not shown). 
 
Discussion 
 
 It has been known for many years that the expression and crystallization of the 
extracellular region of αβ TCRs have posed significant problems, when compared to 
either antibodies or MHC proteins (59).  The explanation for this difficulty lies, at 
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least in part, in the behavior of TCR variable regions. This also accounts for problems 
that have plagued efforts to use single-chain TCR V-region fragments in the same 
way that has been done with antibody single-chain Fv fragments (86). Here, I show 
that it is possible to at least in part overcome these inherent problems by using a 
specific V region family, Vα2 (IMGT: TRAV12 family). This Vα region appears to 
be over-represented among human T cells directed against a number of HLA.A2 
associated antigenic peptides, perhaps most notably peptides from MART1/MelanA 
(ELAGIGILTV) and Epstein Barr Virus protein BMLF1 (GLCTLVAML) (184-186). 
It is possible that the inherent stability of Vα2, observed in the context of scTv 
proteins described here, might contribute to its preferential use in some T cell 
responses, and in the original isolation of the HTLV-1 Tax and HIV-1 Gag-specific 
TCRs, A6 and 868 (149, 187).  
 In previous studies, I have attempted to provide a possible molecular rationale 
for V region mutations that enabled the yeast surface display of mouse scTv (86, 154, 
164, 165) and individual Vβ regions (188). The underlying premise was based on our 
observations that surface display was directly correlated with thermal stability of the 
scTv (154, 166, 189).  In some cases, a possible explanation involved enhanced 
hydrophilicity at positions where a residue was buried at the V:C interface, or 
mutations at the Vα:Vβ interface that improved domain association.  However, a 
significant number of mutations, such as those present within or at the base of CDR 
loops, have less obvious explanations. For example, it is unknown how the CDR3α or 
CDR2β mutations in the 868 scTv that conferred high-affinity also yielded enhanced 
surface display and stability, in the unbound state. In addition, A6 scTv mutants with 
improved stability each contained a mutation within CDR2β, AlaVβ52Val.  We have 
argued that some of the CDR mutations could confer local stability on the CDR 
loops, based on modeling predictions (101).  Similar results with stabilizing CDR 
mutations in scFv fragments have also been observed (170, 172). 
Additional mutations in the framework 3 region or in hypervariable 4 region 
of the Vβ domains may also have contributed to the stability of the A6 and 868 scTv 
fragments. In the case of A6, the AsnVβ62Asp and AsnVβ66Lys mutations within 
framework 3 were conserved among isolated clones.  Although the contributions of 
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each individual mutation has not been determined, their conservation among 14 out of 
20 scTv clones of the A6 TCR (data not shown) suggest that they play a role in 
surface display and stability. 
The mechanism by which residue 49 of the Vα domain confers stability is 
also not clear. It is near the CDR3β (e.g. it is 2.8Å from Glu105β) loop, such that it is 
possible its primary role is in stabilization of the Vα:Vβ interface (Figure 2.10), a 
location that has been proposed should be a priority in the design of stabilized scFv 
fragments (172). This area of the Vβ (i.e. near Glu105β, which can be encoded by 
either N-region addition, the D gene, or the N-terminus of the Jβ gene) could in turn 
influence the stabilizing potential of the Vα and Ser49α. The residue adjacent to 
Glu105β, Gln106β, was mutated to Leu in each of the surface displayed scTv of A6, 
suggesting that this region can be further optimized for enhanced stability in the 
context of the Ser49α residue. Furthermore, CDR3α and CDR3β stabilizing 
mutations (L104αP and T105βA) have been identified previously in the mouse 2C 
scTv (164). Thus, it is apparent that various CDR and framework regions can have 
complex and interdependent impacts on the biophysical properties of the scTv 
molecules, not unlike antibody scFv fragments. 
 Studies with soluble full-length TCRs (VαCα/VβCβ) have shown that an 
interchain disulfide bond formed by a pair of introduced cysteines in the Cα and Cβ 
regions can confer additional stability on the molecule, enabling expression as a 
soluble protein (160). This form of the TCR has been used for binding studies, and as 
a platform for affinity engineering (148-150). The design of stable scTv fragments 
that bind to the specific pepMHC ligands, as shown here, provides additional 
opportunities to use the scTv as a platform for various applications as has now been 
widely done with antibody scFv fragments (190). These include the use of display 
technologies for affinity engineering (176, 191) and more facile production of 
biophysically well-behaved single-chain proteins in E. coli (192, 193). The scTv form 
also provides a platform for use in chimeric, single-chain antigen receptors (155) or in 
soluble form as bispecific fusions that could include, anti-CD3 antibodies, toxins, or 
cytokines (167, 172). 
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Based on the diverse sequences of the HLA.A2-restricted peptides that have 
elicited Vα2+ T cells (e.g. MART1, ELAGIGILTV; EBV, GLCTLVAML; Tax, 
LLFGYPVYV; Gag, SLYNTVATL) I anticipate that it should be possible to generate 
Vα2+ scTv proteins against a wide array of diverse antigens. Two structures are 
available for Vα2+ TCRs in complex with pep-HLA.2, the A6 TCR:Tax/A2 complex 
(194) and the MEL5 TCR/MART-1/A2 complex (195).  The two TCRs dock in 
almost identical orientations on their pep-A2 ligands, and they share CDR1α 
interactions with both the α2 helix and peptide positions 1 and 4.  Peptide specificity 
appears to be achieved in large part through interactions with CDR3β, providing 
support to the notion that the scTv proteins described here, which use distinct Vβ 
regions, can maintain their antigen specificity through the involvement of other 
CDRs. 
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Figures 
Figure 2.1 Yeast Surface Display of Single-Chain TCR Variable Fragments 
(scTv). (A) Schematic of scTv fusions for the human TCRs 1G4, A6, and 868, which 
recognize peptides NYESO, Tax, and HIV-Gag (SL9) in the context of HLA.A2. 
(148-150) (B) Yeast surface expression of scTv fusions was monitored for expression 
of N-terminal expression tag (hemagluttanin (HA), solid gray) with anti-HA antibody 
and goat anti-mouse IgG alexa 488 secondary antibody, or secondary antibody only 
as a control (black line). The negative peak in each histogram is due to yeast that have 
lost plasmid, and serves as an internal control for each induced yeast sample. To 
assess display of properly folded scTv fusions, cells were incubated with 
pep:HLA.A2 streptavidin:phycoerythrin tetramers. Null tetramer staining histograms 
are shown (gray line) as a control, along with the cognate tetramers, as indicated 
(black, solid). 
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Figure 2.2. Sequences of scTv Templates. Yellow: high-affinity CDR mutations as 
identified for 1G4, A6, and 868 (148-150). Orange: conserved immunoglobulin fold 
residues. Both A6 and 868 belong to subfamily TRAV12-2, but 868 shares some 
residues with TRAV12-1 (blue). Position Vα49 is either a polymorphic residue or a 
subfamily variable residue. 
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Figure 2.3. Isolation of Stabilized A6 scTv Mutants and Yeast Display of With 
Full-Length A6 TCR. (A) The high-affinity A6 TCR was cloned as a scTv , and a 
library of random mutants was sorted with Tax/HLA.A2 tetramer.  Clone A6-X15, 
isolated after two rounds of mutagenesis and selection with Tax/A2 tetramer, was 
stained with anti-HA antibody (left panels, solid gray histogram), secondary antibody 
only (left panels, black line histograms), 100 nM Tax/A2 tetramer (right panels, solid 
black histogram), or 100 nM null peptide NYESO/A2 tetramer (right panels, gray line 
histogram). (B) The full-length A6 TCR with β chain expressed as a fusion to AGA-2 
and α chain secreted was used to compare full-length and single-chain formats.  
Surface expression of α and β chains were monitored with anti-Cα or anti-Cβ 
antibody (left panels, black line histograms) or with goat anti-mouse IgG secondary 
antibody only as a control (left panels, gray line histograms). Cells were stained with 
100 nM Tax/A2 tetramer (right panel, solid black histogram), or 100 nM null peptide 
NYESO/A2 tetramer (right panel, gray line histogram). Mean fluorescence units of 
positive peaks are shown. 
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Figure 2.4. Isolation of Stabilized 868 scTv Mutants and Yeast Display With 
Full-Length 868 TCR. (A) The high-affinity 868 TCR was cloned as a scTv, and a 
library of random mutants was sorted with HIV Gag SL9/HLA.A2 (SL9/A2).  Clone 
868-Z11, isolated after one round of mutagenesis and selection with SL9/A2 tetramer, 
was stained with anti-HA antibody (left panels, solid gray histogram), secondary 
antibody only (left panels, black line histograms), 10 nM SL9/A2 tetramer (right 
panels, solid black histogram), or 10 nM null peptide NYESO/A2 tetramer (right 
panels, gray line histogram). (B) The full-length 868 TCR with β chain expressed as a 
fusion to AGA-2 and α chain secreted was used to compare full-length and single-
chain formats.  Surface expression of α and β chains were monitored with anti-Cα or 
anti-Cβ antibody (left panels, black line histograms) or with goat anti-mouse IgG 
secondary antibody only as a control (left panels, gray line histograms). Cells were 
stained with 10 nM SL9/A2 tetramer (right panel, solid black histogram), or 10 nM 
null peptide NYESO/A2 tetramer (right panel, gray line histogram). Note that the 
868-Z11 scTv staining with tetramer is shown again, as in this experiment different 
flow cytometry settings were used compared to (A), yielding the indicated mean 
fluorescence units for comparison with full-length 868 TCR.  
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Figure 2.5. Sequences of Selected A6 and 868 scTv Mutants Showing Highest 
Surface Levels Following Thermal Denaturation.  (A) Mutants of the A6 scTv or 
the (B) 868 scTv were isolated after mutagenesis of the scTv genes, followed by 
surface expression, high-temperature exposure, and selection with tetramers.  
Sequences are coded as follows: yellow, high-affinity CDR mutations for A6 (148) 
and for 868 (149); orange, conserved immunoglobulin fold residues, black-boxed 
residues, mutations identified in selected mutants. Note: for ease of comparing with 
published structures, residues of each variable domain of the scTv are numbered 
sequentially, and thus do not correspond to IMGT nomenclature. 
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Figure 2.6. Polymorphic Residue 49 of the Vα2 Region Influences Thermal 
Stability of the 868 scTv. The serine polymorphism at position 49 was introduced 
into the 868 scTv template.  Yeast cells were incubated at room temperature (top row) 
or at 40°C for 30 min and then stained with 10 nM SL9/A2 SA:PE tetramer (black 
line histograms) or null peptide Tax/A2 SA:PE tetramer (gray line histograms). Mean 
fluorescence units of positive peaks are shown. 
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Figure 2.7. CDR Mutations and the PheVα49Ser Mutation Each Improve the 
Surface Display of the 868 scTv.  Various 868 scTv proteins were expressed in the 
yeast display system with wild-type CDR residues or with high-affinity CDR 
mutations (see Figure 2.5B), with either Phe or Ser at position α49.  Top row, cells 
stained with anti-Vβ5.2 antibody and goat anti-mouse (black line histograms) or 
secondary antibody only (gray lined histograms).  Bottom row, surface expression 
was also monitored with SL9/A2 tetramers (black line histograms) or null peptide 
Tax/A2 tetramers (gray lined histograms). Mean fluorescence units of positive peaks 
are shown (or in cases where only a negative peak is present, the mean of this peak).  
 
 
 
 
 
 
 
 
 
 
 
 
 3α WT: TNSG 
2β WT: YEE
3α MUT: GAHD 
2β MUT: VRG
Pheα49
Vβ5.2
SL9/             
HLA.A2        
100 nM
Serα49
3α WT: TNSG 
2β MUT: VRG
3α MUT: GAHD
2β WT: YEE
Pheα49 Serα49 Pheα49 Serα49 Pheα49 Serα49
1200
700 700
4800 15000 36000 2000 31000
4200 16000 700 7400 1700900
4600 5400
Fluorescence
 51
 
 
Figure 2.8. Expression, Purification, and Surface Plasmon Resonance Binding 
Studies of Soluble scTv Proteins A6-X15 and 868-Z11. A6 clone X15 and 868 
clone Z11 were expressed in the E. coli pET28 expression system. Proteins were 
refolded from inclusion bodies, and purified by Ni-column and size exclusion 
chromatography. (A) SDS-PAGE of purified A6-X15 and 868-Z11 scTv proteins, and 
indicated molecular weight markers (M). (B) Surface plasmon resonance (SPR) traces 
of Tax/A2 binding immobilized A6-X15. Concentrations of injected pepMHC analyte 
are indicated below each injection. Red line represents a fit to a 1:1 binding 
interaction using a kinetic titration scheme as described in the Methods. Fitted 
parameters (KD, kon, koff) are shown in the insert. (C) SPR traces of SL9/A2 binding 
immobilized 868-Z11.  Experiments in B and C were performed by Kurt Piepenbrink 
and Francis Insaidoo in Professor Brian Baker's Lab (U. Notre Dame). 
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Figure 2.9. Recognition of Peptide-Loaded Antigen Presenting Cells with Soluble 
868-Z11 scTv. (A) Titration of various concentrations of the biotinylated 868 scTv 
on antigen presenting cell line T2 (HLA.A2+) pre-loaded with SL9 (10 μM) peptide, 
or null peptide Tax (10 μM).  Cells were stained at room temperature for 30 min with 
scTv, washed, and stained with SA:PE for 30 min. Analysis was performed after two 
additional washes. (B) Mean fluorescence intensity (MFI) values of scTv titration 
shown in (A) were plotted versus scTv concentration, to determine the concentration 
that yielded 50% maximal binding, EC50, for 868 Z11 scTv. (C) The SL9 peptide was 
titrated on T2 cells, and subsequently stained with a saturating concentration (100 
nM) of biotinylated 868-Z11 scTv.   
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Figure 2.10.  Position of the Serα49 Residue in the Structure of the A6 TCR. V 
regions of the A6:Tax/A2 complex (174)  are shown, highlighting the position of the 
Serα49 residue which is 2.8Å from CDR3β residue Gluβ105.  The Tax peptide 
(magenta) is shown for reference. PDB file 1AO7 was used in PyMol for graphics. 
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CHAPTER THREE 
 
TRANSDUCTION OF SINGLE-CHAIN T CELL RECEPTORS LACKING 
CONSTANT REGIONS CIRCUMVENTS MISPAIRING WITH 
ENDOGENOUS TCR  
 
Introduction 
 
 The potential of T cells in eliminating cancer cells has been demonstrated in 
numerous studies.  In patients with clinically apparent cancer, however, T cell 
immunity has clearly failed to effectively reject the malignancy.  Active 
immunization is being attempted to make the host’s own T cells recognize and 
destroy its cancer, but this approach is complicated by the fact that T cells specific for 
the cancer cells, particularly those with high avidity or affinity, may be suppressed or 
have been deleted by central or peripheral tolerance.  To improve the T cell response 
to cancer, recent approaches have combined adoptive T cell transfer with TCR gene 
therapy, in which a TCR of desired specificity and affinity is transduced into a 
patient’s ex vivo activated T cells (196).  This approach shows evidence of therapeutic 
promise (131,132) but also carries potential dangers (135). 
 T cells recognize foreign antigens, in the form of peptides bound to products 
of the major histocompatibility complex (pepMHC)1, through a heterodimeric T cell 
receptor (TCR) consisting of α and β chains (156).  A recognized complication of 
TCR gene therapy is the ability of introduced TCR α and β chains to mismatch with 
endogenous T cell receptors (197).  In two recent studies, TCR mispairing between 
introduced and endogenous TCR α and β chains led to undesirable reactivities.  In the 
first study using a mouse model system, overt autoimmunity (graft versus host 
disease) was observed, to varying degrees, in five different TCR systems (135).  The 
other study with human T cells showed that mismatched heterodimers caused off-
target toxicity, with an estimate of one of every ten mixed TCR heterodimers causing 
neoreactivity (198).  These findings reinforce the idea that TCR mispairing could 
have detrimental, potentially dangerous, consequences. 
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 A number of approaches have been developed to minimize the extent of 
mispairing (reviewed in (137, 197)).  These have included the use of hybrid human 
TCR chains containing mouse constant domains, which associate preferentially with 
each other rather than with the endogenous TCR chains containing human constant 
domains (199).  Another strategy involved fusion of the TCR chains to CD3ζ 
transmembrane and signaling subunits, also leading to preferential pairing of the 
exogenous TCR chains (200).  Finally, several labs have shown that the substitution 
of non-native cysteine residues within the constant domains of the introduced TCR 
(160) also promotes pairing of the exogenous chains, presumably through the 
formation of a disulfide bond at the Cα:Cβ interface (201-203), significantly reducing 
the extent of mispairing and graft versus host disease in mouse models of TCR gene 
therapy (135). However, the full extent to which these strategies can prevent TCR 
chain mispairing is unclear.  
 An additional challenge of TCR gene therapy approach is that the levels of 
exogenous αβ TCRs expressed on the surface of T cells is reduced by the concurrent 
expression of endogenous αβ TCRs, since the total surface levels of TCR are 
controlled by the availability of the CD3 subunits, especially the ζ subunits (204, 
205).  As CD3 subunits are limiting, even the optimized pairing strategies described 
above will necessarily still result in lower exogenous TCR surface levels compared to 
a single, homogenous αβ TCR.  Because TCR surface levels directly impact antigen 
sensitivity (206), it would be useful to develop strategies that enhance the levels of 
the exogenous TCRs. 
 Various single-chain TCR chimeras have been used in attempts to limit the 
problems associated with pairing of endogenous TCRs.  These included three-domain 
TCRs that contain other signaling domains such as the CD3ζ intracellular domain 
(VαVβCβCD3ζ) (207-209) and three domain constructs along with a separate Cα 
domain (210).  While these constructs mediate antigen-specific T cell activity, the 
extent of TCR mispairing and the quantitative comparisons of peptide activity with 
conventional two-chain αβ T cells has often not been examined.  Single-chain T cell 
receptors consisting of only the TCR variable domains (VαVβ) in principle would 
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completely eliminate mispairing, but have been problematic due to instability of Vα 
and Vβ domains in the absence of constant domains (86). 
Here I show that three domain TCR constructs (VαVβCβ) yield mispaired 
receptors in the presence of an endogenous α chain because of the contained 
Cβ domain, but stabilized two domain TCRs (VαVβ) with chimeric signaling 
domains avoid mispairing altogether and mediate T activity.  The high-affinity scTv 
linked to intracellular signaling domains, Lck and CD28, was capable of activating T 
cells in the absence of either the CD3 subunits or the co-receptors CD4 or CD8.  The 
scTv system also worked with a human construct specific for an HLA.A2–restricted 
peptide derived from the HIV-Gag protein.  Our novel approach preserves the 
endogenous TCRs to potentially be triggered via intentional immunization or 
homeostatic proliferative signals, while permitting the introduced scTv TCRs to 
respond to the targeted antigen independent of CD3 subunits, without the transduced 
T cells acquiring any new undefined and potentially dangerous specificities. 
 
Materials and Methods 
 
Peptides, Antibodies, and Cell Lines  
  Peptides SIY (SIYRYYGL), OVA (SIINFEKL), SL9 (HIV-Gag, 
SLYNTVATL), Tax (LLFGYPVYV) and WT-1 (RMFPNAPYL) peptides were 
synthesized by the Macromolecular Core Facility at Penn State College of Medicine 
(Hershey, PA).  Peptides were purified by reverse-phase chromatography using a C18 
column with mass confirmed by MALDI.  
The following antibodies were used: PE-conjugated anti-mouse CD3ε (BD 
Pharmingen, Clone 145-2C11), anti-mouseVβ8.2 (Clone F23.2), 1B2 clonotypic 
antibody, anti-mouse Vβ10 (Clone B21.5, eBiosciences), DimerX Db (BD 
Biosciences), PE-conjugated anti-mouse CD8α (Clone 53-6.7, BD Pharmingen), goat 
anti-Mouse IgG AlexaFluor 647 (Molecular Probes) and anti-human Vβ5.2 (Clone 
1C1, Pierce/Thermo Scientific).  The 2C clonotypic antibody 1B2 was purified from 
hybridoma supernatant by ammonium sulfate precipitation followed by Protein G 
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chromatography (211).  Biotinylation of purified antibody was performed using the 
EZ-Link Suflo-NHS-LC-Biotinylation Kit (Pierce). 
The PLAT-E (Clonetech) retroviral packaging cell line was maintained in 
DMEM with 10% FCS, L-glutamine, penicillin and streptomycin.  T2-Kb, a TAP-
deficient cell line that can present exogenous peptides, and 58-/- T cell hybridoma 
were maintained in RPMI 1640 complete medium supplemented with 10% FCS, L-
glutamine, penicillin and streptomycin.  The 58-/- T cell line was transduced with 
retroviral supernatants of the full-length or scTv constructs as described(102).  
 
Three-Domain and Two-Domain (scTv) Constructs  
 Various TCR constructs (Figure 3.1) were cloned into a murine stem cell virus 
(MSCV) retroviral vector (102).  The two- and three-domain 2C and/or m33 single-
chain TCR constructs contained six stabilizing mutations identified by yeast display 
(Vβ: Glu17Val, His47Tyr, Leu81Ser, Vα: Leu43Pro, Trp82Arg, Ile118Asn) (164, 
165).  2C TCR contains Vα3.1 (TRAV9-4) and Vβ8.2 (TRBV13-2) gene segments.  
The three-domain TCR gene was codon optimized (Genscript) in the Vα3-linker-
Vβ8.2Cβ orientation with a non-native cysteine at position 57 of the β chain constant 
region (Cβ: Ser57Cys), and introduced into the MSCV vector through AgeI/MluI 
restriction sites.  For generation of the m33 Vα-linker-VβCβ-IRES-2CVαCα 
construct, the m33 three-domain construct was introduced into the 2C MSCV vector 
in the AgeI and XhoI restriction sites, replacing the 2C VβCβ chain (102). 
 For generation of scTv chimeric antigen receptor constructs, the murine CD8α 
hinge, CD28, CD3ζ, and LCK gene fusion was codon optimized (Genscript), based 
on sequences from the NIH database (GenBank accession #AAS07035.1) (208).  The 
CD8α hinge was derived from scFv chimeric antigen receptor constructs previously 
described in murine systems (212), and the m33 scTCR (Vα-linker-Vβ) amplified by 
PCR from the three domain construct with a flanking 5’ AgeI restriction site.  
Subsequently, the scTv was fused to the CD8α hinge, CD28, CD3ζ gene by overlap 
extension PCR with a primer that added a 3’ MluI restriction site.  The scTv gene 
fusion was introduced into the AgeI and MluI restriction sites of the MSCV vector.  A 
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XhoI site exists at the 3’ end of the m33 scTCR, prior to the start of the CD8α hinge 
region, allowing for introduction of other scTv genes with appropriate leader 
sequences into the scTv CD28,CD3ζ,LCK fusion protein.  The 2C scTv with wild 
type CDR3α sequence (GFASA) was created by overlap extension PCR, and 
introduced into AgeI and XhoI sites in the m33 scTv construct.  
The human TCR 868 against the HIV Gag peptide called SL9 (149) was 
synthesized as a single-chain Tv.  The 868 scTv gene was amplified by PCR from the 
pCT302 yeast display vector, with a 5’ primer that contained the leader sequence of 
the 2C scTv and an AgeI site, and a 3’ end primer which included a XhoI site.  The 
868 scTv was then introduced into the m33 scTv vector containing CD8α hinge, 
CD28, CD3ζ, LCK fusion in MSCV by the AgeI and XhoI sites, with the 868 scTCR 
replacing the m33 scTCR in the fusion construct.  The 868 scTv gene contained high-
affinity CDR mutations derived from phage-displayed, full-length TCR (149).  
 
T Cell Hybridoma Transductions  
  scTv and full-length TCR genes in MSCV were introduced into the PLAT-E 
packaging line to produce cell supernatant containing retrovirus for introduction into 
58-/- T cells.  The retroviral packaging line was transfected with 40 μg of MSCV 
DNA with the lipofectamine 2000 reagent (Sigma) in Optimem serum-free media 
(Gibco).  After four to six hours, cells were washed with supplemented DMEM and 
placed in 6 mLs supplemented RPMI.  Forty-eight hours later, supernatant was 
collected, filtered, and added to 58-/- T cell hybridoma cells with lipofectamine at a 
final volume of 8 μl/mL.  T cells were centrifuged in retroviral supernatant at 1200 x 
g for 45 min at room temperature, cultured at 37°C for 3 days, and stained for cell 
surface mouse Cβ, mouse Vβ8, or human Vβ5 (868 scTv) with antibodies and 
analyzed on an Accuri C6 flow cytometer.  To enrich for the transduced, positive 
population, cells were sorted with either anti-mouse Vβ8 (F23.2) for 2C and m33 or 
anti-human Vβ5.2 for 868, using a FACS Aria (BD Biosciences). 
The 3D high-affinity TCR contained mouse Vα3 (TRAV9-1 subfamily, 
distinct from TRAV9-4 of 2C TCR, also called Vα3.1), mouse Vβ10 (TRBV4), and 
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CDR3 mutations that conferred higher affinity for WT-1/Db (unpublished data), after 
isolation by T cell display (147).  The 3D receptor contained unmodified TCR 
constant domains (Cα48:Thr, Cβ57:Ser), and was introduced into the 58-/- line as 
described for scTv and three-domain constructs.  The 3D TCR+ population was sorted 
with anti-Cβ antibodies prior to transduction of m33 scTv or m33 three-domain. 
 
PepMHC Multimer Binding  
 Transduced cells were stained with SIY/Kb pepMHC tetramer on ice for 2 
hours.  SIY/Kb tetramer was produced as has been described (102).  After washing, 
cells were resuspended in cold PBS/BSA and analyzed for bound fluorescent 
tetramers by flow cytometry. Non-transduced T cell hybridoma 58-/- line was used as 
a control.  Alternatively, WT-1/Db pepMHC Ig-dimers (DimerX, BD Biosciences) 
were prepared by incubation overnight at 37°C with WT-1 peptide at 120-molar 
excess.  Transduced cells were stained with WT-1/DimerX for 2 hours on ice in the 
dark, washed twice with 10-fold excess volume PBS/BSA (0.5%), and incubated on 
ice for 1 h in the dark with goat anti-mouse IgG APC Fab’ Alexa Fluor 647 at 10 
μg/mL (Molecular Probes). 
 
T Cell Activation Assays  
 T cells (7.5 x 104) were incubated with SIY or OVA peptide loaded T2-Kb 
cells (7.5 x 104), plate bound antibodies (anti-CD3ε or anti-mouse Vβ8 (F23.2)), or 
plate bound pepMHC tetramer (SIY/Kb or OVA/Kb) as described (102).  For the 868 
scTv cell line, cells were incubated with plate-bound antigenic SL9 (HIV 
Gag)/HLA.A2 or null Tax/HLA.A2 streptavidin tetramers or SL9 or WT-1 peptide-
loaded T2 cells (7.5 x 104).  T cells were incubated with the various stimuli for 24 h at 
37°C in a final volume of 200 μL, and supernatants were collected.  For IL-2 
detection, 96-well plates were coated with 2.5 μg/mL anti-murine IL-2 (BD 
Pharmingen) in 0.1 M Na2HPO4 (pH=9.0), and IL-2 in supernatants was detected 
with 6.7 μg/mL biotinylated anti-murine IL-2 (BD Pharmingen), followed by a 
1/10,000 dilution of streptavidin-HRP (BD Pharmingen), and finally, TMB substrate 
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(Kirkegaard & Perry Laboratories).  Absorbance at 450 nm was measured with an 
ELx800 universal plate reader (Bio-Tek Instruments).  
 
 
Results 
 
Three-Domain Single-Chain TCR (VαVβCβ) Containing a Non-Native Cβ Cysteine 
Mispairs with Endogenous TCR Chains  
  Various studies have suggested that a single-chain TCR construct consisting 
of tandem VαVβCβ domains could minimize the potential for mispairing with 
endogenous TCRs.  Inclusion of a non-native cysteine in C regions represents another 
strategy to minimize such mispairing.  Since the Cα:Cβ interaction contributes 
significant binding energy to these pairing interactions, I decided to explore whether a 
single-chain TCR (VαVβCβ) that contains a non-native Cβ cysteine would mispair 
with an endogenous α chain (VαCα), presumably through the interaction of the Cβ 
with the Cα.  To directly assess this, I took advantage of high-affinity probes for two 
different, properly associated VαVβ pairs.  The first probe, for the 2C TCR, is a 
clonotypic antibody, denoted 1B2, that binds only to properly associated 2C VαVβ 
with an affinity of 1 nM (213).  The second probe, for the mutated 2C TCR denoted 
m33 TCR, is the SIY/Kb ligand that binds only to properly associated m33 VαVβ 
with an affinity of 30 nM (101).  The mutations that convert 2C to the high-affinity 
m33 reside in the Vα CDR3 region, and prevent binding of 1B2 (147).  In addition, 
since the affinity of the SIY/Kb complex for 2C is low (30 μM), this tetramer bound 
by m33 only binds to the 2C TCR in the presence of CD8 (214). 
 Expression of the m33 three-domain (VαVβCβ) construct (Figure 3.1) in the 
T cell hybridoma 58-/- resulted in cells that were cell surface positive for Cβ and 
weakly positive for staining with SIY/Kb (Figure 3.2A), but as expected were 
negative for staining with 1B2.  The vector containing the m33 three-domain 
construct was then transduced into 58-/- cells together with the α chain from 2C 
(VαCα).  These cells were not only positive for anti-Cβ and SIY/Kb, but were 
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strongly positive for 1B2.  The only way for the 2C α chain to reconstitute the 1B2-
binding site is for the VβCβ region of the m33 three-domain construct to associate 
with the 2C α chain on the surface.  Thus, the three-domain construct with the non-
native Cβ cysteine did not prevent pairing with the endogenous α chain lacking a 
non-native Cα cysteine. 
 To verify that the three-domain construct was capable of mispairing with 
another TCR, when both the α and β chains were expressed, I used a mouse TCR 
called 3D that is specific for WT-1/Db.  This TCR included mutations that improve 
the binding to WT-1/Db, as engineered by T cell display (unpublished results).  The 
3D TCR allowed detection of binding to a WT-1/Db dimer in the absence of co-
receptor CD8, and thus, like m33 the pepMHC can be used directly to probe for 
properly associated 3D αβ.  The 3D TCR was transduced with unmodified constant 
domains (Cα48:Thr, Cβ57:Ser) in order to provide a direct test of pairing of the 
three-domain m33 construct with the endogenous TCR chains.  The m33 three-
domain construct was then introduced into the 3D TCR expressing 58-/- T cells and 
cells were sorted with an antibody to Vβ8 (m33).  Surface levels of (i) m33 three-
domain construct alone, (ii) 3D TCR construct alone, or (iii) the combination of 3D 
TCR and m33 three-domain constructs were examined with anti-mouse Vβ10 (3D 
TCR), WT-1/Db Ig dimer (3D TCR), and anti-mouse Vβ8 (m33).  In cells co-
expressing the m33 and 3D constructs, binding to the 3D ligand WT1/Db was 
significantly reduced, and binding to the m33 Vβ was significantly increased (Figure 
3.3).  These results would appear to reflect mispairing of the m33 three-domain 
construct with the 3D α chain, resulting in a decrease in 3D heterodimers and the 
associated reduction of binding WT1/Db, and an increase in m33 Vβ expression from 
mispairing with the 3D α chain.  The coexpressed 3D TCR and m33 three-domain 
construct showed similar levels of Vβ10 as the m33 three-domain construct alone 
potentially because of ββ homodimers, as observed by others expressing murine 
constant domains (203). 
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Expression of a scTv (VαVβ) Avoids Mispairing  
 As the three-domain construct mispaired with endogenous TCR chains, I 
reasoned it might be possible to use a single-chain TCR that lacked a Cβ region in 
order to completely avoid mispairing.  Similar approaches have used scFv fragments 
as chimeric antigen receptors (CAR), consisting of various fused signaling domains 
(155).  Although analogous single-chain TCR molecules are typically unstable 
without the Cβ domain, I have shown that it is possible to engineer scTv (VαVβ) by 
incorporating stabilizing mutations in the V regions (86, 154, 164).  
To test this strategy, I cloned the stabilized scTv of m33 as a fusion with 
CD28, CD3ζ, and Lck domains.  The m33 scTv fusion was introduced into 58-/- alone 
or with the 3D TCR and expressed at high levels on the surface of the 58-/- line, as 
detected with both the anti-Vβ8 antibody and the SIY/Kb (Figure 3.4).  The binding 
of SIY/Kb indicated that the Vα and Vβ domains were associated appropriately at the 
cell surface.  Furthermore, the expression of the m33 scTv was not influenced by 
expression of the 3D TCR, nor was the 3D TCR surface levels affected by the m33 
scTv.  These results suggest that significant mispairing was not occurring. 
 
Surface Levels of the Stabilized scTv are Higher Than Conventional TCR  
 To determine whether the surface levels of the scTv fusions of the TCR were 
comparable to the conventional αβ TCR/CD3 complex, I examined transduced cells 
expressing the m33 scTv fusion or the full length m33 αβ chains in the absence of 
endogenous TCRs or the CD8 co-receptor.  The scTv fusion was expressed at 
approximately five-times the surface level (based on mean fluorescence intensities) of 
the full-length αβ TCR, as detected with anti-Vβ8 antibody (Figure 3.5A).  The wild 
type, low affinity 2C TCR expressed as either a scTv fusion or in the full-length form 
was detected at nearly identical levels to m33 (Figure 3.5A).  
 Since typical binding studies with pepMHC tetramers take advantage of the 
avidity achieved through the presence of many TCRs per cell, I next examined the 
binding of SIY/Kb tetramers to low (2C) and high-affinity (m33) forms of the TCR 
expressed as either a scTv fusion or full αβ TCR.  As previously described (102, 214, 
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215), the αβ full-length, high-affinity TCR m33, but not the 2C, was capable of 
binding tetramers in the absence of CD8.  The higher surface levels of the scTv forms 
yielded enhanced staining with the SIY/Kb tetramer, including significant binding by 
the 2C scTv despite its relatively low affinity (KD = 30 μM).  Full titrations with 
SIY/Kb tetramer revealed that the 2C low affinity scTv bound even higher levels than 
the high-affinity m33 expressed as a conventional αβ TCR, despite the 1000-fold 
higher affinity of m33 (Figure 3.5C).  This finding highlights the importance of 
surface densities have on the binding of multimeric ligands. 
 
Efficient T Cell Activation is Mediated by the Stabilized scTv Fusions  
 To examine the activation of T cells mediated by the scTv fusions, I examined 
IL-2 release by the transduced 58-/- lines using various stimulating ligands.  The full-
length TCR was assembled with CD3 subunits, whereas surface expression of the 
scTv did not require nor sustain CD3 as evidenced by the absence of staining with the 
anti-CD3ε antibody (Figure 3.6A).  Despite the absence of CD3ε from the surface of 
cells transduced with scTv fusions, these cells were efficiently stimulated by anti-Vβ 
antibody immobilized on plates (Figure 3.6B).  Cells that expressed the conventional 
αβ TCR were also stimulated by immobilized anti-CD3ε, whereas the scTv cells 
were not simulated by anti-CD3 antibodies (Figure 3.6B). 
 Antigen-presenting cells (T2-Kb) were used in the presence of various 
concentrations of the SIY peptide to determine if cells transduced with different 
forms of the TCRs mediated peptide dependent, CD8-independent activity.  As 
described previously (101, 102, 216), CD8- cells transduced to express the m33 full-
length TCR, but not the 2C TCR, responded to SIY peptide in the presence of T2-Kb 
(Figure 3.6C).  The m33 scTv fusion stimulated activity at approximately the same 
concentration of peptide as the full-length m33 αβ TCR.  In contrast, the 2C scTv 
was not stimulated by SIY-loaded T2-Kb cells, despite the high surface levels of the 
scTv form and the ability of the scTv to bind to SIY/Kb multimers (Figure 3.5C).  
Thus, in the absence of CD8, avidity did not overcome the requirement for an 
inherent binding threshold (102).  However, immobilized SIY/Kb tetramers were 
capable of stimulating the 2C scTv fusions to a greater extent than the T2-Kb 
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presented antigen (Figure 3.6D), consistent with our previous observations that low 
affinity TCRs can be stimulated when the antigen densities are raised above a level 
achievable on APCs. 
 
T Cell Activity Mediated Through a Stabilized Human scTv Fusion 
 To examine the applicability of the scTv system to another TCR, a human 
TCR denoted 868, specific for HIV-Gag/HLA.A2 (149), was introduced as an scTv 
construct.  A stabilized scTv mutant of the parental αβ 868 TCR was engineered by 
yeast display (unpublished results).  The 868 scTv exhibited high-affinity for HIV-
Gag (SL9)/HLA.A2 (KD < 2 nM)(data not shown).  The human 868 scTv was fused 
to the same mouse intracellular signaling domains (Figure 3.7A) as with the 2C and 
m33 systems, the construct was transduced into the 58-/- T cell hybridoma, and the 
868 scTv was detected on the surface as monitored by anti-human Vβ5.2 antibody 
(Figure 3.7B).  The 868 scTv cell line was activated by SL9 peptide presented by T2 
cells and by plate-bound SL9/HLA.A2 tetramer, but not the null peptide ligands WT1 
or Tax (Figure 3.7C,D), consistent with our results with other TCR chains.  This 
experiment shows that scTv chimeric receptors with antigen specificity can be 
generated from other TCRs, and that the strategy can be extended to human epitopes. 
 
Discussion 
 
 Recent studies have introduced virus- or cancer-specific TCRs into T cells as 
a strategy to provide a patient with an enhanced T cell response, and ongoing studies 
are attempting to optimize this approach (131, 137, 196, 197, 217).  In a related 
strategy to provide tumor-reactive T cells, transduced T cells expressing chimeric 
antigen receptors (CARs) that contain a scFv fused to intracellular T cell signaling 
domains (e.g. CD28, CD3ζ, and Lck) have entered clinical testing (155).  Combining 
these approaches, several labs have attempted to use single-chain, three-domain TCRs 
(VαVβCβ) that can mediate proximal signaling through fused intracellular signaling 
domains (207, 208, 218).  In principle, the advantages of these TCR fusions are that a 
single gene product could recognize target cell pepMHC antigens and stimulate the 
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effector functions associated with T cells, independent of endogenous CD3 molecules 
(137).  However, the three-domain strategy has been limited in some instances 
because the TCR surface levels are insufficient for recognition of low levels of 
antigen (209).  Furthermore, while the three-domain TCR construct provides the 
stability necessary for surface expression, I show here that it does not avoid a major 
problem associated with use of exogenous TCRs in gene therapy, mispairing with 
endogenous TCR chains.  This mispairing has recently been shown to result in 
neoreactivities (198), and T cell-induced graft-versus-host disease in mouse models 
(135).  
Improvements in surface levels of exogenous TCRs have been achieved by 
various methods, including codon optimization to enhance transcription levels (219), 
regulation of αβ chain stochiometry to improve proper pairing (220, 221), inclusion 
of non-native cysteines (201, 202), modification of other residues in the C regions 
(222-224), substitution of mouse C regions in human TCRs (199, 225, 226), or direct 
fusion of CD3ζ domains (200) to drive desired pairing of the introduced chains.  
However, the diversity of αβ TCRs makes it unlikely that mispairing can be 
completely avoided using these approaches.  Therefore, attempts to avoid the problem 
altogether have involved use of different recipient cell types such as γδ T cells (227-
229), NK cells (230), or oligoclonal populations of αβ T cells (135, 231). However, 
these approaches also have limitations, including difficulty isolating and transducing 
a sufficient numbers of cells for adoptive transfer.  A method to silence endogenous 
TCR has been developed using siRNA, but the duration and efficiency of endogenous 
TCR suppression is unclear (232). It is worth noting that because CD3ζ subunits are 
limiting in a T cell (205), several of these approaches still lead to competition 
between the exogenous and endogenous TCRs for CD3, resulting in lower levels of 
both receptors. 
Our results show that the inclusion of a Cβ region with a non-native cysteine 
allowed association with endogenous α chains, and that deletion of the Cβ effectively 
eliminated pairing, within the limits of detection by flow cytometry (i.e. 
approximately 1,000 molecules/cell).  The ability of α and β chains to pair is 
dependent on the interactions of the Vα:Vβ regions and the Cα:Cβ regions, but the 
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relative contributions of each are not known. Assembly of the entire αβ/CD3 
complex requires charged residues in the transmembrane domains of the various 
subunits (104).  While the association of the Cα and Cβ domains presumably is the 
same among different TCRs, the Vα:Vβ interaction varies, and is controlled by 
multiple residues at the interface including regions within the CDR3α and CDR3β 
(86, 233). Hence, TCR chain pairing studies often reveal “strong” or “weak” TCRs; 
and the efficiency of a particular αβ association helps determine the surface levels of 
a TCR pair in cells expressing multiple α and β chains (217, 234, 235). Our data 
demonstrates that a TCR with Vα and Vβ regions alone is insufficient to drive 
detectable association with an endogenous α and β TCR chains, suggesting that the 
dimerization constants of the V regions is low, and a large fraction of the association 
energy is driven by interactions between Cα and Cβ regions (210).  As with the 
original principle of linking VL and VH to form scFv fragments (236), the scTv 
provides a strategy for forcing the association between the linked domains.  In 
practice, this is not trivial, and single-chain VαVβ fragments (scTv) are considerably 
less stable than scFv fragments (86).  Our lab has previously overcome this obstacle 
by engineering scTv with key stabilizing mutations in the V regions (86, 154, 164), 
and here I show that these scTv can be generated as fusions with intracellular 
signaling domains that can mediate T cell activation following antigen recognition. 
While chimeric antigen receptors directed by scFv fragments, sometimes referred to 
as T-bodies, have been useful in targeting non-MHC restricted cell surface antigens, 
the recognition of MHC-associated antigens by scTv fragments makes it possible to 
target the vast array of intracellular antigens invisible to scFv on viable cancer or 
virally infected cells.  In addition, scTv can recognize antigens released by cancer 
cells and cross-presented by tumor stroma, which can be critical for eradicating 
antigen-loss variants in a tumor mass and thereby prevent relapse after therapy (138, 
139).  In principle, scFv fragments specific for MHC-restricted antigens could also be 
used for these purposes (237-240). 
In order for a TCR, and presumably a scTv, to mediate activity in the absence 
of CD8 or CD4 binding to the presenting MHC molecules, its affinity needs to be 
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above a threshold of about 1 μM (102).  Because of this threshold limitation, the wild 
type TCR 2C (KD = 30 μM) did not mediate activity against cell-presented antigen 
either as a scTv, or as a full-length TCR in the absence of CD8 (Figure 3.6C). 
Optimization of the fused signaling domains may be able to enhance the sensitivity of 
scTv, or possibly even overcome issues associated with tolerance when T cells must 
function in a suppressive tumor environment (e.g. (241, 242)).   Nevertheless, it still 
remains questionable whether, in the absence of CD8, scTv that have not been 
modified to increase affinity will be capable of targeting the pepMHC levels found in 
many cancer or virus-infected cells.  Fortunately, TCRs with affinities similar to those 
of antibodies can be engineered (159), and using such an engineered TCR targeting 
the HIV Gag antigen (SL9)/HLA.A2 (149), I show that a scTv form of this receptor 
can mediate T cell activation.  Such high-affinity scTv could be used in a TCR gene 
therapy format, without the risk of TCR mispairing that would be associated with 
receptors containing human or mouse Cα and Cβ regions, or their mutated variants.  
Furthermore, the higher affinity scTv would be capable of mediating the activity of 
CD4+ TH cells (147),(309). 
Another potential advantage of the scTv-fusion approach is that the 
endogenous TCR/CD3 complexes remain at the same level on the transduced T cell 
as on the parental cell.  In a study of T cells that expressed two transgenic TCRs, it 
was possible to overcome tolerance mediated by one of the TCRs through signaling 
mediated by the other TCR (241).  It has also been shown that activation of T cells 
through the endogenous TCR can promote the persistence of transduced T cells, 
thereby enhancing their effectiveness against the target antigen of the transduced 
TCR (243). Thus, the ability of the scTv fusions to avoid mispairing could preserve 
efficient signaling through the endogenous TCR, and yet allow the introduced scTv-
fusion to mediate re-directed activity against tumor or viral epitopes.  
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Figures 
 
 
Figure 3.1.  Full Length, Three-Domain, and Single-Chain VαVβ (Tv) TCR 
Constructs.  TCRs derived from the 2C or 3D TCR were introduced into the murine 
stem cell virus (MSCV) retroviral vector.  The m33 high affinity variant of the 2C 
TCR differs only in the CDR3α sequence: 2C CDR3α-GFASA, m33 CDR3α-
LHRPA (designated by gray insert rectangle).  The 3D full-length receptor also 
contained CDR3α mutations that confer higher affinity to WT-1/Db.  The m33 three 
domain constructs contained a non-native cysteine mutation (Cβ: Cys57), indicated 
by the black rectangle. IRES refers to internal ribosome entry site, CD28TM refers to 
the CD28 transmembrane domain, and mVαL refers to the murine Vα leader 
sequence. 
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Figure 3.2. Three-Domain m33 TCR Mispairs with Endogenous TCR α Chains.  
T cell hybridoma 58-/- mock (no vector DNA) transduced cells (gray line) and 
transduced cells (black line) were analyzed by flow cytometry for surface expression 
after transduction with (A) the m33 three-domain construct or (B) the m33 three-
domain construct and the 2C full α chain construct (2C VαCα) transduced cells were 
examined with anti-Cβ antibody, SIY/Kb Tetramer (100 nM) or 1B2 clonotypic 
antibody.  The m33 three-domain cassettes in both constructs contained a Cβ non-
native cysteine while the 2C VαCα chain contained unmodified constant domains. 
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Figure 3.3  Three-Domain m33 TCR Mispairs with Endogenous TCR 3D. The 
WT-1 specific TCR 3D, which contains unmodified murine constant domains, was 
used to mimic an endogenous TCR (3D TCR: mVα3, mVβ10).  3D TCR-positive T 
cell hybridoma 58-/- were transduced with the m33 three-domain TCR (Vβ8+) 
construct. Vβ8-sorted cells were analyzed with anti-Vβ8 (A), anti-Vβ10 (B) or WT-
1/Db DimerX at 125 nM (C).  Transduced 3D cells that co-express the m33 three-
domain construct (gray line) were compared to cells that express only the 3D full-
length TCR (black line), or only the m33 three-domain construct (black dashed line). 
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FIGURE 3.4.  A Single-Chain VαVβ TCR (scTv) Construct Avoids Detectable 
Mispairing with Endogenous TCR 3D.  3D expressing T cells were transduced as in 
Figure 3, but in this instance with the m33 scTv.  Following sorting with anti-Vβ8 
antibody, cells were analyzed with anti-Vβ8 (A), SIY/Kb tetramer at 100 nM (B) anti-
Vβ10 (C), or WT-1/Db DimerX at 125 nM (D). Transduced 3D cells that co-express 
the m33 scTv construct (gray line) were compared to cells that express only the 3D 
full-length TCR (black line), or only the m33 scTv construct (black dashed line). 
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Figure 3.5.  Surface Levels and SIY/Kb Binding by scTv and Full-Length TCRs.  
scTv and full-length 2C (KD=30 μM for SIY/Kb) and m33 (KD=30 nM for SIY/Kb) 
constructs were introduced into 58-/- cells. Cell surface expression was monitored 
with anti-Vβ8 (A) or SIY/Kb SA:PE labeled tetramer at 40 nM (B) by flow 
cytometry.  SIY/Kb tetramer binding to scTv and full-length constructs was examined 
at various concentrations of tetramer (C). 
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FIGURE 3.6. Comparison of m33 (High Affinity) and 2C (Low Affinity) Full-
Length and scTv Constructs for Antigen Specific T Cell Activation.  (A) CD3ε 
surface expression of the m33 scTv (gray line) and full-length TCR (black line).  (B) 
Activation of IL-2 release from m33 scTv and full-length expressing cells with plate 
bound anti-Vβ8 or anti-CD3ε antibodies.  (C) Antigen specific activation of 2C and 
m33 scTv and full-length transduced cells using peptide-loaded T2-Kb cell line at 
various concentrations of exogenous SIY peptide.   (D) Antigen specific activation of 
2C and m33 scTv and full-length transduced cells using plate bound SIY/Kb tetramer.  
Data for B, C, and D is representative of three independent experiments for each 
panel.  OVA peptide (10 μM) loaded T2-Kb cells and OVA/Kb plate-bound pepMHC 
tetramer gave absorbance values from the IL-2 ELISA at background levels (not 
shown).   
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Figure 3.7.  The Human High-Affinity HIV-Specific 868 scTv Mediates Antigen-
Specific Activity in 58-/- T Cells.  (A) The leader from the 2C scTv was introduced 
upstream of the 868 scTv, and the human TCR was expressed as a fusion to murine 
intracellular signaling subunits.  (B) Surface expression of 868 scTv in transduced 
cells was monitored by anti-human Vβ5.2. (gray line - 58-/- cells, black line – 868 
scTv).  To assess antigen specific activation, 868 scTv expressing cells were 
stimulated with (C) SL9 or WT-1 (null) peptide loaded T2 cells or (D) plate-bound 
SL9/A2 or Tax/A2 tetramers at various concentrations. Data in C and D are 
representative of two independent experiments for each panel.   
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CHAPTER FOUR 
 
COMPARISON OF SINGLE-CHAIN T CELL RECEPTOR (SCTV) AND 
ANTIBODY (SCFV) FRAGMENTS IN MEDIATING T CELL ACTIVITY  
 
Introduction 
 
 One recent approach to tumor immunotherapy relies on targeting tumor 
associated antigens (TAAs) with antibodies.  Monoclonal antibodies against TAAs 
are gaining widespread use in clinical cancer immunotherapy as more antigens and 
antibodies with defined specificity are identified (Reviewed in (141),(244), and 
(245)).  For instance, clinical use of the monoclonal antibodies Herceptin and 
Rituximab has improved remission rates for breast cancer (246),(247),(248) and 
various hematological malignancies (249),(250) respectively.  Some patients, 
however, demonstrate cancer progression after treatment with monoclonal antibodies 
due to low levels of antigen expression on cancer cells, or possibly due to inefficient 
antibody Fc-mediated destruction of the cancer cell.  To improve efficacy, numerous 
groups are developing chimeric antigen receptors (CARs) consisting of an antigen-
binding domain (single-chain fragment variable, scFv) fused to intracellular signaling 
domains to redirect T cells to a wide variety of tumor-associated antigens.   
For example, patients with osteosarcoma often express low levels of HER2 
surface protein such that tumors do not respond to treatment with Herceptin, a HER2-
specific antibody.  Introduction of scFv CAR expressing T cells directed at HER2+ 
osteosarcoma allowed for in vivo targeting of cells that expressed the low antigen 
levels  (251).  The identical scFv CAR from that study was subsequently used to 
target HER2+ glioblastoma, a tumor type that was previously resistant to antibody 
therapy (252).  ScFv CARs introduced into T cells are currently being investigated in 
clinical trials because of the ability to rapidly convert an scFv already approved for 
soluble therapy into a CAR format, where the antigen-binding domain does not need 
to be altered, and both specificity and affinity are well-defined.    
 The scFv CAR approach provides a potential advantage for tumor targeting 
because target antigens are often expressed at high surface levels with relatively low 
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levels of expression on non-malignant tissue.  Unlike T cell receptors (TCRs), the 
antigen for scFv is most often not MHC-restricted, allowing a larger population of 
patients to be eligible for treatment than by conventional T cell therapies.  For 
example, some individuals lack common MHC alleles and consequently must be 
excluded from certain TCR-based therapies.  A potential disadvantage of targeting 
non-MHC-restricted antigens, however, is that cross-presentation of antigen by tumor 
stroma can not occur, thereby preventing a major path by which tumors can be 
destroyed (i.e. MHC-restricted peptide antigens from tumors can be cross-presented 
on nearby support cells within solid tumors herein referred to as tumor stroma) 
(253,139,169).  Thus, although peptide:MHC complexes may be present at lower 
surface levels relative to antibody-targeted antigens (a comprehensive list of MHC 
restricted tumor antigens reviewed in (134)), it may be necessary to target these MHC 
restricted antigens to destroy tumor stromal cells and thereby prevent tumor 
outgrowth.   
 In this work, I sought to compare the efficacy of an antibody scFv CAR with a 
T cell receptor based scTv (single-chain TCR variable) CAR to mediate antigen 
specific activity.  A chimeric antigen receptor that is specific for a cell surface protein 
with a tumor associated mutation was generated by fusing the antibody scFv, called 
237, to intracellular signaling domains.  The 237 antibody was derived from an aging 
female mouse that had an immune response to fibrosarcoma (254, 255).  The antigen 
recognized by 237 was subsequently shown to be due to a mutant chaperone protein, 
which resulted in the loss of activity associated with a glycotransferase.  This in turn 
led to the expression of a neo-epitope consisting of the defective carbohydrate linked 
to a peptide on the tumor cell surface. The glycosylation defect recognized by the 237 
antibody is specific for the tumor, as the post-translational defect is only present in 
the transformed cells.  
 The 237 epitope containing the glycosylation defect was originally isolated 
from the OTS8 transmembrane protein between amino acids 75 and 85 
(RGTKPPLEELS), a sialomucin-like transmembrane glycoprotein that lacks a 
galactose group modification.  Further study of the glycosylation defect revealed that 
this post-translational modification existed in many cell surface proteins that contain 
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similar amino acid sequences, and these epitopes are accessible to antibodies on the 
tumor cell surface (254).  Notably, Tn antigens derived from a similar glycosylation 
defect, have been identified in breast cancer (256), gastrointestinal tract tumors (257), 
and metastatic melanomas (258).  As a consequence, antibodies like 237 directed 
toward sugar moieties specific to tumor cells could provide clinical benefit against a 
broad range of human tumor types. The crystal structure of the 237 antibody in 
complex with the mutated glycopeptide revealed that 237 recognizes the carbohydrate 
moiety with relatively weak interactions directed to the peptide backbone (259).  This 
finding is rare among glycopeptide-specific antibodies, which are most often directed 
against the peptide and as a result cross-react with non-malignant and embryonic 
tissue (260).  The affinity of 237 for the glycopeptide has been measured (259), 
(KD=140 nM) which is greater than wild-type TCR affinities for peptide:MHC (KD ~ 
1,000-500,000 nM). The 237 affinity for the native cell surface epitope has not been 
measured, and thus it may be even higher. 
To assess the efficacy of the scTv approach, the 237 scFv CAR was compared 
with the high affinity m33 scTv (KD=30 nM) (described in chapter 3) that targets the 
model tumor antigen SIY/Kb (102).  In the first half of this chapter, I compare the 237 
scFv CAR and the m33 scTv CAR in targeting antigen-positive tumor cells, and I 
assess the contribution of the CD8 coreceptor in scFv and scTv antigen recognition. 
To examine the scFv and scTv cell lines, the antigen was also immobilized on wells 
to determine the role of other cell:cell interactions (e.g. CD8 and class I MHC) in the 
sensitivity of T cell stimulation mediated through the CARs.   
Design of the intracellular signaling domains in CAR constructs is important 
to elicit maximal T cell activation in response to antigen. T cell activation is thought 
to require two distinct signals: signal 1 is mediated by the αβ TCR and associated 
subunits, and signal 2 is provided by costimulatory receptors on the T cell surface 
interacting with ligands on the surface of antigen presenting cells (APCs).  I utilized 
single-chain constructs that contained components capable of mediating both signal 1 
and signal 2.  Numerous reports demonstrate T cell activity mediated by CARs that 
contain components of CD3ζ (signal 1) fused to extracellular antigen receptors that 
mediate effector function independent of the full TCR signaling machinery (261). 
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Fusion of a costimulatory domain or multiple domains (signal 2) to CD3ζ could also 
improve antigen specific T cell activity in CAR constructs (262, 263).  Since a more 
potent cytokine release profile has been observed with the fusion of kinase domains, 
such as LCK, that promote T cell activation (208, 264, 265), I included a fusion 
construct that contained CD28, CD3ζ, and LCK.   
 In the second half of this chapter, I examined a more recently adopted 
modification of the CD28, CD3ζ, LCK intracellular signaling cassette of the m33 
scTv CAR, with the goal of further improving T cell persistence and antitumor 
activity.  Accordingly, recent human CAR systems have demonstrated that inclusion 
of the 4-1BB costimulatory domain within the intracellular signaling domains of the 
CAR promoted T cell persistence, even 6 months after transfer (266, 267).  To assess 
the ability of 4-1BB containing constructs to mediate T cell activity, I evaluated m33 
scTv constructs containing the signaling domains of the original scTv (CD28,CD3ζ, 
and LCK) as well as a construct consisting of CD28, 4-1BB, and CD3ζ.  The 
transmembrane domain (Tm) was also evaluated for effects on surface expression, 
comparing type I murine Tm sequences derived from either CD28 or CD8 on 58-/- T 
cells. The results showed that the CD28 Tm domain allowed for improved 
transduction efficiency. 
The most significant finding was that both the high-affinity scTv and the scFv 
constructs were capable of mediating antigen-specific activation, in the presence or 
absence of CD8, when class I expressing antigen presenting cells were used as 
stimulators.  However, CD8 had a dramatic negative effect on stimulation of T cells 
through both the scFv and scTv receptors when the purified antigens were coated on 
wells.  I speculate that the effect of CD8 has to do with the sequestration of the 
intracellular, associated protein LCK.  In the case of immobilized antigens, where 
CD8 is not adequately recruited to the point of the T cell synaptic interaction, LCK is 
sequestered by CD8 and unavailable for signaling through the scTv or scFv CAR.   In 
contrast, when the antigen presenting cell is present, class I MHC on the antigen 
presenting cell can interact with CD8 that is concentrated within the T cell synapse, 
thereby allowing enhanced signaling through the proximal scFv or scTv molecules.  
These results are important, as they support a role for CD8 in interactions that do not 
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directly involve the TCR/CD3 complex (i.e. non-cognate class I). In addition, it 
suggests that current approaches using CARs may need to consider whether class I 
deficient tumor cells might still have a reduced ability to be destroyed by the 
transduced T cells, due to this role for CD8. 
 
Materials and Methods 
 
Antigenic Glycopeptides, Antigenic Peptides, Antibodies, and Cell Lines 
 Peptides (SIY (SIYRYYGL), OVA (SIINFEKL)) used in activation assays 
were synthesized by Penn State Macromolecular Core Facility at Penn State College 
of Medicine (Hershey, PA).  Peptides were purified by reverse-phase chromatography 
using a C18 column with mass confirmed by MALDI. The glycopeptide antigen (237 
antigen) used for activation assays with 237 constructs was provided as a generous 
gift from Stephen Evans (U. of Victoria, Canada). 
 Antibodies used in the current study included: goat anti-mouse F(ab')2 IgG 
AlexaFluor 647 polyclonal antibody (Molecular Probes), anti-mVβ8 (Clone F23.2), 
PE-conjugated anti-mouse CD8α (Clone 53-6.7, BD Pharmingen), PE-conjugated 
anti-mouse CD3ε (BD Pharmingen, Clone 145-2C11), anti-CD8 antibody (Clone CT-
CD8α, Cedarlane Labs), and anti-Kb antibody (Clone B8.24.3).  Soluble, high affinity 
m67 scTv specific for SIY/Kb was expressed, refolded in vitro, purified and labeled 
as described (102).  Soluble SIY/Kb peptide:MHC was expressed, refolded, and 
incubated with SA or SA:PE to form tetramers has been described (102). 
 PLAT-E (Clonetech) retroviral packaging cell line was maintained in DMEM 
with 10% FCS, L-glutamine, penicillin and streptomycin.  T2-Kb, a TAP-deficient 
cell line that presents exogenous peptides, tumor cell lines (Ag104, AcosM, EL4, 
MC57, and B16),  and 58-/- T cell hybridoma cell lines were maintained in RPMI 
1640 complete medium supplemented with 10% FCS, L-glutamine, penicillin and 
streptomycin.  All cell lines were maintained at 37 degrees C, 5% CO2.  The 58-/- T 
cell line was transduced with retroviral supernatants of the scFv or scTv constructs 
with or without plasmids that expressed CD8α and CD8β genes, as described 
(Chapter 3) (153).  The C57/BL6 splenocytes used as APCs in activation assays were 
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harvested from mice and treated with ACK lysis buffer to remove RBCs.  The 
remaining splenocytes were resuspended in RPMI for activation assays.  The AcosM 
cell line was derived from the Ag104 tumor line by transfection with the CosMc 
chaperone protein at the University of Chicago (Hans Schreiber) (254).  Thus, the 
AcosM cell line does not express the 237 antigen.  The MC57 SIY Hi, MC57 SIY Lo, 
and B16 SIY tumor cell lines were transduced with a plasmid containing the SIY 
peptide by the Schreiber Lab as has been described (139),(268),(140). 
 
Chimeric Receptor Gene Construction 
 The 789 bp DNA fragment comprised of the 237 scTv was introduced into the 
m33 scTv CD28, CD3ζ, LCK construct (chapter 3) by AgeI and XhoI restriction sites 
added by PCR to the 5' and 3' ends of the scFv respectively.  The plasmid containing 
the 237 scFv was provided by Hans Schreiber.  A XhoI restriction site within the 237 
coding sequence was removed by introducing a silent mutation into the protein 
sequence by Quikchange (Agilent Technologies) to allow for introduction of the 237 
scFv into the CAR construct.  The 237 scFv CD28, CD3ζ, LCK (Figure 4.1A) 
construct was initially designed with two separate leader sequences derived from 
either the Human IgKappa antibody leader (267) (Sequence: 
MDFQVQIFSFLLISASVIMSRG) or the murine IgG heavy chain leader (Sequence: 
MGWSCIILFLVATATGVHS).  I chose to pursue the human IgKappa leader sequence 
based on preliminary experiments which demonstrated equal transduction efficiency 
and antigen specific cytokine release in the 58-/- cells in comparison with the identical 
237 construct with the murine IgG heavy-chain leader (data not shown).   
 For construction of the 4-1BB gene constructs (Figure 4.1B) the gene 
sequences of the CD8αHinge, CD8Tm, 4-1BB, CD3ζ or CD8αHinge, CD28Tm, 4-
1BB, CD3ζ subunits were introduced into the m33 scTv CD28, CD3ζ, LCK by XhoI 
and MluI sites, with the 4-1BB containing cassettes replacing the existing 
CD8αHinge, CD28Tm, CD28, CD3ζ, LCK subunits.  The genes for the 4-1BB 
construct were derived from the murine 4-1BB sequence, at residues homologous to 
the human 4-1BB intracellular subunits in preparation for CARs in clinical trials 
(267).  The m33 full-length TCR construct has been previously described (102). 
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Retroviral Gene Transfer 
 DNA for each of the gene constructs (Figure 4.1) was isolated by Maxiprep 
(Qiagen kit) and packaged into retroviral particles using the PLAT-E cell line as 
previously described (chapter 3).  In brief, 1x106 58-/- cells were transduced with 
retroviral supernatants for 24 hours.  Three days after transduction cells were 
monitored for scFv or scTv surface expression with either goat anti-mouse IgG 
AlexaFluor647 (10 ug/mL) or anti-mVβ8 (10 ug/mL), respectively.  Cells were sorted 
to obtain populations expressing scTv or scFv CAR for T cell activation assays. 
 
T cell Activation Assays 
 For T cell activation assays. T cells were incubated with various stimuli for 24 
hrs at 37 degrees C, 5% CO2.  For all assays where peptide was titrated on antigen 
presenting cells or T cells were exposed to plate bound antigen, 1 equivalent of T 
cells, 7.5x104 T cells per well, was used.  For experiments where the effector to target 
(E:T) ratios were varied, 7.5x104 target cells were used.  After a 24 hour incubation, 
T cell supernatants were harvested and IL-2 release was quantified in an ELISA 
format (described in chapter 3).  In experiments where plate-bound anti-mVβ8.2 
(Clone F23.2) was used as stimulus, antibody was coated overnight at 10 ug/mL.  For 
B16-SIY experiments, cells were incubated with IFN-γ at 10 ng/mL in a T75 flask 24 
hour prior to the assay. Primary Cell Transduction and T Cell Killing Assays  
 Primary T cells were isolated from C57/BL6 splenocytes and treated with 
ACK lysis buffer to remove RBCs.  Subsequently, cells were separated into CD4 or 
CD8 T cell populations using magnetic beads (MACS, Miltenyi Biotec).  1 x 106 
purified cells were stimulated with anti-CD3/anti-CD28 Dynabeads (Invitrogen) per 
manufacturer’s instructions and 30 U/mL of IL-2 24 hours prior to transduction.  
Retroviral supernatant was prepared as described for 58-/- cells. Primary cells were 
centrifuged at 1200 x g, 30 °C for 1 hour (spinfection) with full-length TCR, scTv 
fusion (CD28, 4-1BB, CD3ζ) or mock (no vector DNA) retroviral supernatants, 
placed at 37 °C, 5% CO2 overnight followed by a second spinfection the next 
morning.  Cells were cultured in the presence of IL-2 (20 U/mL, day 3 post-
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activation) and on day 6 were incubated with 51Cr labeled T2-Kb cells pulsed with 
either 1 uM SIY or 1 uM OVA for four hours at 37 °C.  Supernatents were isolated 
and 51Cr was quantified for each sample using a scintillation counter.  Percent specific 
lysis was determined relative to maximal 51Cr release.   
 
Results 
 
Expression of scFv and scTv Chimeric Antigen Receptors in 58-/- T Cells  
The scFv and scTv chimeric antigen receptors (CARs) were cloned as fusions 
to the extracellular portion of CD8 (CD8α hinge), the CD28 transmembrane domain, 
and the intracellular domains of the CD28, CD3ζ, and LCK proteins (Figure 4.1A).  
The genes were expressed in the MSCV vector and transduced into 58-/- αβ negative 
T cells as described (Chapter 3).  As recent studies demonstrated that inclusion of the 
4-1BB intracellular signaling domain in CAR constructs (Figure 4.1B) improved in 
vivo T cell persistence (267),(266),(144), this domain was also tested for activity (see 
below).   
 I first sought to evaluate the surface expression of the 237 scFv CAR in 58-/- T 
cells.  Cell surface expression of the 237 scFv CAR was detected using a polyclonal 
antibody that is specific for anti-mouse IgG (Figure 4.2A).  Because this reagent is 
polyclonal, I reasoned that it contained antibodies capable of binding to IgG epitopes 
within the VL and VH domains of the 237 scFv.  Indeed this reagent stained the 
transduced cells, and was used to sort a positive population (Figure 4.2A).  Similarly, 
the scTv construct containing the high-affinity TCR m33 was transduced into 58-/- 
cells, and sorted with the monoclonal anti-Vβ8 antibody (Figure 4.2B).  Because the 
anti-IgG reagent is polyclonal, and different secondary reagents were used, it was not 
possible to directly compare the surface levels of 237 scFv relative to the m33 scTv.  
Nevertheless, both transduced populations were greater than 90% positive for surface 
expression and could be used to assess function. 
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Antigen Specific Activation of scFv- and scTv-Transduced T Cells 
The 237 scFv fragment targets a tumor-specific, mutated glycopeptide 
expressed by the murine tumor cell line Ag104 (254).  AcosM is an Ag104-derived 
cell line that lacks the 237 epitope; it was generated by introducing the enzyme that 
repairs the defect in glycosylation (responsible for the 237 neo-epitope) (254).  The 
237 scFv CAR-positive cells were incubated at various E:T ratios with either the 
Ag104 tumor line or the antigen null AcosM cell line, and IL-2 release was used to 
assess antigen specific activation (Figure 4.2C).  The 237 CAR expressing cells were 
active at multiple E:T ratios with Ag104 as the antigen presenting cells (target cells), 
whereas no activation was observed at any E:T ratio with the AcosM line as antigen 
presenting cells.    
To compare the efficacy of an antibody-based scFv CAR to a TCR-based scTv 
CAR for tumor targeting, I assayed cells that express the m33 scTv construct 
containing identical CD28, CD3ζ, and LCK signaling domains.  Because TCRs 
recognize MHC-restricted peptide antigens, the scTv approach provides the potential 
advantage of targeting tumor stroma cells that cross-present specific pepMHC 
complexes in the tumor microenvironment.  The scTv-positive cells were active at 
multiple E:T ratios in the presence of excess SIY antigen, but they were not active 
with the null peptide OVA (Figure 4.2D).  Thus the scTv and scFv CARs could 
mediate similar levels of antigen-specific T cell activation.   
 
CD8 Co-Expression Has Minimal Impact on scFv CAR-Mediated Activity with Tumor 
Cells 
 CD8 is thought to sequester LCK, promoting T cell activation in the context 
of class I MHC restricted antigens when the CD8/LCK complex is recruited to the 
immunological synapse and positioned in proximity to the cognate TCR:class I 
pepMHC interaction (269),(270).  However, for ligands that are not class I MHC, 
intracellular CD8 binding of LCK could reduce the level of activation due to the 
sequestration of LCK away from the synapse (151),(271).  As the constructs 
described here contained the active domain of LCK, this sequestration may not 
impact activity (e.g. if free cellular LCK activity is not required).  To assess the 
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impact of the coreceptor CD8 on scFv CAR activity, the CD28,CD3ζ,LCK 
containing constructs were introduced into the CD8+ 58-/- T cell hybridoma line.  The 
237 scFv CAR CD8- and CD8+ expressing T cell lines were examined for surface 
expression of the scFv and CD8 (Figure 4.3A).  High levels of CD8 were observed on 
the 237 scFv, CD8+ line, allowing the analysis of the impact of CD8 on activity 
against a non-class I MHC ligand. 
Transduced T cells were incubated with either the Ag104 tumor line or the 
AcosM (null) tumor cell line.  The CD8+ and CD8- 237 lines mediated similar activity 
in the presence of the Ag104 tumor line, although the CD8+ line yielded slightly 
higher maximal IL-2 release at optimal E:T ratios (Figure 4.3B).  Both CD8+ and 
CD8- lines were not stimulated by the antigen-negative cell line AcosM.  
 
CD8 Co-Expression Completely Inhibits scFv CAR-Mediated Activity with 
Immobilized Antigen, in the Absence of Class I MHC 
While CD8 appeared to have little impact on stimulation of the 237 scFv-
mediated activation, it was possible that CD8:class I MHC interactions may still be 
involved since the antigen presenting cells express class I MHC.  To examine this 
possibility, the activity of the 237 scFv CAR expressing T cell lines were examined 
with plate-bound glycopeptide antigen (provided by Stephen Evans, U. of Victoria, 
Canada (259) at various concentrations to evaluate T cell activity.  The CD8- 237 
scFv CAR T cell line was stimulated effectively (SD50=0.7 μg/mL) by plate-bound 
glycopeptide antigen (Figure 4.4A).  Surprisingly, the CD8+ 237 scFv CAR T cell 
line was completely inactive at any concentration of the plate-bound glycopeptides.  
A control T cell line that expresses the m33 scTv was also completely negative, as 
expected.  Thus, despite effective stimulation of the CD8+ scFv cell line by antigen-
positive tumor cells (Figure 4.3B), the presence of CD8 completely inhibited antigen-
specific activity in the absence of an antigen-presenting cell. 
To verify these results, the CD8+ cell line was sorted a second time with anti-
mouse IgG antibodies in order to obtain a line that expressed more homogenous 
levels of the 237 scFv (Figure 4.4B, compared to Figure 4.3A).  This line expressed 
the 237 scFv at similar, homogenous levels as the CD8- cell line (Figure 4.4B). The 
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CD8+ 237 scFv-sorted line was also inactive in the presence of glycopeptide antigen 
(Figure 4.4C), although it was active in the presence of the Ag104 cell line (data not 
shown). To test the hypothesis that CD8 contributed to T cell recognition of the 
Ag104 tumor line, Ag104 cells were incubated with 237 CD8+ cells in the presence of 
an anti-CD8 antibody (clone CT-CD8α).  We and others have shown previously that 
this antibody can inhibit T cell activation, presumably by blocking the association of 
CD8 and the TCR complex (151),(272),(273).  Incubation with the anti-CD8 antibody 
at 10 μg/ml led to reduced IL-2 release by the CD8+ T cell line (Figure 4.4D). This 
result suggests that full cell-mediated activation required association of CD8 and the 
237 scFv CAR-containing the CD3ζ domains.  Incomplete inhibition may indicate 
that some CD8 molecules could act at a greater distance from the 237 scFv CAR, 
through interactions with class I MHC at the synapse.  
 
Similar Effects of CD8 on Activation Mediated by scFv and scTv CAR  
Similar experiments were performed with the m33 scTv in CD8- and CD8+ 
cells to assess coreceptor function in cells where a class I pepMHC is the ligand.  
However, in contrast to the normal TCR, the Cα, Cβ, or CD3 subunits are not 
involved in the function of the scTv, and thus CD8 may or may not be capable of 
associating directly with the scTv CAR upon binding to class I MHC.  Cell surface 
levels of scTv were monitored by flow cytometry with anti-mVβ8 (Figure 4.5A).  
Activation of CD8+ m33 scTv CAR expressing cells with peptide-loaded antigen 
presenting cells resulted in slightly decreased peptide sensitivity relative to CD8- m33 
scTv T cells (Figure 4.5B).  By this measure, the CD8 coreceptor did not appear to 
contribute to scTv-mediated recognition of the same class I MHC-restricted antigen.  
This reduction in sensitivity may be a result of sequestration of LCK, perhaps 
combined with the inability of CD8 to associate with the m33 scTv CAR.   
To further evaluate the ability of CD8+ m33 scTv cells to mediate cytokine 
release with plate bound antigen, m33 scTv cells with or without CD8 coreceptor 
were incubated with plate-bound SIY peptide:MHC tetramer. The CD8+ cells were 
only active at the highest antigen concentrations (Figure 4.5C).  In contrast, the m33 
scTv CD8- cell line responded to immobilized peptide-MHC at lower concentrations, 
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and the maximal release of IL-2 was greater.  The lower activation induced by plate 
bound pepMHC (Figure 4.5B) compared to cell-associated pepMHC (Figure 4.5B), is 
similar to observations with the 237 scFv system.  However, in the m33 scTv system, 
the plate bound antigen is a class I MHC ligand, which in principle would allow CD8 
to bind to the same molecule as the scTv.  If this were the case (i.e. the m33 scTv and 
CD8 bound to the same molecules), one would expect enhanced signaling, as occurs 
with the synergistic acton of TCR and CD8 in normal T cell responses (274),(215).  
Thus, the results shown here are consistent with the interpretation that m33 scTv and 
CD8 are unable to bind to the same MHC molecule.  Accordingly, enhanced 
activation by cells that express pepMHC, compared to immobilized pepMHC, may be 
due to interactions between CD8 and class I MHC molecules that are proximal to the 
scTv:SIY/Kb interaction. Collectively, the scFv and scTv results suggest that 
interactions with their cognate antigens may be necessary, but not sufficient, for 
activation. 
 
Effect of Antigen Density on T cell Activity Mediated by scTv and Full-Length TCRs 
 The cell line used for stimulation of the m33 scTv was the TAP-deficient line 
T2-Kb, which does not express endogenous peptides bound to Kb. These endogenous 
pep-Kb complexes could in principle provide synergistic responses if they are 
recognized as co-agonists by m33, or if they were bound at the synapse by CD8.  
However, the endogenous peptides also potentially decrease the density of specific 
antigenic pepMHC (SIY-Kb, in the case of m33), possibly affecting sensitivity of the 
T cells. To examine these possibilities, the activity of cells that express the high 
affinity CD8- m33 scTv CAR was first compared to cells that express the standard 
m33 CD8- full-length TCR.  The CD8-negative lines were examined as CD8 did not 
appear to contribute to an increase in sensitivity using the T2-Kb antigen presenting 
cells (Figure 4.5).  
 Cells that express the m33 scTv (Figure 4.6A) or full-length TCR (Figure 
4.6B) were incubated with antigen presenting cells that express endogenous peptides 
(EL4, C57/BL6 splenocytes, or MC57) or with T2-Kb which expresses primarily the 
exogenous SIY antigenic peptide only.  In the presence of endogenous peptides, both 
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the scTv (28,ζ,LCK) and the conventional full length TCR exhibited decreased 
sensitivity as judged by the responses to EL4, C57/BL6 splenocytes, and MC57 
(Figure 4.6). In order to determine if this reduction in sensitivity could be attributed 
exclusively to lower levels of the cognate antigen (SIY/Kb), I used a high-affinity 
soluble TCR (m67) to quantitatively determine the relative levels of SIY/Kb on T2-Kb 
compared to EL4 and MC57.  In both cases, the decrease in activity was associated 
with lower levels of specific antigen (data not shown), no doubt due to the 
competition for Kb binding by the endogenous peptides.  The decrease in sensitivity 
for the the scTv CAR was approximately 10-fold greater for the scTv relative to the 
full-length TCR based on the sensitization does yielding 50% maximal signal (SD50).  
Although the basis for this is not clear, it is possible that the scTv form may rely more 
heavily on clustering with a sufficient density of antigenic peptide-MHC for 
signaling.  
 
Transmembrane and Intracellular Domains Influence scTv CAR Transduction 
Efficiency and Surface Levels 
 Many studies have shown that different transmembrane regions or 
intracellular domains can impact CAR expression and activity.  For example, some 
investigators have used the transmembrane domain from the CD28 molecule (as used 
in the constructs described above), while others have used the transmembrane domain 
from CD8 ((142)).  In addition, it has been shown that the 4-1BB domain, derived 
from the co-stimulator molecule, provided primary T cells that express a scFv CAR 
with increased persistence in vivo in humanized murine adoptive transfer models 
(266), (267). The ability of a CAR to mediate T cell survival and proliferation will be 
important in the adoptive T cell setting.  In addition, the m33 scTv-CD28,CD3ζ,LCK 
construct proved problematic for transduction of primary murine T cells, possibly 
because of the size of the DNA construct (communication with Boris Engels, U. of 
Chicago)(e.g. the LCK gene is 1424 bp, which may result in inefficient packaging 
into retroviral particles).   As the 4-1BB gene is approximately ten times smaller (147 
bp), it may allow for more efficient packaging and T cell transduction. 
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 Initially, I compared the transduction efficiency of m33 scTv constructs that 
contained either the CD28,CD3ζ,LCK or the CD28,4-1BB,CD3ζ fusions, each with 
the CD28 transmembrane domain (Figure 4.1).  The transductions were monitored 
with an antibody to mVβ8 (Figure 4.7A).  The construct containing the 4-1BB 
domain showed a higher T cell transduction efficiency, 92.9% of cells transduced 
compared to the LCK containing fusion (28.7%).  The trend was consistent in two 
separate transductions with the 4-1BB construct allowing for greater than 90% 
transduction efficiency.  This result is consistent with the difficulty encountered in 
transducing primary activated mouse T cells with the LCK containing construct. 
To compare the impact of transmembrane domains, a construct that contained 
the CD28Tm and CD8Tm were examined (Figure 4.7B).  The transduction 
efficiencies of the two constructs, each containing the 4-1BB domain, were very 
good. However, the surface level of the construct that contained the CD28 Tm region 
was almost 10-fold higher than the construct that contained the CD8 Tm region 
(Figure 4.7C).   
 
Comparison of LCK and 4-1BB Fusions in Mediating T Cell Activation 
 The three m33 scTv CAR constructs (Figure 4.1B) were compared with full-
length m33 αβ TCR for surface expression levels after enrichment of transduced cells 
by cell sorting (Figure 4.8A).  The two scTv CAR constructs that contained the 
CD28Tm were expressed at 3-fold higher surface levels than the full-length TCR, as 
was previously observed with the CD28,CD3ζ,LCK construct (Chapter 3).  As noted 
above, the CD8Tm containing receptor was expressed at 10-fold lower surface levels 
than the CD28Tm scTv constructs, in agreement with analysis of T cells prior to cell 
sorting (Figure 4.7C).   
 To directly examine the ability of the m33 scTv CARs and full-length 
receptors to mediate T cell activity, cells were first tested with plate-bound anti-
mVβ8 antibody as the stimulatory ligand (Figure 4.8B).  T cells that expressed each 
of the constructs were stimulated by immobilized antibody, although the m33 
CD8Tm-containing construct mediated significantly reduced activation. This result is 
consistent with the much lower surface levels of this receptor (Figure 4.8A). To 
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assess antigen specific activation, the T cell lines were incubated with SIY-peptide 
loaded T2-Kb cells (Figure 4.8C).  The m33 scTv CD28,ζ,LCK construct mediated 
cytokine release with sensitivity comparable to the m33 full-length TCR.  However, T 
cells expressing the m33 scTv CD28Tm CD28,4-1BB,ζ  construct were induced only 
at very high concentrations of peptide. This result suggests that the LCK domain may 
be required for proximal signaling, or perhaps that the CD28 and CD3ζ domains need 
to be in tandem to promote cytokine release.  
Despite the weak induction of IL-2 release mediated by the m33 scTv 
construct that contained the 4-1BB domain in the presence of varying SIY peptide 
concentrations, it is possible that higher levels of activation might be achieved at an 
optimal ratio of effector to target (APC).  Accordingly, the scTv and full-length TCR 
expressing cell lines were incubated with T2-Kb SIY peptide loaded target cells 
loaded with excess peptide. In the presence of excess peptide (1 μM SIY, no wash), 
the m33 scTv CD28,ζ,LCK and the m33 full-length TCR showed similar activity at 
low E:T ratios (Figure 4.9).  Although the LCK containing construct, and full length 
TCR, mediated higher levels of activation, the 4-1BB construct was clearly capable of 
mediating significant IL-2 release at almost every ratio, and the activation was 
specific as judged by the inability of the null peptide OVA to induce release. 
 In another set of experiments, I examined whether tumor cell lines that 
express the SIY peptide as an endogenous processed antigen were capable of 
stimulating T cells that express the various scTv and full-length TCR contructs. In the 
first system, the murine melanoma line B16 that expresses the endogenous peptide 
SIY and Kb was used (275).  B16 expresses low levels of MHC Kb but incubation 
with IFN-γ results in upregulation of MHC and antigen presentation.  Incubation of 
B16/SIY with IFN-γ resulted in upregulation of the MHC allele Kb and improved 
expression of SIY/Kb as monitored by an anti-Kb antibody and the soluble high-
affinity m67 scTCR, respectively (Figure 4.10A).  Incubation of the IFN-γ induced 
B16/SIY cell line with the various m33 scTv and full-length constructs revealed that 
only the LCK containing scTv and full-length TCR construct were able to release 
cytokine.  In the case of the non-IFN-γ-induced B16/SIY, only the full-length TCR 
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mediated significant IL-2 release. Thus, the hierarchy of sensitivity for the three 
consructs was full-length TCR>scTv-LCK>scTv-4-1BB.   
A similar set of experiments was carried out with the murine-derived MC57 
lines that were previously transduced with a vector that expresses the SIY peptide 
endogenously, yielding high and low levels of SIY antigen (268).  In each of these 
systems only the m33 full-length TCR was able to mediate cytokine release (Figure 
4.10B).  
 
Comparison of m33 scTv/4-1BB Fusion and Full-Length TCR in Mediating Cytolytic 
T Cell Activity 
While the T cell hybridoma serves as a surrogate for examining some 
properties of T cells, it can not be used to study many aspects of T cell function. 
These include cytotoxic activity, T cell proliferation, or in vivo properties such as T 
cell persistence and proliferation.  In fact, the original premise of using the 4-1BB 
domain involved its ability to serve a co-stimulatory function in the proliferation of T 
cells.  Thus, it is possible that the 4-1BB containing constructs will be of sufficient 
potency to kill target cells and possibly to mediate proliferation when introduced into 
primary T cells.   
To begin to address these issues, I have worked with Dr. Adam Chervin in the 
lab to transduce primary T cells, activated with immobilized anti-CD3/anti-CD28 
antibodies (activation is required for transduction).  Our results showed that about 1 
to 5% of CD8+ and CD4+ cells were transduced with the m33 TCRs, as indicated by 
staining with SIY/Kb tetramer (Figure 4.11A, C).  Despite this relatively low 
frequency of transduced cells, both the full-length TCR and the m33 scTv containing 
the CD28Tm and 4-1BB domains were capable of mediating efficient lysis of T2-Kb 
cells incubated with SIY peptide in both CD8+ (Figure 4.11B) and CD4+ T cells 
(Figure 4.11D).  This result shows that the m33 scTv/4-1BB construct could be 
transduced into primary T cells, that the receptor could directly recognize and 
mediate signaling that leads to the destruction of target cells, and that not only CD8+ 
T cells, but CD4+ T cells were capable of mediating lysis.  Future studies will allow 
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us to examine if these transduced T cells persist in vivo, and can undergo antigen-
induced, and/or homeostatic proliferation.  
 
Discussion 
 
Despite numerous studies utilizing CARs against a wide array of tumor 
antigens (reviewed in (155)), often as fusions to CD28 and CD3ζ, the mechanism and 
efficiency (compared to normal TCRs) by which these receptors are able to mediate 
activity is not well understood.  Assuming that the mechanism of signal transduction 
by the CAR is similar to a full-length TCR, there are two possible mechanisms of 
signaling; both mechanisms require that the kinase LCK phosphorylates specific 
intracellular tyrosine activation motifs (ITAMs) within various transmembrane 
proteins, including CD3ζ, that subsequently potentiate T cell activation (Reviewed in 
(103)).  One hypothesis proposes that there is a mechanical force effect on the full-
length TCR that causes conformational changes within the TCR, such that ITAMs 
(immune tyrosine activation motifs) on accessory CD3 proteins are made more 
accessible within the cell, thereby facilitating ITAM phosphorylation by the kinase 
LCK (106),(276).  Another hypothesis suggests that the clustering of TCRs results in 
aggregation of LCK at the immunological synapse near CD3 subunits, resulting in T 
cell activation (277),(278),(279).  In this work, I do not distinguish between these two 
models, but rather propose that some basal level of LCK interaction with CD3 
subunits on CARs is necessary to drive T cell activity (108).  
Chimeric antigen receptors derived from both an scFv and scTv were 
compared with the goal of evaluating targeting overexpressed MHC unrestricted cell 
surface antigens relative to overexpressed tumor associated peptide-MHC complexes 
respectively.  Collectively, my data demonstrated that scFv and scTv CARs 
containing CD28, CD3ζ, and LCK intracellular subunits were able to mediate similar 
cytokine release when antigen was presented at high levels, as long as the scTv was 
engineered to have higher affinity than a wild type TCR (Figure 4.2).  Experiments 
comparing scTv constructs that lacked LCK (4-1BB constructs) with the CD28, 
CD3ζ, LCK scTv showed that the CD28, 4-1BB, CD3ζ construct (lacking LCK) had 
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lower maximal cytokine release in response to APCs (Figures 4.8, 4.9 and 4.10). In 
perhaps the most unexpected aspect of the current work, I show that CD8 is important 
in the activity of the scFv- and scTv-CARs, presumably through interactions with the 
non-cognate class I molecules on the surface of the target cells.  Discussions of the 
proposed mechanism involved in this effect, and other implications of these studies 
follow. 
 
Non-CAR-Associated LCK Appears to be Required for Maximal CAR-Mediated 
Cytokine Release  
Other studies have demonstrated that CD8 associates with intracellular LCK, 
decreasing the pool of ‘free’ (noncoreceptor-associated) LCK available to localize 
with cell surface proteins (151), (271).  In the context of full-length TCR, CD8-
associated LCK is brought into proximity with the TCR/CD3 complex, and thus CD8 
acts as a coreceptor, improving the T cell sensitivity to antigen (61).  However, in 
these cases, the same cognate class I pepMHC molecule recognized by the TCR could 
be bound by CD8, thereby “delivering” LCK to the site of its substrates (e.g. CD3ζ).  
I sought to determine if CD8 could also play a similar role with scTv and scFv 
constructs, even though in the latter case the cognate antigen is not a class I ligand 
and thus not capable of direct binding by CD8.   
Based on my results, the chimeric antigen receptors that contained CD28, 
CD3ζ, and even the LCK domain appeared to still require the LCK associated with 
CD8 to allow productive signaling and cytokine release. Most strikingkly, this 
interpretaion is supported by the finding that 237 CD8+ CAR constructs showed no 
detectable activity in response to plate-bound antigen, whereas the same cell line was 
stimulated very efficiently by target cells that expressed the antigen, and class I 
MHC.   Conversely, the same construct was stimulated by plate bound antigen when 
expressed in a CD8-negative T cell (Figure 4.4A, 4.4C).  The most straight forward 
interpretation of these results is that CD8 could not participate in recognition of the 
plate bound glycopeptide antigen because MHC was absent, and in this case, the 
requisite LCK was sequestered away from the scFv-CAR at the point of contact 
between scFv and antigen (i.e. the immunological synapse).  Similarly, CD8+ m33 
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scTv could have been much less active with plate-bound pepMHC because CD8 
could not interact with the same antigenic pepMHC molecule as the scTv.  In both 
instances, LCK sequestration away from the scTv or scFv by CD8 prevented or 
decreased T cell cytokine release.  
In the presence of antigen presenting cells (APCs), CD8+ 237 scFv (Figure 
4.3B, blue line) and CD8+ m33 scTv (Figure 4.5B, blue line) could mediate efficient 
cytokine release, presumably because CD8 interacted with MHC molecules on the 
APCs, thus recruiting LCK to the synapse at the TCR:APC interface. However, the 
CAR-associated LCK appeared to also be important for cytokine release as shown for 
experiments where LCK was not part of the CAR-fusion, as the CD28, 4-1BB, CD3ζ 
m33 scTv construct (Figure 4.8).  Thus, my experiments suggest that CAR-fused 
LCK and the CD8-associated LCK were both important for maximal CAR-mediated 
T cell activity.  
 These results suggest that the fused LCK domain is not by itself sufficient for 
mediating activity.   One possible explanation involves the partitioning of cell surface 
receptors into lipid rafts, which are less accessible to regulators of proteins involved 
in proximal T cell signaling events. A bulky transmembrane protein phosphatase, 
called CD45, regulates LCK function by de-phosphorylation of a tyrosine; CD45 is 
not incorporated into cholesterol rich lipid rafts where TCR and associated 
coreceptors often exist (109),(110).  Hence, it is possible that the observed 
requirement for non-CAR-associated LCK is due to the inefficiency by which LCK 
on CAR fusions is activated because of its reduced accessibility to CD45.  This model 
is complicated by the fact that LCK has two regulatory phosphorylated residues, at 
positions Tyr394 and Tyr505; these  need to be phosphyorylated and 
dephosphorylated respectively to initiate LCK activity (280).  Lack of CD45 within 
lipid rafts prevents removal of the phosphate at Tyr394, allowing activation of LCK.  
Tyr505 is dephosphorylated, upon T cell signaling, by the kinase Csk which is 
associated with rafts.  In contrast, association of CD45 and Tyr394 of LCK results in 
removal of phosphate at this tyrosine and loss of kinase activity (281).  Thus, CD45 
has both a stimulatory and regulatory role for T cell function which may modulate 
LCK in CAR activity (282).   Future studies will be required to evaluate the relative 
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localization of CD45 to scTv and scFv CARs (e.g. by fluorescence resonance energy 
transfer (FRET) or immunoprecipitation (IP) pull-downs/western blots) and the 
phosphorylation status of the CAR-associated LCK versus the cellular LCK under 
different activation conditions. 
 
A Model for the Contribution of CD8 to scFv CAR Activity 
Previous studies have shown that the addition of tyrosine kinases such as LCK 
to CAR constructs improved maximal cytokine release (264),(283), as my results 
imply in comparison of the LCK and 4-1BB constructs (Figure 4.8).  However, the 
previous CAR studies did not assess the contribution of CD8 in mediating T cell 
activity since most CARs evaluated to date recognize antigens unassociated with 
MHC proteins. I used the 237 scFv-fusion system to examine this issue, comparing 
the responses to plate-bound antigen (without class I MHC) or tumor cells (with class 
I MHC). As described above, the CD8+ 237 scFv T cells were inactive with plate-
bound glycopeptide antigen (Figure 4.4A, 4.4C) but mediated cytokine release in the 
presence of the Ag104 tumor cell line that expresses 237 antigen and MHC molecules 
(Figure 4.3B).  I propose that this difference in response is based on the CD8 
recognition of MHC molecules that are in close proximity to antigenic 237 epitopes 
on the tumor cell lines;  the proximity allows CD8-associated LCK to be brought into 
proximity with the 237 scFv CAR, initiating T cell signaling.  A similar role for the 
CD4 coreceptor has been observed with full-length TCR by FRET, whereby CD4 can 
bind to MHC molecules that neighbor the TCR:pepMHC interaction and contribute to 
initiation of T cell signaling (284).  However, to my knowledge, this productive 
signaling interaction between CD8 and non-cognate class I MHC has not been 
revealed in previous studies. 
Further, I propose a model where in the absence of CD8 coreceptor, signaling 
through the scFv and scTv CAR molecules is facilitated by the activity of non-CD8-
associated cellular LCK (called “free” LCK in some studies), which initiates T cell 
activation upon antigen binding (Figure 4.12A).  In the presence of CD8, however, 
LCK sequesters CD8 away from the scTv CAR complex (Figure 4.12B).  In the case 
of the m33 scTv, the CAR cannot act cooperatively with CD8 to recognize the same 
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pepMHC antigen as the scTv, and CD8 also sequesters LCK away from the 
immunological synapse, effectively decreasing T cell sensitivity to antigen (Figure 
4.5B).  Alternatively, LCK could be brought into close proximity of the scTv-CAR 
through CD8 binding to MHC molecules that neighbor the pepMHC class I antigen 
bound by the scTv (Figure 4.12C).   
Partial inhibition of the activity of 237 scFv CAR in CD8+ T cells with an 
anti-CD8 antibody (Figure 4.4B) is consistent with this model.  The incomplete 
inhibition could be due to several factors. The anti-CD8 antibody is thought to bind at 
a site that does not prevent interaction with class I MHC, but interferes with 
interactions with the normal TCR complex.  Thus, the antibody-bound CD8 could act 
at a longer distance to interact with scFv (relative to scTv) through recognition of 237 
antigen epitopes in different orientations from the membrane, or by trans activation 
of two neighboring scFv CAR molecules (i.e. LCK from the neighboring scFv 
phosphorylating the ITAMS of other nearby scFv molecules).  Regardless of the 
explanation, my experiments support a model where CD8 contributes to target cell 
recognition and signaling even in cases where the CAR recognizes antigens that are 
not MHC proteins.   
 
Implications of the Role of CD8 on scFv-CAR-Mediated Adoptive T Cell Therapies 
A role for CD8 participation in tumor cell recognition with scFv receptors 
targeting non-MHC antigens has important implications for tumor immunotherapy.  
Many tumor cells downregulate MHC molecules to evade the immune response, 
creating 'hard lesions' within tumors that often evade T cell responses (reviewed in 
(285)).  In these instances scFv directed at MHC unrestricted antigens would be 
unable to mediate maximal T cell response to tumor, because CD8 could not 
contribute to T cell:APC interaction (Figure 4.12D).  This mechanism has important 
implications for CARs directed against non-MHC antigens, since CAR constructs are 
often transduced into CD8+ T cells to destroy cancer cells and MHC loss on tumor 
cells would potentially decrease the efficacy of CD8+ T cell activity.    
 The lack of cooperativity between CD8 and scTv in antigen recognition, as 
opposed to the cooperative effects of CD8 with full-length TCR is interesting in that 
 96
it is not well understood if the CD8 coreceptor associates with the extracellular 
domains of the TCR to provide enhancement or if the MHC mediates CD8/TCR 
surface aggregation (286),(287) .  The scTv system provides an opportunity to probe 
CD8 association with TCR in antigen binding by comparing the role of CD8 in scTv 
and full-length TCR.  An additional unresolved issue with CAR constructs is the 
mechanism of CD28 costimulation.  One hypothesis suggests that CD28 in the CAR 
transmembrane domain permits heterodimerization with other CD28 subunits 
allowing for costimulatory signal from CD28 ligands on target cells, but has yet to be 
explained (288).  Thus, a multitude of issues regarding TCR and CAR assembly, 
mechanism of action, and function could potentially be studied in the 58-/- system 
with the m33 scTv and 237 scFv in future experiments.   
 
Modification of Intracellular Signaling Domains to Include 4-1BB For Improved 
CAR Expressing T cell Persistence 
A major challenge in adoptive therapy is assuring that T cells expressing CAR 
constructs persist, to eliminate and prevent outgrowth of tumor. To provide maximal 
activity of the scTv constructs, I explored the use of 4-1BB signaling for improved 
persistence of transduced T cells.  Although the 4-1BB constructs are transduced with 
high efficiency, they did not mediate cytokine release with similar maximal IL-2 
release or antigen sensitivity in comparison to the CD28, CD3ζ, LCK construct in 
vitro.  Two possible explanations for the decreased antigen sensitivity of the 4-1BB 
constructs are that 1) the CD28 and CD3ζ constructs are ineffective when separated 
by the 4-1BB domain in cis for mediating cytokine release or 2) that the murine 
homologue of 4-1BB is not functional.  Modifications of the intracellular signaling 
domains may improve T cell cytokine release, either by swapping of domain 
orientation or inclusion of other signaling domains.  It will be important to assess the 
potency of other intracellular signaling domains, namely receptors containing only 
CD3ζ Tm and intracellular CD3ζ, as recent work has shown these receptors provide 
maximal T cell activity (289).  It is unclear if T cells expressing CARS containing the 
CD3ζ Tm would persist, as another study has shown that receptors containing this 
transmembrane domain fail to persist in vivo in murine models (267).  Another 
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possibility would be to express two CARs of differing specificity in the same 
retroviral vector with different signaling subunits.  For instance, other groups have 
introduced two CARs with different signaling subunits (i.e. CD3ζ in one CAR and 
CD28 in another CAR) to allow for maximal signal 1 (CD3ζ membrane proximal) 
and maximal signal 2 (CD28 membrane proximal) (290).    
Although preliminary data with the murine tumor lines overexpressing SIY 
suggested that the 4-1BB and LCK containing scTv were inefficient in mediating 
cytokine release (Figure 4.10), it is possible that the costimulatory domains present in 
these constructs allow for targeting by T cells in differing states of activation (291).  
In point of fact, preliminary results with the m33 scTv 4-1BB construct introduced 
into primary T cells have demonstrated that the transduced cells were able to lyse 
SIY-expressing target cells (Figure 4.11, experiment performed by Dr. Adam 
Chervin).  Thus, the costimulatory domains may be sufficient to drive T cell killing of 
target cells and this response may be sufficient to eliminate tumor burden if 
transduced T cells can persist in vivo.  Improvements in transduction of primary 
murine T cells, particularly with the smaller 4-1BB containing constructs, will allow 
for comparison of the 237 scFv with the m33 scTv for targeting tumors in adoptive 
transfer formats.  It should be noted that the lysis of SIY/Kb+ target cells by scTv and 
scFv transduced primary T cells was quite potent, especially given the low levels of 
expression currently obtainable (< 10% in most cases) in primary cells.  
To date, there are no reports to my knowledge using the murine homologue of 
4-1BB in chimeric antigen receptor formats.  It is important that the murine versions 
of these proteins be evaluated in vivo in murine models, as the humanized versions of 
two CARs specific for tumor antigens led to adverse events, which potentially could 
have been avoided by evaluation of a murine model system (292), (293).  In one of 
these instances, it is hypothesized that low levels of target antigen were present on 
non-malignant tissue, which caused autoimmunity from CAR transduced T cells 
targeting self-tissue.  This led to systemic inflammation and multi-organ failure (292).  
Thus, there is a clear need to explore murine model systems with CARs that express 
antibodies targeting murine antigens to understand reactivity with self tissue, as many 
of the preclinical studies are performed in humanized murine systems where target 
 98
antigen expression is limited to a xenograft tumor.  Such model systems often fail to 
mimic the effect of low levels of self-antigen on non-malignant tissue.  This is less of 
a concern for the 237 antigen, since expression is thought to be limited to tumor 
tissue.  From the existing murine studies evaluating scFv-derived CARs, it is apparent 
that the T cell mediated response is much more potent than the response mediated by 
the soluble antibody (294), and future work will need to evaluate the appropriate 
conditions for adoptive transfer of CAR expressing T cells which could be evaluated 
with the 237 and m33 CAR constructs (i.e. choice of antigen target, or number of 
transduced T cells to introduce to patients).   
 
Antigen Density Effects on scTv and scFv Function 
 In the context of the tumor environment the amount of antigenic peptide:MHC 
is lower in surface density than in the context of SIY loaded T2-Kb cells that only 
express one antigenic peptide (data from SIY/Kb system not shown).  I observed 
decreased antigen sensitivity of the m33 scTv and m33 full-length construct using 
antigen presenting cells which present other endogenous peptides.  Quantification of 
the surface levels of antigen demonstrated that the decrease in sensitivity was due to 
lower levels of antigen in the cell lines expressing endogenous peptides.  The 
decrease in sensitivity was larger for the scTv relative to the full-length TCR, further 
implying that the signaling of the CAR constructs might rely on clustering to mediate 
activity.  
Others have demonstrated that scFv CARs require 10,000 - 15,000 antigen 
epitopes/target cell for half-maximal lysis, with ~1,000 epitopes required for T cell 
activation (as observed by TCR downmodulation) (295).  This number is much larger 
than the number of antigens recognized by conventional full-length αβ TCRs as it is 
estimated that with CD8+ full-length TCR can mediate activity with as few as 10 
peptide:MHC molecules (296),(297).  In the context of cancer cells, the number of 
specific pepMHC are likely lower than the number of surface molecules targeted by 
scFv therapies, and hence, it will be important to find ways to improve scTv CAR 
function by either modification of the intracellular signaling domains or by 
developing fusion proteins that allow CD8 coreceptor to aid in scTv target cell 
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recognition by modification of the hinge region.  Work is on-going to determine the 
number of antigenic molecules present on Ag104 cells and the various SIY/Kb 
expressing tumor cell lines to draw quantitative comparisons and determine the 
parameters for scFv and scTv activation.   
 Because CD8 is a fixed length from the T cell membrane, some antigenic 
pepMHC epitopes may not be in close enough proximity to MHC molecules to allow 
for CD8 coadhesion at the T cell:APC interface.  For instance, the m33 scTv 
recognizes peptide-MHC antigen at a fixed length and orientation from the membrane 
and steric effects could possibly limit the ability of CD8 to bind to the same or 
neighboring MHC complexes as the scTv (i.e. Figure 4.12B).  The length of the 
CD8α hinge spacer connecting the scTv to the T cell may also be too long or short to 
accommodate binding by CD8 to the same MHC as the scTv fusion.  In contrast, the 
237 scFv has epitopes at varied distances from the cell membrane which may allow 
for CD8 coadhesion to neighboring MHC molecules spanning longer distances across 
the membrane.  I speculate that variation in the hinge length may potentially afford 
advantages in creating CD8 cooperativity for scTv constructs at yet to be defined 
distances from the APC membrane.   
 
The Effect of Hinge Region Length Between scFv or scTv and Tm Domain   
 Others have demonstrated with different scFv the importance of CAR hinge 
region for improving CAR activity depending on the length if antigen from the APC 
membrane.  Epitopes that were in close proximity to the target cell membrane were 
targeted more effectively (295),(298).  Another study using BiTe molecules (BiTe: 
bispecific T cell engager), which consist of antibodies with similar affinity for antigen 
fused to scFv anti-CD3 antibodies, also showed that epitopes closer to the target cell 
membrane were efficiently targeted (299).  Notably, the antibodies used in this study 
were of comparable affinity for antigen, suggesting that the primary determinant of 
BiTe molecule efficacy was target antigen distance from the APC membrane.  In full-
length TCR systems increasing the length of peptide:MHC from target cell membrane 
caused less potent T cell activation, consistent with a model where TCR-ligand pairs 
are large and CD45 infiltration near the TCR negatively regulates T cell signaling 
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(300). Yet other studies state that the length of the hinge region can compensate for 
distance from the target cell, with longer hinge regions for some antigens promoting 
improved T cell activity (301).  These studies all suggest that for each antigen, there 
may be an optimal length for CAR interaction, and potentially a specific length of 
antigen:receptor interaction that would allow CD8 coreceptor association.  
Specifically, in the context of the m33 scTv, an appropriate sized linker may allow for 
CD8 cooperativity improve scTv sensitivity, such that fewer antigenic pepMHC 
molecules could be recognized.  A thorough analysis of the effect of spacer region or 
Tm domain has not been undertaken and is needed, as few groups have evaluated 
scFv CAR hinge length in regards to antigen choice.   
 The importance of the hinge length in CAR function is highlighted by the 
multitude of spacer regions used in various different scFv-based constructs.  Given 
that different spacer regions can improve CAR function and could potentially allow 
for CD8 cooperativity with the scTv, a selection strategy to determine the optimal 
hinge region would be valuable.  Our lab has previously developed a selection 
strategy for introduction of TCRs into T cells and isolation of receptors with 
improved biological properties (147).  One potential strategy to determine the optimal 
spacer region for a given antigen would be creation of a library of the 10-20 most 
prevelent spacer regions in a CAR format derived from human extracellular cell 
surface proteins.  ScFvs of a wide variety of specificities could be introduced into a 
template CAR and subsequently, libraries containing spacer regions of different 
lengths could be generated.  A similar strategy could be used with the m33 scTv 
CAR, to attempt to isolate hinge regions that might permit CD8 cooperativity.  An in 
vitro (IL-2 release assay) or in vivo (a mouse containing antigen presenting tumor 
cells) selection strategy could then be used to isolate the cells which mediate the 
greatest level of cytokine release or tumor infiltration.  Such a strategy would be 
extremely valuable to the field, as scFv could be evaluated for the optimal spacer 
without the need to evaluate each spacer region individually, a time consuming 
process for every antigen.  More importantly, a hinge region that promoted CD8 
cooperativity with an scTv could allow for recognition of low numbers of pepMHC 
molecules and mimic full-length TCR recognition in the presence of CD8. 
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CD28Tm Domain Provides an Advantage for Improved Surface Expression Levels in 
Murine T cells 
I also compared the murine CD8Tm and CD28Tm domains, as many CAR 
constructs use different transmembrane domains derived from various cell surface 
proteins (reviewed in (142)).  CD8Tm was chosen for evaluation as recent clinical 
trials used receptors with an identical CD8Tm for constructs targeting CD19 for B 
cell malignancy (302), (303) and HER2 for metastatic melanoma (267).  The CD8Tm 
conferred a marked reduction in surface levels of scTv relative to the CD28Tm.  
Importantly, the CD8Tm sequence is identical in mouse and man, suggesting that 
there may be some issues associated with using this sequence in human CARs.  The 
CD8Tm is shorter in length than the CD28Tm domain, but has a very similar 
hydrophobicity index (data not shown), suggesting that the improved surface levels of 
the CD28Tm constructs are due to undefined characteristics of this transmembrane 
protein sequence.  Others have shown that the CD8α transmembrane domain 
promotes homodimerization with other CD8α subunits, but the transduced 58-/- cells 
lacked CD8, so it is possible that lower surface levels were due to a lack of 
endogenous CD8 that would permit heterodimer formation with introduced CAR.  It 
is also possible that CD28 is able to dimerize with endogenous CD28, enhancing 
CAR surface levels of the CD28Tm.   
The CD28Tm is not as highly conserved between murine and human proteins, 
suggesting that the enhanced surface levels obtained in the CD28Tm system will not 
necessarily provide benefit in human systems.  As many CARs directed at human 
antigens use the CD28Tm, using this Tm is beneficial because it is the closest Tm 
mimic to analogous human receptors.  A selection strategy similar to that described 
for identifying optimal CAR hinge regions could be used to select the most 
advantageous transmembrane domain to improve CAR surface levels, and determine 
which transmembrane domains permit that most efficient surface expression while 
retaining CAR signaling capabili 
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Figures 
 
 
 
 
Figure 4.1. Schematic of 237 scFv and m33 scTv CAR Constructs. 
Tm=Transmembrane Domain.  mVαL= murine Vα Leader sequence from 2C TCR.  
The gray box represents the mutations which confer enhanced affinity of the m33 
mutant of the 2C TCR that improves affinity for SIY/Kb. 
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Figure 4.2. Surface Expression and Activation with Tumor or Peptide Loaded 
Antigen Presenting Cells.  (A) Surface expression of the 237 scFv CAR (black line) 
or 58-/- CD8- T cell line (gray).  (B) Surface expression of the m33 scTv CAR (black 
line) or 58-/- CD8- T cell line (gray).  (C) Activation of the 237 scFv line from (A) 
with Ag104 (red, antigen +) or AcosM (black, antigen null) tumor cells.  Data is 
representative of 3 independent experiments.  (D) Activation of m33 scTv line from 
(B) with T2-Kb cells pulsed with SIY (red) or OVA (black) peptide.  Data is 
representative 2 independent experiments. 
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Figure 4.3. Activation of CD8- and CD8+ 237 scFv CAR Expressing T cells with 
Tumor Cell Lines. (A) Surface expression of 237 scFv and CD8α with 58-/- (gray, 
filled histogram), 237 CD8- (black solid line), and 237 CD8+ (black dashed line) cell 
lines as indicated. (B) CD8+ (squares) cells from (A) were stimulated with Ag104 
(blue) or AcosM (null, black).  CD8- cells (circles) from (A) were also stimulated 
with Ag104 (red) or AcosM (null, black).  Data from B is representative of three 
independent experiments. 
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Figure 4.4. Activation of CD8- and CD8+ 237 scFv CAR Expressing T cells with 
Plate-Bound Glycopeptide Antigen and Effect on T cell Activation from 
Blocking CD8:CAR Association. (A) Plate-bound glycopeptide activation of 237 
CD8- scFv (red), 237 CD8+ scFv (blue), or m33 CD8- scTv (null T cell, gray).  (B) 
Surface expression and CD8 expression of 237 HI CD8+ expressing line after sorting 
for homogenous CAR expression. (C) Plate-bound glycopeptide activation of cell 
lines shown in (B).  Data from A and C is representative of three independent 
experiments.  (D) 237 HI CD8+ cell line from (B) was incubated with Ag104 cells at 
given E:T with (light blue) or without (black) pretreatment with anti-CD8α blocking 
antibody at 10 μg/mL.  Data represents the mean of 4 wells for each sample.  
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Figure 4.5. Surface Expression and Activation of m33 scTv CAR With or 
Without CD8 Coreceptor. (A) Surface expression and CD8α levels of m33 CD8- 
and CD8+ scTv cell lines as indicated. (B) Activation of CD8- (red) or CD8+ (blue) 
cell lines with peptide pulsed T2-Kb cells.  No activity was observed with OVA 
pulsed cells (data not shown).  Data is representative of three independent 
experiments.  (C) Activation of m33 CD8- (red) or CD8+ (blue) scTv cell lines from 
(A) with plate bound SIY/Kb tetramer.  No activity was observed with OVA/Kb 
tetramer (data not shown).  Data is representative of two independent experiments. 
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Figure 4.6. Endogenous Peptides Decrease SIY/Kb Surface Levels and Receptor 
Antigen Sensitivity. (A) SIY peptide was loaded onto T2-Kb (black), EL4 (green), 
C57/BL6 splenocytes (gray), or MC57 (blue) cells for 24 hrs with m33 CD8- scTv 
and IL-2 release was measured.  (B) m33 CD8- full-length TCR was used in place of 
scTv with the APCs from (A). 
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Figure 4.7. Transduction Efficiency and Initial Surface Levels of m33 scTv 
Constructs. (A) Surface expression of scTv containing CD28, CD3ζ, LCK or CD28, 
4-1BB, CD3ζ intracellular signaling subunits (ζ= CD3ζ).  Untransduced 58-/- T cells 
(gray filled histograms) or transduced cells (black line) were analyzed for Vβ8 
expression.  Percentage represents portion of cells within marker shown for 
transduced cells before cell sorting.   (B) Alignment of CD28 and CD8 murine 
transmembrane domains.  (C) Comparison of CD8Tm and CD28Tm with CD28, 4-
1BB, CD3ζ scTv constructs. Untransduced 58-/- T cells (gray) or transduced cells 
(black line) were analyzed for Vβ8 expression as in (A).  Peak mean fluorescence 
intensity is labeled for each histogram, and CD28Tm constructs were expressed with 
7-fold higher MFI than CD8Tm constructs. 
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Figure 4.8.  Surface Expression and Characterization of 4-1BB Containing scTv 
Constructs. (A) Surface levels of scTv and full-length constructs after selection.  
MFI=mean fluorescence intensity of the entire population of T cells.  (B) T cell 
activation with plate-bound mVβ8 antibody.  Data is representative of two 
independent experiments.  (C) T cell activation with SIY peptide loaded T2-Kb cells 
and T cells shown in (A).  Cell lines as indicated.  Levels of IL-2 release with OVA 
peptide loaded cells were below background (data not shown).  Data is representative 
of two independent experiments. 
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Figure 4.9.  Activation of CD28Tm scTv CAR Constructs and Full-Length TCR 
with Excess SIY Peptide.  m33 full-length TCR (black), m33 scTv CD28, CD3ζ, 
LCK (blue), and m33 scTv CD28Tm, CD28, 4-1BB,ζ (red) were incubated with 
target T2-Kb cells pulsed with 1 μM SIY peptide.  A similar trend for T cell activation 
was observed with 100 nM SIY peptide, with T cell activation in the order of full 
length TCR>LCK scTv>4-1BB scTv, with lower levels of maximal IL-2 release for 
all cell lines (data not shown). 
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Figure 4.10.  Activation of CD28Tm scTv Constructs and Full-Length TCR with 
Tumor Cells. (A) Activation of B16-SIY melanoma line (B16) with (top row) or 
without (bottom row) IFN-γ treatment 24 hrs before activation assay.  Cells were 
analyzed by flow cytometery for SIY/Kb surface expression with m67 high affinity 
scTCR or anti-Kb.  m33 full-length TCR (black), m33 scTv CD28, CD3ζ, LCK 
(blue), or m33 scTv CD28Tm, CD28, 4-1BB, CD3ζ (red) T cell activation as shown.  
(B) m67 high affinity TCR stain of MC57 fibrosarcoma cell lines expressing varying 
levels of SIY antigen.  Activation data for corresponding cell line at right with colors 
corresponding to T cell lines as in (A). 
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Figure 4.11. Transduction of Primary Murine T cells with m33 Full-Length or 
m33 scTv (CD28,4-1BB,CD3ζ) and Cytotoxic Activity of T cells.  (A) Transduced 
CD8+ primary T cells were assessed for binding to SIY/Kb phycoerythrin tetramer 
(full-length TCR or scTv expressing cells, Y-axis), and CD8 surface levels (anti-
CD8α, X-axis).  Percentages of cells in each quadrant as indicated.  (B) T cells killing 
of target cells pulsed with either 1 μM SIY peptide (red), 1 μM OVA peptide (black) 
or no peptide (white).  (C) Transduced CD4+ primary T cells were analyzed as in 
(A).  (D) T cell killing with CD4+ cells from (C).  Experiments in B and D are 
representative of two independent experiments, performed by Dr. Adam Chervin. 
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Figure 4.12. Model for scFv Cooperativity for Recognition of Non-MHC 
Restricted Antigens. (A) The scTv CAR (Dk. gray, antigen binding domain) 
recognizes SIY/Kb pepMHC (blue, as indicated). Intracellular LCK (‘free’ LCK, 
yellow) that is not fused to the CAR can associate with ITAMs (immune tyrosine 
activation motifs), and phosphorylation occurs at these ITAMS in CD3ζ (magenta) by 
‘free’ LCK.  (B) In the presence of CD8 (green), ‘free’ LCK associates with CD8.  In 
the case of the m33 scTv, CD8 cannot readily associate with the same antigenic 
pepMHC as the scTv, and CD8 sequesters LCK away from the synapse.  ITAMs are 
not efficiently phosphorylated (gray squares) because CD8 is inefficient in the 
recognition of neighboring MHC molecules, since the pepMHC is at a fixed 
orientation and distance from the membrane.  (C)  Recognition of 237 antigen (red) 
by the 237 scFv (black) can be enhanced by CD8 recognition of neighboring 
pepMHC molecules (blue) on tumor cells.  CD8 is sequestered to the TCR:tumor cell 
interface permitting phosphorylation of ITAMs (magenta).  (D) In tumor cells that 
downregulate MHC, 237 scFv can still bind to 237 antigens on the surface of T cells, 
but CD8 cannot associate because of loss of MHC surface expression.  LCK is 
sequestered from the scFv:tumor cell interface, decreasing the potency of T cell 
activation.    
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CHAPTER FIVE 
 
ENGINEERING MOUSE HIGH-AFFINITY T CELL RECEPTORS AGAINST 
WILM'S TUMOR ANTIGEN USING T CELL DISPLAY 
 
Introduction 
 
 A promising approach to tumor elimination involves the use of adoptively 
transferred T cells directed against tumor associated peptide-MHC complexes.  
Regression of tumors using adoptive immunotherapy has been demonstrated 
successfully subsequent to lymphodepletion in melanoma patients (128-131). In these 
studies, the persistence of T cell populations specific for cancerous tissue was 
observed one month after transfer (128).  The potential value of T cell adoptive 
therapies is that they provide a route to target cancer tissue specifically, while 
generating a T cell memory population that could eliminate residual disease.  
Antigens targeted by adoptively transferred T cells, a tumor associated peptide-MHC 
complex, can include overexpressed self peptides or mutated peptides.  Because 
CTLs against “self” peptides are deleted in the thymus during T cell development, 
individuals may be left with a T cell repertoire that has a reduced capacity to 
eliminate the cancer tissue.  The absence of these T cells represents a major problem 
with many T cell based strategies: that is, an individual may lack appropriate anti-
tumor T cells due to tolerance mechanisms that operate against self-antigens. T cell 
expansion ex vivo, followed by in vitro T cell receptor (TCR) gene transfer, may 
overcome this problem by introducing TCRs that are specific for these overexpressed 
antigens.   
Recently, it was demonstrated that gene transfer of a melanoma specific TCR, 
directed against the MART-1/HLA.A2 antigen, into peripheral blood leukocytes and 
subsequent adoptive transfer back into patients with advanced melanomas led to 
cancer regression in 2 of 15 patients (131). A follow up study demonstrated objective 
regression in as high as 30% of patients receiving gene modified T cells specific for 
MART-1 or gp100 (132).  These studies demonstrated the feasibility of using a TCR 
reagent that recognizes a tumor associated antigen, even in patients that fail to have 
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adequate tumor reactive lymphocytes in their T cell repertoire.  However, the modest 
but significant clinical effects of the introduced TCR may in part have been related to 
the observation that the affinities of the TCR for MART-1/HLA-A2 or 
gp100/HLA.A2 were not optimized.  Although the selected clones were considered to 
be of high avidity, the binding parameters of these receptors have not been 
characterized.  We and others have demonstrated that monomeric binding affinity 
does not alone determine T cell functional avidity in recognition of tumor cells (304).  
Although the affinity of the TCR against the cognate tumor antigen should be 
optimized, it is also important that the affinity and cross-reactivity for self-peptide 
antigens be examined in order to avoid overt autoimmunity against low levels of self-
pepMHC in non-malignant tissue.  For instance, preclinical studies have 
demonstrated overt autoimmunity from introduced T cells in murine models due to 
recognition of self-antigen on non-target tissues by cancer-antigen specific T cells 
(305). In fact, in the clinical trials targeting melanoma by TCR gene transfer, a 
positive indicator of regression was often the loss of pigment in skin and hair follicles 
(306). Another complication from TCR transduced T cells is the mispairing (Chapter 
4) of exogenous TCR chains with the endogenous chains, which can lead to lehal 
graft versus host disease (135),(136).  
Although T cell targeting of melanoma antigens has been the most studied 
system, numerous other pepMHC antigens are overexpressed on other tumor types 
and these also need to be evaluated for TCR gene therapy.  For example, the Wilm’s 
tumor antigen (WT-1) is overexpressed in a variety of tumor cell types and represents 
an attractive target for adoptive immunotherapy for malignancies aside from 
melanoma. The Wilm’s tumor protein is a zinc-finger transcription factor that has 
been predicted to have an oncogenic role in developed cancerous tissue (Reviewed in 
(307)).  Isolation and expansion of WT-1 specific T cells demonstrated that CTL 
killing of peptide WT-1126-134/HLA.A2 positive tumor cells was dependent upon the 
presence of IFN-γ (308). This finding implies that a low extent of killing by T cells in 
the absence of IFN-γ was due to low pepMHC surface levels.  As stated by Stauss and 
colleagues in their article regarding WT-1 specific TCR detection in early breast 
cancer in the context of adoptive therapies “strategies that allow high level of 
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peptide/MHC complex presentation and/or improved CTL avidity may be of clinical 
benefit (308)”. This makes the WT-1 tumor antigen a strong candidate for 
development of high affinity T cell receptors, as CD8+ T cells with higher affinity 
receptors may be able to recognize fewer pepMHC complexes on the antigen 
presenting cell surface (206).  In addition, recruitment of CD4+ T cells through a 
high-affinity, class I restricted (WT-1/MHC) TCR could promote enhanced IFN-γ 
secretion as has been observed in adoptive transfer model systems (225). The ability 
of class-I specific high-affinity TCRs to mediate killing in CD4+ cells has also been 
shown, further illustrating the value of a potent CD4+ TCR response (309).  Increased 
cytokine release in the tumor microenvironment is crucial for maintenance of CD8+ T 
cells, as tumor infiltrating lymphocytes often lose cytotoxic function in the absence of 
CD4+ T cell help (310). 
An immunodominant peptide of WT-1 (WT-1126-134, RMFPNAPYL) has been 
demonstrated to be expressed on the surface of tumor cells in the context of the 
human MHC human leukocyte antigen A2 (HLA.A2) in multiple tumor types 
(311),(312),(313), (314).  WT-1 derived peptides presented by HLA.A2, the most 
common class I allele present in 40-50% of the population, have recently been shown 
to promote clearance of acute myeloid leukemias (AML) in clinical trials when the 
peptides were introduced by mRNA electroporation into dendritic cells in a vaccine 
format (315). This study demonstrated that in AML there was sufficient antigen on 
tumor cells to promote immune clearance given sufficient priming of WT-1 specific T 
cells and validates WT-1 as a target for immunotherapy.  The murine homolog of the 
WT-1 peptide is identical to the human HLA.A2 binding peptide, and is presented by 
the murine MHC allele Db.   Consequently, murine tumors that overexpress WT-1 
could provide a comparable model system to explore the efficacy of T cell treatments 
with high-affinity receptors and thus better define the optimal range of affinities for 
targeting overexpressed self-antigen. There is also a need for a model murine WT-1 
system, as most model systems for WT-1 TCR gene transfer have used humanized 
mice which do not allow for the evaluation of potential autoimmune effects when 
targeting a self-antigen (316),(317).  
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The focus of the current study was to engineer high affinity T cell receptors 
against a murine peptide-MHC WT-1/Db.  To improve T cell responses to tumor 
antigen, we and others have engineered T cell receptors for enhanced affinity to 
defined antigens using yeast, phage, or T cell display (Reviewed in (146)).  Yeast 
display and phage display are limited by the potential instability of full-length or 
single-chain TCRs, as evidenced by the fact that only a handful of TCRs have been 
engineered for enhanced affinity using phage or yeast display (157),(154), 
(148),(150),(149).  Although rational design has been used to raise the affinity of 
TCRs 100-fold (318), to date these methods have required structural information 
about the lower affinity TCRs in complex with pepMHC, an approach that is also 
hindered by difficulties in expressing and crystallizing full-length TCRs in complex 
with antigens (reviewed in (59)).    
Recently, we developed a T cell display platform using the 58-/- T cell 
hybridoma to display TCR variants, and select for high-affinity T cell receptors using 
pepMHC multimers in combination with fluorescence activated cell sorting (147).  
The T cell display system allows for the generation of libraries on the order of 105 to 
106 variants without the need for additional in vitro engineering to assure TCR is cell 
surface expressed.  Here, I used a TCR called 3D that is specific for the model murine 
Wilm’s tumor antigen (WT-1, peptide RMFPNAPYL) in the context of the MHC Db, 
to isolate enhanced affinity TCR variants of the 3D TCR.  The variants were capable 
of redirecting T cells independently of the coreceptor CD8.  This chapter describes 
the refinement of T cell display to allow for isolation of high-affinity variants of the 
3D TCR, as well as highlights the possibility of using murine high affinity mutations 
to direct the engineering of human TCRs against an analogous human WT-1 antigen. 
 
Materials and Methods 
 
Peptides, Antibodies, Dimer Reagents, and Cell Lines 
Peptide gp100 (EGSRNQDWL) and WT-1 (RMFPNAPYL) that bind to the 
MHC allele Db were synthesized by the Macromolecular Core Facility at Penn State 
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College of Medicine (Hershey, PA).  Peptides were purified by reverse-phase 
chromatography using a C18 column with mass confirmed by MALDI.  
The following antibodies and peptide:MHC multimers were used: PE-
conjugated anti-mouse Vβ10 (Clone B21.5, eBiosciences), DimerX Db (BD 
Biosciences), PE-conjugated anti-mouse CD8α (Clone 53-6.7, BD Pharmingen), 
Goat anti-Mouse IgG AlexaFluor 647 (Molecular Probes) or AlexaFluor 488, and PE-
conjugated anti-Cβ (Clone H57-597).  DimerX Db was loaded with 120-fold excess 
peptide of interest at 37 degrees C for 16 hours as outlined by BD biosciences 
protocol.   
PLAT-E (Clonetech) retroviral packaging cell line was maintained in DMEM 
with 10% FCS, L-glutamine, penicillin and streptomycin.  T2-Db, a TAP-deficient 
cell line that presents exogenous peptides, the EL4 tumor line and 58-/- T cell 
hybridoma were maintained in RPMI 1640 complete medium supplemented with 
10% FCS, L-glutamine, penicillin and streptomycin.  The 58-/- T cell line, with or 
without CD8α/CD8β, was transduced with retroviral supernatants of the full-length 
TCR mutant constructs described as previously described (153).  
 
Creation of 3Dα-P2A-3Dβ TCR Construct 
 The 3D TCR insert was amplified from the codon-optimized (GeneArt) 3Dα-
P2A-3Dβ (Vα3, Vβ10) construct in the pMig2R cloning vector (Greenberg Lab).  An 
AgeI site and MluI site were introduced at the 5’ and 3’ end respectively by PCR, and 
the 3D P2A TCR insert was introduced into the MSCV retroviral vector which 
previously contained the 2C TCR cassette as has been described (Chapter 3).   
 
Library Creation and FACS for Isolation of Improved Affinity 3D TCR variants 
 The 3D TCR in MSCV was used as a template for the creation of three 
separate degenerate amino acid libraries, each of three codons in length, spanning 
CDR3α (Sequence: TAPMDSNYQ).  The mutated TCR insert was generated by 
overlap extension PCR, and the inserts with the three amino acid degeneracy were 
subsequently cloned into the MSCV vector using AgeI and BspEI restriction sites.  
The BspEI site is within the Cα of the 3D TCR.  Ligation gave libraries of at least 
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7,000 transformants (Table 1), with at most 20% of library as unmodified, 
background 3D wild type TCR.  The DH5α cell libraries were expanded and plasmid 
DNA was isolated.  Library DNA was introduced into the PLAT-E packaging cell 
line using lipofectamine, and 24 hours after packaging cells were detoxified (removal 
of supernatant from transformation) and resuspended in 6 mLs RPMI + L-glutamine.  
24 hrs later retroviral supernatants were harvested.  Viral supernatants were 
spinfected on top of 1X106 58-/- cells and cells were sorted as described (Results).   
 
Identification of CDR Mutations that Improve Affinity for WT-1 from L3 Library 
 Total RNA was isolated (Qiagen RNeasy kit) from the L3 library after 3 sorts 
(3D L3).  RNA was converted to cDNA (Biorad, iScript cDNA kit) and then 
subjected to two rounds of nested PCR.  The PCR product was sequenced, yielding 
two species that were predicted to respresent separate products:  a predominant 
sequence, called Q103H (CDR3α: TAPMDSNYH), and the minor sequence, called 
N101P, Q103Y (CDR3α: TAPMDSPYY).  
 
Characterization of Q103H and N101P, Q103Y Cell Lines  
 The mutations from the two PCR products from the antigen-selected 3D L3 
library were introduced into the 3D MSCV vector by Quikchange mutagenesis 
(Stratagene) using the exact nucleotides that were isolated from nested PCR. The two 
vectors were then transfected into the PLAT-E cell line, and the supernatant was used 
to transduce the 58-/- T cell hybridoma line that lacks the CD8 coreceptor.  Cell lines 
were characterized for binding to WT-1/Db DimerX (BD Biosciences).  The gp100/Db 
DimerX was used as a control.  
 
Results 
 
T Cell Display of a Murine WT-1 Specific TCR 
 The 3D murine T cell receptor was introduced into the MSCV retroviral 
vector (schematic, Figure 5.1A), and subsequently used to tranduce the 58-/- T cell 
hybridoma line.  Cells were sorted to express >95% Cβ positive T cells.  Notably, 3D 
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TCR+ cells that lacked CD8 did not bind to WT-1/Db dimer on ice at detectable levels 
(Figure 5.1B, top panel).  To improve the affinity of the WT-1 specific TCR, I 
generated three different T cell display libraries in CDR3α (complementary 
determining region 3) as performed with the 2C T cell system (147).  Previous 
engineering projects have demonstrated that high affinity binding solutions often exist 
within CDR3α (157), (101).  Moreover, we and others have shown modest increases 
in affinity for pepMHC by single or dual amino acid changes in TCR CDR regions 
(319), (320),(321), 
Hence, I generated several three-codon libraries, designated as L1, L2, and 
L3, that spanned the CDR3α loop of the 3D TCR (Figure 5.1A) using the T cell 
hybridoma 58-/- to display the mutated TCRs.  The ligated plasmids were transformed 
into E. coli and the number of independent transformants was calculated by plating a 
sample of the transformants, prior to preparation of the mutated pool of plasmids 
(Table 5.1).  The purified plasmid preparations were transfected into PLAT-E cells 
for the production of packaged viruses.  T cell hybridoma cells were transduced with 
the packaged viruses, and CDR3α libraries were analyzed for anti-Cβ cell surface 
expression after 4 days in culture (data not shown). From the per cent of cells that 
were positive, and the total number of 58-/- cells, it was possible to calculate the total 
number of independent transductants for each library (Table 5.1).  From these 
calculations, it was possible to deduce that the limiting factor in final 58-/- library size 
(range from 7 x 103 to 3.6 x 104) was not T cell transduction but was transformation 
of the ligated, retroviral vector into E. coli (Table 5.1).  Our lab has subsequently 
used in vitro enzymatic reaction to improve this transformation efficiency for other 
TCRs and can currently generate greater than 1 X 106 variants by homologous 
recombination, sufficient to cover the theoretical diversity of a three amino acid 
degeneracy library (data not shown).  
 After the 3D L1,L2, and L3 libraries were introduced into the 58-/- line (Table 
5.1, efficiency of transduction), cells were sorted one time with anti-Cβ antibody to 
obtain populations that expressed greater than 50% Cβ+ T cells (Figure 5.1B, and S1 
in Figure 5.2).  The sorted cells were expanded in culture, and analyzed by flow 
cytometry for ability to bind to the WT-1/Db dimer at 125 nM (Figure 5.1B).  The 3D 
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L3 library (wild type: CDR3α: NYQ) appeared to contain a small population of T 
cells that bound to WT-1/Db dimer at 125 nM (0.56% in APC positive gate for L3 
compared to 0.19% average for 3D wild type TCR, L1, and L2). The L1, L2, and L3 
libraries were sorted once with WT-1/Db dimer at 300 nM (Sort 2); however, only a 
positive population which bound WT-1/Db dimer was observed for the L3 library 
(Figure 5.2, S2 cells after 1 dimer sort).  I chose to pursue this L3 library and sorted it 
a second time with WT-1/Db dimer at 200 nM (Sort 3, L3 S3).  After two sequential 
rounds of sorting with the WT-1/Db dimer (S2 and S3, Figure 5.2), the L3 library 
contained a population that bound to WT-1/Db dimer with a 13-fold increase in mean 
fluorescence intensity (S3 population), despite expressing equivalent surface levels of 
anti-mVβ10 (Figure 5.2).  Thus, the L3 library yielded a T cell line with improved 
affinity for WT-1/Db relative to the wild-type 3D TCR.   
 
Isolation of CDR3α Sequences With Enhanced Affinity for WT-1/Db 
 To determine the specific TCR mutations that improved affinity for WT-1/Db, 
RNA was isolated from the L3 library T cell line after the second sort with dimer (L3 
S3 in Figure 5.2) and cDNA was generated.  Nested PCR using α-chain primers was 
performed from cDNA template.  The DNA sequence of the PCR product revealed 
two predominant sequences (Figure 5.3) that differed from the 3D wild type at codons 
101 and 103.  Based on the intensity of the predominant species, the sequence yielded 
a single mutation of the 103 codon from CAG to CAC (a Q103H mutation).  Based 
on the minor species in the sequence, there were two mutations, one at codon 101 
from AAC to CCC (a N101P mutation) and the other at codon 103 from CAC to TAC 
(a Q103Y mutation).  Because the relative intensities of the sequences for the minor 
species were about equal, I hypothesized that a single double mutant N101P/Q103Y 
may represent this clone.  While it was possible that other solutions existed within the 
3D L3 line that are even more minor products, the predominance of these two 
sequences prompted me to explore the single (Q103H, called NYH for the sequence 
of this region) and double mutant (N101P,Q103Y, called PYY for the sequence of 
this region) TCRs, and the effects of these mutations on affinity and T cell function. 
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Single and Double Mutations in CDR3α Enhance Affinity for WT-1/Db and the 
Double Mutant Allows for CD8-Independent T Cell Activation 
 The single (NYH) and double (PYY) mutations isolated from 3D L3 were 
introduced using “quick change” mutagenesis into the 3D MSCV vector, and the 
mutants were transduced into the 58-/- T cell line.  Cell surface expression was 
monitored with anti-mVβ10 antibody (Figure 5.4A).  The NYH TCR was expressed 
at about 2-fold higher surface levels than the 3D wild type TCR or the PYY variant in 
CD8- cells.  Titration of WT-1/Db dimer on the three cell lines revealed that the NYH 
and PYY mutants bound to DimerX at concentrations as low as 10 nM, with the 
double mutant having a slightly higher relative affinity compared to the single mutant 
(Figure 5.4B).  The wt 3D TCR required almost 100-times more dimer to bind at 
relatively low levels.   
 The 3D CD8- T cell lines were incubated with various concentrations of the 
WT-1 peptide in the presence of TAP-deficient T2-Db antigen presenting cells 
(APCs) to determine the impact of improved TCR affinity for antigen on T cell 
activation (Figure 5.4C).  T cells that expressed the PYY mutant were activated 
efficiently by WT-1 peptide, but not by null peptide gp100 peptide (data not shown).  
The NYH mutant and wild-type 3D expressing cells were only activated at very high 
peptide WT-1 concentrations in the absence of CD8, suggesting that the affinity of 
the NYH expressing cells may be below the threshold for CD8 independence.  In 
contrast, it is likely that the affinity of the active mutant, PYY, is above the CD8 
independence threshold, and that it has a KD value less than about 1 μΜ (102). 
 
The Single and Double Mutant Mediate Enhanced Peptide Dependent Activation in 
CD8+ T Cells 
 The NYH and PYY mutant WT-1 specific TCRs were introduced into 
CD8αβ+ 58-/- T cells to assess the ability of the high-affinity mutations to function in 
the presence of the CD8 coreceptor.  Surface expression of the TCRs were similar, as 
judged by staining with the anti-mVβ10 antibody and CD8 coreceptor levels were 
equally high among the lines, as judged by staining with an anti-CD8α antibody 
(Figure 5.5A).  The CD8+ cell lines were incubated with various concentrations of the 
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WT-1 peptide and the Db+ APC line EL4, and IL-2 release was measured.  T cells 
expressing the NYH and PYY mutants yielded about a 10-fold improvement in 
antigen sensitivity, suggesting that the affinity of the wild type TCR is not optimized 
for CD8-enhanced T cell activity, and that the mutant TCRs might provide some 
advantage in the detection and lysis of target cells that express lower levels of the 
endogenous WT-1 peptide.   
 
Endogenous Peptides Improve T Cell Sensitivity to WT-1 Peptide In the Presence of 
CD8 
 The surface of APCs contains many other peptides distinct from WT-1 that T 
cells normally must survey to identify target cells.  To better define the role of 
endogenous peptides in the recognition of WT-1 by the T cell lines, two Db 
expressing T cell lines, T2-Db and EL4, were compared for their ability to stimulate 
3D wild type TCR and the PYY mutant TCR.  The T2-Db cell line presents 
exogenous peptides, predominantly, due to its defect in TAP, the transporter for 
endogenously processed peptides. In contrast, the EL4 cell line presents a plethora of 
endogenous peptides in addition to the exogenously added peptides. In the absence of 
CD8, the 3D wild type TCR is not active with T2-Db or EL4 (Figure 5.6A), 
presumably because the receptor is not of sufficient affinity to mediate activity 
without the synergistic binding of CD8.  T cells with the affinity-engineered TCR 
PYY were activated by WT-1 peptide at similar sensitivities with EL4 or T2-Db APCs 
(Figure 5.6B), suggesting that the endogenous peptides did not influence T cell 
antigen sensitivity in the absence of CD8.   
In distinct contrast, CD8 expression allowed both the 3D wild type (Figure 
5.6C) and PYY (Figure 5.6D) TCRs to mediate improved antigen sensitivity with the 
EL4 APC line relative to T2-Db.  This finding is consistent with the hypothesis that 
the endogenous peptides present on EL4 APCs act as coagonists, improving 
recognition of antigen.  While one could argue  that higher surface levels of Db on 
EL4 versus T2-Db could have cause improved WT-1 recognition, then one would 
have expected the PYY CD8- cells to show improved antigen sensitivity with EL4 
cells relative to T2-Db cells (Figure 5.6B). The phenomenon of coagonist activity has 
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been demonstrated by multiple groups and is thought to facilitate the proliferation of 
low affinity T cells specific for antigen during the course of infection 
(322),(323),(324),(325).  While it is possible that this activity is the result of binding 
of self pep-MHC by the 3D and PYY TCRs, the results in the absence of CD8 
suggest this is not the case (i.e. there was not an enhancement of activity with EL4). 
Thus, the enhancement in activity in the presence of CD8 appears to be due to 
CD8:self pepMHC interactions, perhaps similar to that observed with the 237 scFv 
CAR in Chapter 4. 
 
Homology Between Human and Murine WT-1 Receptors 
 To successfully target WT-1 tumor antigen in humans, it will be necessary to 
raise human T cells specific for WT-1 peptide in the context of HLA.A2.  Phil 
Greenberg’s lab (U. Washington) has now isolated a number of human CD8+ T cell 
clones that are specific for WT-1/HLA.A2, including clones CE4, CE10, P20, P22, 
P1 and P18.  In addition, they have isolated another murine WT-1 specific TCR 
called mWT-1.  Because the WT-1 peptide presented by the human MHC HLA.A2 is 
identical to the nonomer peptide presented in mice by MHC alleles Db or Kb (WT-1 
sequence: RMFPNAPYL), I sought to compare the sequences of murine and human 
WT-1 restricted TCRs.   
Alignment of the variable domains of six human and murine TCRs specific 
for WT-1 peptide revealed that there are conserved residues among the 
complementarity determining regions (CDRs) of some of the TCR sequences (Figure 
5.7, red indicates identity between at least one murine and one human TCR). The 
presence of identical residues between the mouse and human TCRs could either be 
due to evolutionary conservation at these positions, or their shared antigen (peptide) 
specificity. For example, it has been demonstrated that germline-encoded CDR1 and 
CDR2 residues may have evolved to contact disparate MHC molecules (326),(99). To 
assess this, any position where there were identical residues between the mouse and 
human WT1-1 specific TCRs were examined among all Vα and Vβ from mouse and 
human.  Those positions which showed greater than 50% identity between species 
(Figure 5.7, shown in red) were eliminated from the analysis, leaving a subset of 
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residues that were shared between the WT-1 TCRs.  I hypothesize that these 
remaining residues, predominantly located within CDR3α and CDR3β, may serve as 
the focus for peptide:TCR contacts that confer specificity of the interaction.  Thus, 
one might predict that these residues could serve as points for engineering higher 
affinity that would also translate to the human system.    
Two of the human TCRs, P20 and P22, use the Vα2 gene segment shown to 
be amenable to engineering by yeast display in Chapter 2, and work is underway to 
engineer single-chain TCR versions of these human WT-1 specific TCRs.  The 
observed sequence identity among the WT-1 specific TCRs should guide these 
engineering efforts.  A recent study demonstrated that there was some preference for 
specific TCR Vβ (TRBV 12, Vβ8) gene usage in response to WT-1 in patients with 
myeloid malignancies (327), but this Vβ gene segment was not used by any of the 
clones isolated to date by the Greenberg lab.  Αn additional two human T cell clones, 
P1 and P18, contained homologous CDR3α regions to the 3D TCR (Figure 5.7).  At 
the time of writing this thesis, our collaborators (Greenberg Lab, U. Washington) are 
attempting to introduce the 3D improved affinity CDR3α mutations into these human 
TCRs to see if these mutations also improve affinity for human WT-1 pepMHC.  
Other experiments in the Greenberg lab are examining the 3D single and double 
mutant TCRs to see if these receptors escape central tolerance mechanisms.  These 
experiments will provide insight into whether the mutant TCRs will react with self-
tissue and cause autoimmunity, and provide an additional model system to define the 
optimal affinity of TCR for adoptive transfer. 
 
Discussion 
 
 Tolerance mechanisms limit the repertoire of T cells that are specific for many 
human tumor associated antigens. This process can leave the immune system 
unequipped to eliminate cancer cells.  To improve the immune response to 
overexpressed-self cancer antigens, I sought to engineer T cell receptors for enhanced 
affinity to a defined murine tumor antigen, WT-1/Db, which serves as a model for 
human cancers that express the same WT-1 peptide antigen.   Using the mouse T cell 
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hybridoma line 58-/- for the expression of libraries of mutants in the TCR, two high 
affinity TCR variants were isolated that bound to WT-1/Db dimer independent of the 
coreceptor CD8 as detected by flow cytometry.  Thus, the T cell display system could 
be used to isolate higher affinity variants in T cell system other than the well-
characterized 2C TCR (147).  In addition, one of the TCR mutants was shown to 
mediate CD8-independent activity against the WT-1 on target cells, a hallmark of a 
higher affinity TCR:pepMHC interaction. 
Although the size of libraries obtainable by T cell display is two orders of 
magnitude lower than that achieved by yeast display, this system eliminates the need 
to create stable templates on which to engineer high affinity TCRs.  This is because 
the TCRs are expressed with associated CD3 subunits, in the context of the T cell 
membrane.  An additional advantage of the T cell display system is that the isolated T 
cell lines expressing high affinity TCRs can be assessed for functional activity 
without the need for subcloning, as is required for yeast or phage display.  Others 
have demonstrated that single and dual amino acid changes can improve the affinity 
of TCR for pepMHC (319),(320),(321).  The single most significant disadvantage of 
these studies is that they rely on the construction and examination of individual 
mutations, without the higher throughput afforded by libraries of mutants combined 
with a selection system. Thus the T cell display system provides a high-throughput 
(>104 mutants) approach that rapidly assesses and selects for combinations of 
advantageous binding mutations . Given that higher affinity TCR mutants can be 
obtained with relatively few mutations in some instances, three-codon libraries were 
created for the 3D TCR.  Although I was unable to cover the diversity of a three-
codon library (323) for two of the libraries (L1 and L2), the L3 library contained 
91,000 T cell transductants. Consistent with the larger size of this library, high 
affinity variants were isolated only from the L3 library.  It is possible that other high 
affinity solutions would have been isolated from the L1 and/or L2 libraries, if their 
size had allowed the entire sequence space to have been included.  Further refinement 
of the T cell display technology has allowed for generation of libraries of larger size 
(as high as 1 x 106) using an enzyme that catalyzes recombination in vitro (Clontech, 
InFusion Reaction Kit, unpublished data). This avoids the need to clone individual 
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sequences by ligation into the MSCV vector, a process that often yields reduced 
efficiencies of transformation.  For future engineering projects using the T cell 
display system, it is likely that the T cell transduction efficiency will thus limit the 
library size (not the step involving transformation of E. coli with the retroviral 
vector).   
The system used in the current study produced two high affinity variants 
which were subsequently characterized in CD8-negative and CD8-positive T cells. 
Characterization of T cells that expressed the double mutant, PYY, revealed activity 
in the presence of WT-1 peptide loaded cells, even in the absence of CD8.  The single 
mutant of 3D, however, required CD8 to redirect T cells to WT-1 target cells.  These 
data suggest that the double mutant should be able to redirect the helper activity of 
CD4+ T cells to a WT-1/Db-postive tumor.  In the presence of CD8, the single and 
double mutant receptors provided a 10 to 100-fold increase in half-maximal 
sensitizing dose to WT-1 peptide loaded cells relative to the template TCR.  This 
increase in sensitivity is analogous to that seen with high affinity variants of the 2C 
TCR directed against Ld (153) and Kb (101), where increased affinity led to similar 
increases in activity in the presence of CD8.   
There is likely an affinity range where self-reactivity will lead to deletion of T 
cells with high-affinity TCRs, as has been observed for high-affinity variants of the 
2C TCR (Boris Engels, Schreiber Lab, U. of Chicago).  Peripheral tolerance 
mechanisms prevent self-reactive T cells from persisting. The two high affinity 
variants of 3D provide an additional model system to explore the optimal affinity 
window for tumor antigen specific TCRs in adoptive therapy formats, where the 
TCRs can improve or redirect the activities of CD8+ or CD4+ cells and avoid 
tolerance. Experiments are underway in our collaborator, Professor Greenberg’s lab, 
to determine: 1) the activity of the variants in primary T cells and 2) if the two high 
affinity variants escape central and/or peripheral tolerance.  In development, T cells 
expressing self-reactive TCR (i.e. TCR with too high of affinity for self antigen) are 
deleted in a process called negative selection (central tolerance).  The affinity 
threshold for negative selection has been suggested to be between 1 and 5 μM KD 
(328).  Others have demonstrated that the levels of CD8 vary during selection, and 
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that the level is tuned to contribute to binding to self-antigens and deletion of many 
would be tumor specific TCRs (329),(330).  
A potential problem with an adoptive transfer regimen, where CD4+ T cells 
are “redirected” with a high-affinity class I-restricted TCR, is the potential for the 
generation of CD4+ regulatory T cells which could suppress the immune response to 
the antigen-positive tumor.  A recent study has demonstrated that the affinity of the 
TCR can dictate the formation of regulatory T cells (331), and thus TCRs with a 
range of affinities need to be examined for their propensity to develop into Tregs in 
adoptive transfer models. The two high-affinity TCRs against self-antigen WT-1 
described here, along with the wild type 3D TCR, should allow further examination 
of these issues, and will better define the optimal affinity TCRs for transfer into CD4+ 
and CD8+ T cells.  
 Isolation of 8 T cell clones raised against murine (2 clones) and human (6 
clones) WT-1 tumor antigen led to the identification of a number of conserved 
residues within the CDR3 regions. Others have observed similar conservation in 
response to a specific viral or tumor antigen (reviewed in (332)), but there are no 
instances I am aware of where homology in the CDR3 loops existed for T cell 
receptors across species directed against the same peptide. The sequence similarity 
observed for these clones may provide insight into future affinity engineering of other 
WT-1 specific TCRs and the immune system response to this particular self-antigen.   
 
 
 
 
 
 
 
 
 
 
 
 129
Figures 
 
 
Figure 5.1. 3D Construct, CDR3α Library Design and T Cell Surface 
Expression. (A) Schematic of the 3D TCR construct.  The CDR3α Region consists 
of 9 residues as highlighted.  The nine residues were separated into 3 libraries 
respectively called L1, L2, and L3.  (B) Surface expression of template TCR and 
CDR3α libraries L1, L2, and L3 as monitored by anti-Cβ after 1 round of selection 
with anti-Cβ.  Notably, a population of DimerX WT-1 positive cells was present in 
the L3 library. 
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Figure 5.2. CDR3α L3 Library Surface Expression and DimerX WT-1/Db 
Binding After Rounds of Selection.  Cells were assessed for mVβ10 surface levels 
and WT-1/Db binding after each sort as indicated.  The 3D L3 Library (CDR789) was 
sorted with anti-Cβ for sort 1 (S1), DimerX WT-1/Db at 200 nM for sort 2 (S2), and 
DimerX WT-1/Db at 200 nM for sort 3 (S3).  
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Figure 5.3. CDR3α DNA Sequence Analysis. DNA sequencing of the 3D full-
length TCR template (NYQ) (A) and the L3 library after two sorts (B).  The L3 
library contained a major species (NYH, single mutant) and minor species (PYY, 
double mutant) within the DNA sequencing trace. 
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Figure 5.4. Characterization of Single and Double Mutant 3D TCRs in 58-/- T 
Cells.  (A) Surface expression of 3D wild type (NYQ), single mutant (NYH), and 
double mutant (PYY). Staining with antibody or WT-1/Db DimerX at 125 nM or 
antibodies is as indicated (black line) with 58-/- parental line as a control (gray 
histograms).  MFI for Vβ is of the gate shown.  For WT-1/Db DimerX, MFI is 
expressed for the entire population of cells. (B) WT-1/Db DimerX titration analysis 
by flow cytometry at 4 degrees C.  (C) T cell activation in the presence of WT-1 
peptide titrated on T2-Db cells with wild type, NYH, and PYY mutants of 3D.   
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Figure 5.5. Characterization of  NYH and PYY Mutants in CD8αβ+ 58-/- T cells. 
(A) Surface expression of NYH and PYY mutants in CD8+ cells as monitored by 
indicated antibodies.  MFI for Vβ is for cells within the marker shown.  MFI for WT-
1/Db DimerX is expressed for the entire population. (B) T cell activation of cells lines 
from  (A) in the presence of WT-1 peptide loaded T2-Db cells. 
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Figure 5.6. Comparison of Antigen Presenting Cell Lines with 3D and PYY 
Mutant. (A) CD8- T cells expressing 3D TCR or PYY mutant were incubated with 
either EL4 (gray) or T2-Db (black) WT-1 peptide loaded cells.  The EL4 cell line also 
presents other peptides, whereas the TAP-deficient T2-Db cell line only presents 
exogenous WT-1 peptide. (B) The 3D TCR and double mutant (PYY) were expressed 
in CD8+ T cells and incubated with either EL4 or T2-Db as in (A).  The coagonist 
activity of EL4 is apparent, as the sensitivity to WT-1 peptide was improved with 
EL4 relative to T2-Db for both TCRs. 
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Figure 5.7.  Alignment of WT-1 Specific Murine and Human TCRs. Alignment of 
murine (3D and mWT-1) and human (CE4, CE10, P1, P18, P20, P22) WT-1 specific 
TCRs. Red or pink: homology between at least one human and murine TCR.  Green: 
Position of mutations that enhance affinity of the 3D murine TCR for WT-1/Db.  
Residues that are conserved in more than 50% of mouse or human TCRs were 
eliminated from the analysis. 
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Table 1.  3D CDR3α Library Sizes 
Library Transformants 
(E. coli) 
T cell Transduction 
Efficiency (Percent, # 
of cells Transduced) 
Library 
Diversity 
L1 (TAP) 25,900 13.3% (133,000) 25,900 
L2 (MDS) 7,000 2.5% (25,000) 7,000 
L3 (NYQ) 36,600 9.1% (91,000) 36,600 
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RESEARCH EXPERIENCE CONTINUED 
 
• Laboratory for Organic Synthesis Research                                   May 2003 to April 2004 
      Advisor: Prof. Ram Mohan                 
o Developed applications of bismuth compounds in organic synthesis 
(environmentally friendly organic synthesis) 
 
• Inorganic Chemistry Research Assistant                                     August 2001 to April 2003 
      Advisor: Prof. Rebecca Roesner           
o Developed synthetic reactions using hexamolybdate ions 
   
   
TEACHING EXPERIENCE 
 
University of Illinois at Urbana-Champaign                       Spring 2006 to Present 
Graduate Teaching Assistant, College of Liberal Arts and Science, Molecular and Cellular Biology      
                                                College of Medicine - UIUC 
              Served as occasional lecturer, grader, and led discussion sections 
• Molecular and Cellular Biology: Immunology (MCB408) 
• College of Medicine: Medical Microbiology and Immunology 
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Presentations 
[1] Engineering Human Tumor Specific TCRs for Improved Stability and Affinity.  Cell and 
Molecular Biology Training Grant Seminar Series, UIUC, November 6th, 2007. 
 
[2] Engineering Human Tumor Specific T Cell Receptors.  Department of Biochemistry Graduate 
Student Seminar Series, UIUC, April 23rd, 2008. 
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AWARDS AND HONORS 
• Cell and Molecular Biology Training Grant Trainee (UIUC Institutional Award) 
(August 2007-August 2009) 
• Best Basic Science Poster: College of Medicine Research Symposium (April 2009) 
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• Sigma Xi Scientific Research Honor Society (ISU/IWU Chapter, Spring 2004) 
• Chemistry Council of Illinois Scholarship Recipient (Spring 2004) 
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